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Ischaemia causes irreversible tissue damage in cardiovascular disease. Since 
regenerative angiogenesis fails to consistently induce sufficient reperfusion to 
facilitate repair, targeted manipulation of angiogenesis is clinically desirable. 
The Wilms’ tumour suppressor (Wt1) is a transcription factor which regulates 
numerous genes and cellular processes, including many intrinsic to 
angiogenesis. We hypothesise that WT1 in the endothelium influences the 
angiogenic function of endothelial cells. 
WT1 was identified in endothelial and non-endothelial cells comprising vessel 
outgrowths generated by cultured aortic rings from WT1-GFP reporter mice. 
Inducible deletion of WT1 from the endothelium (VE-Wt1 KO) significantly 
delayed angiogenesis in this assay (p<0.05 relative to controls). 
In vivo, WT1 expression was evident in vascular endothelial and perivascular 
cells of the hindlimb as early as 3 days following femoral artery ligation to 
induce ischaemia, often in cells expressing epithelial and mesenchymal 
markers simultaneously. However, VE-Wt1 KO had no effect on hindlimb 
reperfusion (laser Doppler; days 0-28) or on vessel density (day 28). Similarly, 
VE-Wt1 KO had no effect on vessel density or expression of angiogenic factors 
(qRT-PCR) in sponges inserted subcutaneously in mice (20 days). To further 
understand the role of WT1 in angiogenesis, transcriptomic RNA expression 
analysis was performed in WT1+ and WT1- cells isolated (FACs) from sponges 
after implantation in WT1-GFP mice. WT1+ cells exhibited higher expression 
of genes involved in a number of processes relevant to tissue repair, including 
angiogenesis (p=3.11x10-8), wound healing (p=3.45x10-7) and epithelial-to-
mesenchymal transition (EMT) (p=5.86x10-4). 
These results shed new light on the role of WT1 in ischaemic angiogenesis. In 
concurrence with previously published work, we show that deletion of 
endothelial WT1 can delay angiogenesis however, WT1 is not just 
instrumental in endothelial cells in this context. WT1 has a broader role in 
tissue repair in ischaemia, in part through regulation of cell transition (EMT). 
This work has improved our understanding of the regulatory role of WT1 in 
angiogenesis and repair, while revealing a number of novel insights into the 
iv 
 
function of WT1. This highlights WT1 as a potentially beneficial therapeutic 
target to facilitate regeneration in cardiovascular disease. 
Lay Summary 
In cardiovascular disease, blockage of blood vessels results in some tissues 
becoming starved of oxygen. Angiogenesis – the formation of new blood 
vessels from existing vasculature – occurs in response, but often fails to 
completely resupply blood to these damaged tissues. It is important, therefore, 
to establish new ways to improve this process. One gene of interest, the 
Wilms’ tumour suppressor (WT1) is a transcription factor and so effectively 
acts as a ‘master switch’ to activate a number of other genes. We hypothesise 
that WT1 acts in blood vessels to regulate the process of angiogenesis and so 
could be a promising target to improve regeneration of damaged tissues in 
cardiovascular disease. 
WT1 was found to be expressed in blood vessels in two models of 
angiogenesis simulated in mice; implantation of sponges under the skin and a 
model of critical limb ischaemia, simulated by tying off the femoral artery. 
However, WT1 was also expressed in a number of other parts of damaged 
tissue, including in damaged muscle and immune cells. While reducing the 
expression of WT1 in the inner cell layer of blood vessels did not seem to 
reduce angiogenesis in these models, it did reduce angiogenesis in a simpler 
model. In this model, aortic blood vessels would spontaneously form new 
blood vessels by angiogenesis when removed from the mouse and grown in 
a petri dish. 
Using a mouse which expresses a green fluorescent protein when WT1 is 
expressed, we were able to separate out cells which expressed WT1 from 
those which did not and screen for the expression of thousands of genes to 
understand what WT1 expressing cells do differently from non-expressing 
cells. This revealed that WT1 expressing cells were not only involved in the 
process of angiogenesis, but generally influenced the healing process. These 




This work sheds new light on the role of WT1 in angiogenesis and 
cardiovascular disease. We show that WT1 is indeed an important factor in 
angiogenesis and may be able to regulate angiogenesis to improve repair. 
Intriguingly though, WT1 seems to have a more general role in enabling 
regeneration and repair of damaged tissues. In summation, WT1 appears to 







List of Abbreviations 
+/-KTS – +/- Lysine, Threonine and Serine 
5-HT – 5-hydroxytrytamine (Serotonin) 
AA – Amino acid 
Ach – Acetylcholine 
APC – Adipose progenitor cell 
CC – VE-Cadherin CreERT2 control  
CD31 – Cluster of differentiation 31 
CHIP-seq – Chromatin immune-precipitation sequencing 
CVD – Cardiovascular disease 
DAPI - 4′,6-diamidino-2-phenylindole 
EC50 – Effective concentration for 50% contraction 
Emax – Pharmacological efficacy 
EMT – Epithelial-to-mesenchymal transition 
EndMT – Endothelial-to-mesenchymal transition 
EPC – endothelial progenitor cell 
FACs – Fluorescence-activated cell sorting 
FCS – Foetal calf serum 
GFP – Green fluorescent protein 
HCl – Hydrochloric acid 
HIF – Hypoxia induced factor 
HLI – Hindlimb ischaemia 
HSC – Haematopoietic stem cell 
HUVEC – Human umbilical vein endothelial cell 
IF – Immunofluorescence 
IHC – Immunohistochemistry 
IL – Interleukin 
vii 
 
KO – knock-out 
KO – Vascular endothelial Wt1 KO (kindly provided by Kay and Nicole 
Wagner) 
KPSS – Physiological saline solution + K+ 
MET – Mesenchymal-to-epithelial transition 
miRNA – Micro ribonucleic acid 
mRNA – Messenger ribonucleic acid 
MSC – Mesenchymal stem cell 
NA – Noradrenaline 
NO – Nitric oxide 
PBS – Phosphate-buffed saline 
PCNA – Proliferating cell nuclear antigen 
PCR – Polymerase chain reaction 
PD2 – -log10 EC50 
PDGF – Platelet derived growth factor 
PDGFR – Platelet derived growth factor receptor 
PSS – Physiological saline solution 
qRT PCR – Quantitative reverse transcriptase polymerase chain reaction 
RA – Retinoic acid 
shRNA – Short hairpin ribonucleic acid 
siRNA – Short interfering ribonucleic acid 
SNP – Serotonin 
SSI – Subcutaneous sponge implantation 
UTR – Untranslated region 
VC – Vehicle control 
VEGF – Vascular endothelial growth factor 
VE-Wt1 KO – Vascular endothelial Wt1 knock-out 
viii 
 
Wt1 - Wilms’ tumour 1 gene 
WT1 - Wilms’ tumour 1 protein 





Table of Contents 
Declaration ............................................................................................................... i 
Acknowledgements ................................................................................................... i 
Abstract ................................................................................................................... iii 
Lay Summary .......................................................................................................... iv 
 
Chapter 1: Introduction ......................................................................................... 1 
1.1 The Wt1 Gene ................................................................................................................ 3 
1.1.1. Molecular Genetics of WT1 .................................................................................... 4 
1.1.2. WT1 in Development ............................................................................................. 7 
1.1.3. WT1 in Adult Tissue Homeostasis and Repair .................................................... 14 
1.1.4 WT1 in Cancer ...................................................................................................... 18 
1.2 Angiogenesis ................................................................................................................ 22 
1.2.1 Cellular and Molecular Mechanisms of Angiogenesis .......................................... 23 
1.2.2 Non-Vascular Cells in Angiogenesis ..................................................................... 29 
1.2.3 Developmental Angiogenesis ............................................................................... 33 
1.2.4 Physiological Angiogenesis .................................................................................. 34 
1.2.5 Tumour Angiogenesis ........................................................................................... 35 
1.2.6 Pathological Angiogenesis .................................................................................... 36 
1.2.7 Regenerative Angiogenesis .................................................................................. 36 
1.3 WT1 in Angiogenesis ................................................................................................... 37 
1.4 Hypothesis .................................................................................................................... 40 
1.5 Aims ............................................................................................................................. 40 
Chapter 2: Materials and Methods ...................................................................... 41 
2.1 Experimental Animals .................................................................................................. 42 
2.2 Genotyping ................................................................................................................... 43 
2.3 Isolation of Mouse Aorta .............................................................................................. 45 
2.4 Aortic Ring Assay ......................................................................................................... 46 
2.5 Myography .................................................................................................................... 46 
2.6 Anaesthesia and Analgesia .......................................................................................... 47 
2.7 Hindlimb Ischaemia ...................................................................................................... 49 
2.8 Murine Models of Arterial Remodelling ........................................................................ 49 
2.9 Murine Menstruation Model .......................................................................................... 50 
2.10 Quantitative PCR ....................................................................................................... 51 
2.11 Histological Techniques ............................................................................................. 53 
2.12 Immunofluorescent Staining ....................................................................................... 54 
2.13 Transcriptomics .......................................................................................................... 56 
2.14 Statistics and Analysis ............................................................................................... 58 
2.7 Hindlimb Ischaemia ...................................................................................................... 49 
2.8 Murine Models of Arterial Remodelling ........................................................................ 49 
x 
 
Chapter 3: WT1 in Angiogenesis and Vascular Function Ex Vivo .................... 59 
3.1 Introduction................................................................................................................... 60 
3.2 Materials and Methods ................................................................................................. 64 
3.3 Results ......................................................................................................................... 67 
3.3.1 The VE-Wt1 KO Mouse Model .............................................................................. 67 
3.3.2 Myography in C57Bl/6 Mice .................................................................................. 72 
3.3.3 VE-Wt1 KO Results in Increased Vasoconstriction .............................................. 74 
3.3.4 Ex Vivo Angiogenesis in the Aortic Ring Assay .................................................... 77 
3.4 Discussion .................................................................................................................... 86 
3.4.1 Ex Vivo Angiogenesis ........................................................................................... 86 
3.4.2 Endothelial WT1 KO Impairs Ex Vivo Angiogenesis............................................. 88 
3.4.3 Vasoconstriction is Altered by Endothelial WT1 KO ............................................. 91 
3.4.4 Endothelial WT1 has a Role in the Adult Testis and Male Gonad ........................ 94 
3.4.4 Conclusions ........................................................................................................... 96 
Chapter 4: The Role of WT1 in In Vivo Angiogenesis ....................................... 97 
4.1 Introduction................................................................................................................... 98 
4.2 Materials and Methods ............................................................................................... 103 
4.3 Results ....................................................................................................................... 108 
4.3.1 The Subcutaneous Sponge Implantation (SSI) Model of Angiogenesis ............. 108 
4.3.2 WT1 Expression in the Subcutaneous Sponge Model (SSI) .............................. 110 
4.3.3 Endothelial WT1 KO in the Subcutaneous Sponge Implantation Model ............ 112 
4.3.4 VE-Wt1 KO in the Subcutaneous Sponge Model ............................................... 121 
4.3.5 The Hindlimb Ischaemia (HLI) Model of Angiogenesis ....................................... 129 
4.3.6 WT1 Expression in the HLI Model ...................................................................... 133 
4.3.7 VE-Wt1 KO in the HLI Model .............................................................................. 142 
4.4 Discussion .................................................................................................................. 153 
4.4.1 Endothelial cell-selective Wt1 KO does not impair Angiogenesis In Vivo .......... 153 
4.4.2 WT1 Does Have a Role in Angiogenic Vasculature ........................................... 156 
4.4.3 The Pathophysiological Function of WT1 is Not Restricted to the Vasculature . 158 
4.4.4 Conclusions ......................................................................................................... 160 
Chapter 5: The Gene Expression Profile of Wt1+ Cells In Vivo ....................... 161 
5.1 Introduction................................................................................................................. 162 
5.2 Materials and Methods ............................................................................................... 164 
5.3 Results ....................................................................................................................... 169 
5.3.1 A Small Proportion of WT1+ Cells from WT1-GFP FACS in Sponges express   
CD31 ............................................................................................................................ 169 
5.3.2 RNA-Sequencing and Transcriptomic Analysis of WT1-GFP Sponges ............. 172 
5.4 Discussion .................................................................................................................. 187 
5.4.1 Issues to Consider in Transcriptomic Analysis ................................................... 187 
5.4.2 WT1 is Expressed in a Number of Non-Endothelial Cell Types ......................... 188 
xi 
 
5.4.3 The Gene Expression Profile is Consistent with a Role for WT1 in Angiogenesis
 ..................................................................................................................................... 191 
5.4.4 WT1 Expressing Cells have a Number of Non-Angiogenic Functions ............... 192 
5.4.5 Conclusions ......................................................................................................... 193 
Chapter 6: Discussion & Conclusions ............................................................. 195 
6.1 WT1 in Angiogenesis ................................................................................................. 197 
6.2 The Angiogenic Implications of Endothelial WT1 KO ................................................ 199 
6.3 Physiological Roles of Vascular WT1 ........................................................................ 201 
6.4 Non-Vascular Functions of WT1  ............................................................................... 204 
6.5 Future Work ............................................................................................................... 206 
6.6 Conclusions  ............................................................................................................... 210 
References .......................................................................................................... 213 




















Current Understanding of Wt1 and its 
Role in Cardiovascular Disease 
2 
 
The Wilms’ Tumour Suppressor gene (Wt1), first identified in 1990 (Call et al., 
1990; Gessler et al., 1990), was originally recognised as a gene whose 
mutation causes the eponymous renal paediatric cancer, Wilms’ tumour 
(Haber et al., 1990). Since then, the number of contexts identified in which 
WT1 is intrinsic has steadily increased and it is now accepted to be an 
important regulator in a range of cancers, in embryogenesis, in reproductive 
tissue and in kidney function, amongst others. On a cellular level, WT1 is 
known to influence cell growth, cell proliferation, apoptosis, generation of 
mesenchymal progenitors and crucially, cell differentiation by epithelial-to-
mesenchymal transition (EMT) and the reverse process mesenchymal-to-
epithelial (MET) (Hastie, 2017).  
To imagine a single gene having such diverse functions may seem 
confounding. However, WT1’s far-reaching impact is attributable to its role as 
a transcription factor; essentially acting as a master switch for expression of 
other genes, some of which may themselves be transcription factors. Mapping 
to chromosome 11p13, WT1 is a Krüppel type zinc finger protein (Rauscher et 
al., 1990; Bickmore et al., 1992). It is primarily involved in transcriptional 
regulation of DNA, but has also been found to have a role in post-
transcriptional RNA processing (Burdach et al., 2012). 
Cardiovascular disease (CVD) is the leading cause of mortality worldwide, 
accounting for 4 million deaths a year across Europe, 45% of all mortality 
(Townsend et al., 2016). CVDs such as myocardial infarction and stroke occur 
when arterial occlusion disrupts the blood supply to crucial organs, resulting in 
downstream oxygen deprivation and ischaemia. Prolonged ischaemia causes 
irreversible tissue damage; in CVD this increases mortality and detrimentally 
impacts quality of life. Angiogenesis, the process of neovascularisation from 
pre-existing blood vessels may act to resupply blood to ischaemic tissues in 
CVD, but, regenerative angiogenesis fails to consistently induce sufficient 
reperfusion to facilitate repair. Therefore, targeted therapeutic manipulation of 
angiogenesis is clinically desirable. 
WT1 is important for regulating vascular progenitors and some developing 
vasculature, but is absent from adult, quiescent blood vessels (Scholz, 
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Wagner and Wagner, 2009; Duim et al., 2016). There is increasing evidence 
that WT1 may have a role in angiogenesis in the adult, both in cancer and in 
CVD. Following induction of myocardial infarction, WT1 is expressed in the 
coronary vasculature proximal to the site of infarction (K. Wagner et al., 2002). 
There is also growing evidence that WT1 is regulated by hypoxia inducible 
factor 1 alpha (HIF-1α) and, in turn, transcriptionally regulates vascular 
endothelial growth factor (VEGF), both of which are major angiogenic factors 
(Graham et al. 2006; Hosen et al. 2007; Amin et al. 2011; McCarty et al. 2011; 
Iranparast et al. 2014). Despite recent studies into WT1 in angiogenesis 
(Wagner et al., 2014; Duim et al., 2015), the role of WT1 in angiogenesis and 
cardiovascular disease is imperfectly understood.  
The work described in this thesis is primarily concerned with the role of WT1 
in cardiovascular disease, specifically in the process of angiogenesis (new 
blood vessel formation from existing vasculature). In order to contextualise the 
work contained herein, this introduction will summarise the current 
understanding of the field, to date. First, WT1 will be discussed in more detail, 
encompassing its molecular biology and the numerous biological processes in 
which it functions. Then, the response to ischaemia in cardiovascular diseases 
will be discussed, with a specific focus on angiogenesis; its molecular 
processes and importance in cardiovascular disease. Finally, these topics will 
be brought together in a summary of what is known about WT1 in 
cardiovascular diseases and ischaemic angiogenesis. 
1.1 The Wt1 Gene 
Wt1 has a high degree of evolutionary conservation in its sequence homology 
between humans, mice, rats, birds, amphibians and fish (Miles et al., 1998; 
Carmona et al., 2001; Ladomery et al., 2003; Yamamura et al., 2005; 
Eisermann et al., 2008). This demonstrates a degree of indispensability of 
WT1 on a molecular level, which is reflected on a phenotypic level. Mutations 
in the Wt1 gene lead to development of Wilms’ tumour, a renal paediatric 
cancer, due to the essential role of WT1 in kidney development (Dong, Pietsch 
and Englert, 2015). In mice, homozygous deletion of Wt1 during development 
results in complete absence of gonads, kidneys and spleen, with death mid-
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gestation due to heart failure (Kreidberg et al., 1993; Herzer et al., 1999). Even 
in adults, where Wt1 is only expressed in a small proportion of cells, Wt1 
deletion undermines normal tissue homeostasis, resulting in multiple organ 
failure (Chau et al., 2011). In a number of diseases, WT1 expression is 
upregulated and dependent on context, contributes to pathological and 
regenerative processes. It would not, therefore, be unwarranted to consider 
WT1 a major transcriptional regulator of physiological and pathophysiological 
function. 
1.1.1 Molecular Genetics of WT1 
The mammalian Wt1 gene is roughly 50kb in length and spans 10 exons on 
chromosome 11p13 (Hohenstein and Hastie, 2006). Wt1 encodes a zinc-
finger transcription factor with four C-terminus C2H2 Krüppel-type zinc-fingers 
(Figure 1.1). In this sense, WT1 is a relatively typical zinc-finger transcription 
factor, with a high specificity for GC-rich regions and each zinc finger capable 
of binding to three base pairs (Rauscher et al., 1990; Bickmore et al., 1992). It 
incorporates a transcriptional repression domain between residues 71-180 
(Wang et al., 1993) and a transcriptional activation domain between residues 
180-250 (Madden, Cook and Rauscher, 1993). Therefore, WT1 is capable of 
both activating and repressing gene expression.   
Combinations of alternative transcription start sites, RNA editing and RNA 
splicing give rise to somewhere between 24 and 36 human WT1 protein 
isoforms (Hohenstein and Hastie, 2006; Toska and Roberts, 2014). Four of 
the most widely studied and functionally important isoforms arise from 
alternative splicing at two sites; exon 5 and exon 9. In exon 5, there is a 
possible insertion event of 17 amino acids (+/- 17AA) between the 
proline/glutamine-rich N-terminus and zinc finger domain of the C-terminal. In 
exon 9, there is a possible insertion of three amino acids, (lysine, threonine 
and serine (+/-KTS)) into the linker sequence between the third and fourth zinc 
fingers. These four major isoforms (+17AA/+KTS, +17AA/-KTS, -17AA/+KTS, 
-17AA/-KTS) have been shown to be expressed in different cell types, tissues 
and contexts, and have different functions (Ito et al., 2006; Jomgeow et al., 
2006). For example, the +17AA isoforms seem to be co-activated by Par4 
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which function together to regulate cell survival and proliferation (Richard, 
Royer-Pokora and Roberts, 2001). Interestingly, isoform-specific WT1 knock-
outs also have varying phenotypic outcomes and survival, perhaps suggesting 
some isoforms are more essential than others. Selective loss of +KTS or –
KTS isoforms, both result in neonatal death, though loss of –KTS isoforms 
induces a more severe and acute effect (Hammes et al., 2001). Conversely, 
loss of the +17AA isoform (Natoli et al., 2002), or other isoforms generated by 
alternative translational start sites (Miles et al., 2003), produces essentially no 
phenotype. It is also worth noting that, from an evolutionary perspective, only 
the –KTS isoform is conserved across vertebrates (Davies, Bratt and Hastie, 
2000). 
The +KTS and –KTS isoforms are particularly important to the function of WT1. 
It was found that, while –KTS isoforms were found in transcription factor 
domains in the nucleus, +KTS isoforms were found to be associated primarily 
with splice factors. This prompted, the hypothesis that +KTS isoforms are 
involved in transcriptional regulation of DNA, while –KTS isoforms have a post-
transcriptional role in RNA processing (Larsson et al., 1995). It has 
subsequently been demonstrated that both isoforms can bind RNA and DNA, 
though +KTS has a higher affinity for RNA than –KTS, which more readily 
associates with DNA (Morrison, Viney and Ladomery, 2008). Concurrently, –
KTS isoforms bind DNA much more readily than +KTS isoforms (Morrison et 
al. 2008). While both +KTS and –KTS bind to RNA in vitro, in vivo it appears 
that +KTS binds RNA much more efficiently and that the first zinc finger of 
WT1 is important for this RNA binding.  
The ability of +KTS to bind RNA, is not unique to WT1 and has been observed 
in other zinc finger transcription factors (Burdach et al., 2012). While all four 
zinc fingers bind to DNA, it appears that zinc finger 1 is essential for RNA-
binding (Caricasole et al., 1996) while fingers 2 and 3 contribute to the RNA 
binding affinity (Weiss and Romaniuk, 2009). To date, it has been found that 
+KTS WT1binds to a constitutive transport element (CTE) within the sequence 
of unspliced mRNA to facilitate transport from the nucleus (Bor et al., 2006) 
and shuttles between the nucleus and cytoplasm (Niksic et al., 2004). +KTS 
WT1 also binds alpha-actinin 1 (ACTN1) mRNA (Nurmemmedov et al., 2010) 
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and a recent, comprehensive study confirmed that WT1 binds to the 3’ 
untranslated regions (UTRs) of target mRNAs involved in developmental 
processes and regulates their turnover (Bharathavikru et al., 2017). There is 
undoubtedly much more to be discovered in relation to +KTS WT1, its function 












Figure 1.1. The Wt1 gene. The structure of the WT1 gene is shown in A) mammals 
and B) non-mammalian vertebrates. Consistently transcribed exons are shown in 
blue, with alternative splices, RNA editing and alternative transcriptional and 
translational start sites in orange. Functional annotations are indicated in green. In 
mammals, this can give rise to 36 potential isoforms, in non-mammalian vertebrates, 
only +KTS and –KTS isoforms are currently documented. Adapted from Hastie 2017. 
 
Hundreds of direct WT1 target genes, too many to discuss comprehensively 
here, have been discovered in mammals, with many more yet to be discovered 
no doubt (Toska and Roberts, 2014). There is strong in vivo evidence for many 
factors associated with WT1 and Chromatin immune-precipitation sequencing 
(ChIP-seq) has proved a powerful tool for validating these targets (Kim et al., 
2007, 2009; Sunny Hartwig et al., 2010; Motamedi et al., 2014; Kann et al., 
2015). Toska & Roberts (2014) review many of these validated direct targets 
of WT1 and others will be discussed later in this chapter in relation to the 
relevant roles of WT1. However, these genes are involved in a range of 





EMT/MET), cell adhesion and cytoskeletal organisation, cell proliferation, cell 
migration and apoptosis. Many of these direct targets of WT1 are, themselves 
transcription factors. 
A number of high-affinity WT1-binding motifs have been discovered (Rauscher 
et al., 1990; Wang et al., 1993; Hamilton, Barilla and Romaniuk, 1995; 
Nakagama, Heinrich and Pelletier, 1995; Little et al., 1996). As an added level 
of complexity, WT1 also binds to transcriptional co-factors including CREB-
binding protein (CBP) (Wang et al., 2001; Essafi et al., 2011), Ewing’s sarcoma 
gene (EWS) (Reynolds et al., 2003), Brain acid soluble protein 1 (BASP1) 
(Green et al., 2009) and Ten-eleven translocation protein 2 (TET2) (Wang et 
al., 2015). These WT1 complexes may recognise different sequences, 
depending on the cofactors. WT1 also binds to a number of proteins involved 
in RNA turnover including, Wilms’ tumour associating protein 1 (WTAP1) 
(Little, Hastie and Davies, 2000; Horiuchi et al., 2013), U2AF65 (Davies et al., 
1998) and RBM4 (Markus et al., 2006). Further, WT1 has regions capable of 
self-association (residues 1–45 and 157–253), which may act to inactivate the 
WT1 protein and antagonise its transcriptional regulation (Moffett et al., 1995; 
Holmes et al., 1997).  
Considering the molecular genetics of the Wt1 gene and WT1 protein; its 
multiple isoforms, role in transcriptional and post-transcriptional regulation, 
capacity to bind to DNA and RNA, multiple co-factors and target genes and its 
ability to self-regulate, it starts to become more evident why it is capable of so 
many functions and is intrinsic to so many processes. Some of these key roles 
of WT1 will be elaborated on in the following sections. 
1.1.2 WT1 in Development 
WT1 is an intrinsic factor in mammalian development with an essential role in 
normal development of a number of tissues and organs. WT1-null mice fail to 
develop complete gonads, spleen, kidneys, diaphragm and adrenal glands 
(Kreidberg et al., 1993; Herzer et al., 1999; Moore et al., 1999; Hammes et al., 
2001). These mice die at an embryonic stage from heart failure characterised 
by malformation of the heart, lack of coronary vasculature and disrupted 
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epicardial development (Kreidberg et al., 1993; Moore et al., 1999). It is 
important to understand the role of WT1 in development, not only to 
understand its role in the adult, but also in disease and regeneration in which 
a recapitulation of developmental processes often occurs. 
1.1.2.1 Development of the Cardiovascular System 
In the foetal human and murine heart, WT1 is primarily expressed in the 
mesothelial lining of the heart (the epicardium) with temporal expression in 
endothelial cells of the cardiac vasculature, during development (Duim et al., 
2015, 2016). Cell fate mapping within the developing heart, revealed that a 
proportion of coronary vascular smooth muscle and endothelial cells derive 
from the WT1+ cells of the proepicardium and septum transversum (Cano et 
al., 2016). When WT1 is deleted only in the epicardium, the epicardium 
remains primarily intact, but mice die at E16.5-E18.5 with a dramatic depletion 
of both the coronary vasculature and epicardium-derived mesenchymal 
cardiovascular progenitor cells (Martínez-Estrada et al., 2010).  
It appears that much of the developmental role WT1 play in the heart is due to 
regulation of EMT. The result of epicardial WT1 KO (described above) was 
primarily attributed to disruption of EMT, with WT1 important for activating the 
major EMT regulator Snail and repressing E-Cadherin (Martínez-Estrada et 
al., 2010). In a separate study, it was proposed that WT1 regulates epicardial 
EMT through the β-Catenin and retinoic acid (RA) pathways (von Gise et al., 
2011). Concurrently, WT1 regulates Raldh2 and Pdgfrα (components of RA 
pathways) (Bax and Oorschot, 2011; Guadix et al., 2011) and cardiac 
malformations in Pdgfrα are associated with increased WT1 expression (Bax 
et al., 2010). Epicardial WT1 Knock-down or mutation resulted in increased 
EMT and cell migration, attributed to WT1 directly upregulating Slug, another 
major regulator of EMT and member of the Snai family (Takeichi et al., 2013). 
In reality, given the range of WT1 target genes, it is probable that all of these 
proposed mechanisms are valid. WT1 also activates the neurotrophin receptor 
TRKB (NTRK2), a key regulator of vascular development  (Wagner et al. 
2005). Epicardial WT1 also regulates the inhibitory chemokines Ccl5 and 
Cxcl10, both directly and indirectly through IRF7 (Velecela et al., 2013). These 
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chemokines inhibit epicardial cell migration and cardiomyocyte proliferation, 
both important in cardiac development. Thus, WT1 is controlling development 
of the epicardium and cardiac muscle through suppression of these cytokines 
(Velecela et al., 2013). In the foetal heart, WT1 is also expressed in endothelial 
cells of the developing vasculature, implicating it in vasculogenesis and 
developmental angiogenesis (Duim et al., 2015, 2016) 
1.1.2.2 Development of the Renal System 
Wilms’ tumour is a striking example of how perturbations of normal WT1 
function in utero can adversely affect kidney development. Further, germline 
Wt1 mutations play a role in development of Denys-Drash (Pelletier et al., 
1991) and Frasier syndromes (Barbaux et al., 1997); one feature of which is 
glomerulosclerosis due to abnormalities in kidney podocytes. The kidney 
develops from two separate, interacting components derived from the 
intermediate mesoderm; the metanephric mesenchyme, which gives rise to 
nephrons and the ureteric bud, which gives rise to ureters. WT1 is expressed 
at varying levels throughout metanephric kidney development (Pritchard-
Jones et al., 1990; Armstrong et al., 1993; Hastie, 2017), first at low levels in 
the intermediate mesoderm, with expression increasing as the metanephric 
mesenchyme condenses around the uretic bud and an MET event is initiated. 
WT1 expression remains widespread throughout nephrogenesis, eventually 
becoming restricted solely to the podocytes (Guo et al., 2002). The 
development of the metanephric kidney is reviewed by Short & Smyth (2016), 
herein the role of WT1 will be discussed. 
Inhibition at various stages of development has shown WT1 to be essential to 
all stages of kidney formation (Davies et al., 2004; Berry et al., 2015). WT1 
appears to be essential for the regulation of metanephric mesenchyme 
survival (Motamedi et al., 2014) and deletion of WT1 results in apoptosis of 
the metanephric blastemal and failed outgrowth of the ureteric bud from the 
Wolffian duct (Kreidberg et al., 1993).  Intriguingly, Wilms’ tumours arising from 
Wt1 mutations will often entail ectopic formation of muscle and occasionally 
bone, cartilage and fat within the kidney tissue (Schumacher et al., 2003). 
Accordingly, WT1 deletion in the metanephric mesenchyme during kidney 
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development results in expression of myogenic markers and muscle formation 
(Berry et al., 2015). 
ChIP-seq experiments have been carried out to identify WT1 target genes in 
a renal context and have identified genes known to be essential to normal 
kidney development (Hartwig et al. 2010; Motamedi et al. 2014).These 
included Sall1, Bmp4, Pax2 and Bmp7, a podocyte-derived protein essential 
for nephron development (Kazama et al., 2008). Indeed, WT1 appears to be 
essential for normal development of podocytes; specialised glomerular cells 
of epithelial origin, but with many mesenchymal characteristics, that form a 
filtration barrier with endothelial cells. WT1 regulates the key podocyte gene 
Podocalyxin (Pdxl) at a transcriptional and post-transcriptional level (Palmer 
et al., 2001; Bharathavikru et al., 2017). In fact, WT1 binds to the regulatory 
regions of around half of the roughly 200 identified podocyte-specific genes 
and 18 of the 31 genes mutated in podocyte diseases (Dong, Pietsch and 
Englert, 2015; Kann et al., 2015; Lefebvre et al., 2015). As in the epicardium, 
WT1 also regulates Wnt4 in the kidney (Sim et al., 2002). The major MET 
event in early kidney development and essential for nephron formation is 
initiated by Wnt4 and therefore, interfering with WT1 at this stage disrupts 
MET, nephron formation and Wnt4 expression (Kispert, Vainio and McMahon, 
1998; Essafi et al., 2011). Conversely, in the epicardium which undergoes the 
reverse process (EMT) WT1 represses Wnt4 and this occurs through 
switching the chromatin from an active to a repressive state; a mechanism 
termed chromatin “flip-flop” (Essafi et al., 2011). 
1.1.2.3 Gonadogenesis 
The well-established role of WT1 in sex determination and gonadogenesis in 
male and female tissues will be discussed in this section. Before WT1 was 
even discovered as the pivotal factor for Wilms’ tumour it was known that 
patients with Wilms’ tumour-aniridia (WAGR) syndrome often had 
gonadoblastoma and gonadal dysgenesis (Andersen et al. 1978). Despite 
their disparate localisation in the adult, the gonads and adrenal glands, derive 
embryonically from a common precursor, the adrenogonadal primordium 
(AGP). When WT1 is absent during development, mice fail to develop adrenal 
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glands and gonads (Kreidberg et al., 1993). It is, therefore, intuitive that WT1 
is affecting development of these two steroidogenic organs from an early 
stage. Indeed, WT1 transcriptionally activates the key AGP survival factor Sf1 
(Wilhelm and Englert, 2002), without which the AGP undergoes widespread 
apoptosis (Luo, Ikeda and Parker, 1994). 
The gonad develops as a bipotential organ with the capacity to be directed 
down the male testicular development path or the female ovarian development 
path. In mammals, this is primarily determined by Sry, which activates Sox9 in 
male sex determination and R-Spondin 1 (Rspo), which activates β-Catenin in 
female sex determination (DeFalco and Capel, 2009). Sry and Müllerian 
inhibiting substance (Amh/Mis), a key sex determining hormone, are both 
directly regulated by WT1, particularly WT1 +KTS in association with GATA4 
(Hossain and Saunders, 2001; Miyamoto et al., 2008). This is in accordance 
with two observed instances of sex reversal, in Frasier syndrome (Barbaux et 
al., 1997) and in the absence of +KTS WT1 which resulted in a reduction of 
Sry expression (Hammes et al., 2001), establishing WT1 as an important 
factor in sex determination. 
Following this event, WT1 has further roles in male and female 
gonadogenesis. In the testis, Sertoli cells form from Sry/Sox9 expressing cells 
which orchestrate testis development, recruiting germ cells, vascular 
endothelial cells and myoid cells to form the seminiferous tubules and 
testicular cords. WT1 is widely expressed throughout (De Santa Barbara et 
al., 2000), and is essential for testicular development (Wen et al., 2014). 
Conditional Wt1 deletion in Sertoli cells resulted in Sertoli cell death, disruption 
of developing seminiferous tubules and testicular cords, the latter due in part 
to WT1 regulation of basal lamina components Col4a1 and Col4a2 (Gao et al., 
2006; S.-R. Chen et al., 2013). WT1 also inhibits β-Catenin in Sertoli cells 
(Chang et al., 2008). Sertoli cells establish testis steroidogenesis and initiate 
differentiation of Leydig cells. While Sertoli cells continue to express Wt1 into 
adulthood, Leydig cells stop expressing Wt1 after forming from Sertoli cells 
(De Santa Barbara et al., 2000). 
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Considerably less is known about WT1 in female gonadogenesis, however, a 
few studies have begun to dissect the relationship between WT1 and female 
fertility. The developing ovaries are formed from two cell populations: the 
granulosa cells of the coelomic epithelium and steroidogenic Theca cells. WT1 
is expressed in the granulosa cells of follicles and the surface epithelium 
during development, with potential regulation of Inhibin-α (IhbA). This 
expression decreased over time. WT1 mutation in mice resulted in reduced 
ovary size and ova number, with a concurrent, dramatic reduction in fertility 
(Kreidberg et al., 1999; F. Gao et al., 2014; Nathan et al., 2017). Among the 
factors controlling mammary development are Pax2 and Insulin like growth 
factor (IGF1) (Brown et al., 2002; Silberstein, Dressler and Van Horn, 2002; 
Kleinberg et al., 2009), both of which have been shown to be direct 
transcriptional targets of WT1 (Tajinda, Carroll and Roberts  Jr., 1999; 
Discenza et al., 2003). 
1.1.2.4 Other Developmental Contexts 
Other developmental contexts in which WT1 has been shown to have some 
influence are discussed below. Congenital diaphragmatic hernia (CDH), 
incomplete development of the diaphragm, can occur as a result of Wt1 
mutation in Denys-Drash, WAGR and Meacham syndromes (Scott et al., 2005; 
Suri et al., 2007; Antonius et al., 2008). A recent study in which Wt1 was 
deleted specifically from the septum transversum mesenchyme during 
diaphragmatic development showed a reduction in formation of a crucial 
mesenchymal cell population owing to impaired EMT and lower Raldh2 
expression, with retinoic acid (RA) also implicated (Carmona et al., 2016). 
Therefore, this parallels the known role of WT1 in cardiac development, 
described previously (1.1.2.1). 
During lung development, WT1 is discretely expressed in the embryonic 
mesothelium and this tissue gives rise to smooth muscle cells, endothelial 
cells, myocytes and cells of the bronchial and tracheal cartilage (Que et al., 
2008; Cano, Carmona and Munoz-Chapuli, 2013). Wt1 deletion disrupts 
pulmonary development, with reduction in formation of these cell populations 
potentially attributable to impaired EMT (Cano, Carmona and Munoz-Chapuli, 
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2013). In liver development, WT1+ septum transversum mesothelial cells 
generate hepatic stellate cells, perivascular mesenchymal cells, smooth 
muscle cells, portal fibroblasts and fibroblasts (Asahina et al., 2011), with WT1 
and RA shown to be important for stellate cell formation (Ijpenberg et al., 
2008). In the intestine, WT1 is expressed discretely in the coelomic epithelium 
and WT1+ cells give rise to the visceral musculature, Cajal and Cajal-like 
interstitial cells and all cells of the intestinal vasculature (Carmona et al., 2013). 
One group has also examined the role of WT1 in the development of the retina 
and olfactory system. In the olfactory system, Wt1 deletion resulted in thinner 
olfactory epithelia and fewer neuronal progenitor cells, with Wt1 +KTS deletion 
having a more severe phenotype than Wt1 –KTS deletion (Wagner et al. 
2005). In retinal development, Wt1 deletion resulted in thinner retinas, 
apoptosis of retinal ganglion cells and disruption of optic nerve growth (K.-D. 
Wagner et al., 2002; N. Wagner et al., 2002). WT1 has also been implicated 
in development of the sensory nervous system of the circumvallate taste buds 
(Y. Gao et al., 2014). This begins to implicate WT1 in neuron development. 
Immunohistological examination of human foetal tissues has also revealed 
extensive WT1 expression in skeletal muscle myofibres throughout 
development (Salvatorelli et al., 2011; Magro et al., 2015), though this requires 
further investigation. A relatively novel and exciting role for WT1 appears to be 
in adipose tissue formation, where it was shown that a proportion of visceral, 
but not subcutaneous adipose tissue develops from progenitors which arise 
from the adipose mesothelium and are WT1+ (Chau et al., 2014). This perhaps 
goes some way to explaining the otherwise idiosyncratic observation that 
Wilms’ tumours occasionally form ectopic adipose tissue (Schumacher et al., 
2003). 
WT1 is implicated in a broad range of developmental contexts, regulating 
development in numerous tissues in a temporal-specific manner. This 
suggests the actions of WT1 relate to regulation of the same cellular and 
molecular processes across contexts. Study to date suggests one of these 
processes is the regulation of EMT and MET (indeed the mammalian embryo 
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is generated by a number of cycles of EMT and MET) though there are 
undoubtedly other related or unrelated roles for WT1 in development. 
1.1.3 WT1 in Adult Tissue Homeostasis and Repair 
Despite its widespread expression and function in development, Wt1 is 
expressed only in a few discrete cell populations in the healthy mammalian 
adult. Many of these cells are from tissues in which WT1 has an intrinsic 
developmental role. These include the podocytes of the kidney, a small 
proportion of the epicardial cells of the heart, the Sertoli cells of the testis, 
granulosa cells of the ovaries and a small proportion of cells in the bone 
marrow (Hastie, 2017). WT1 expression is also found in cells of the mammary 
gland, though this has not been examined in much detail (Artibani et al., 2017). 
As previously shown, Wt1 mutation or deletion in the developing embryo 
causes severe defects in numerous tissues. However, in a pioneering study, 
Wt1 deletion in adult mice resulted in acute multiple organ failure (Chau et al., 
2011), specifically, oedema, glomerulosclerosis, deterioration of fat and bone, 
reduction in red blood cells, atrophy of the pancreas and spleen and a 
reduction in heart weight. This was attributed to effects on organ-specific 
progenitor and stem cell populations and a general reduction in some 
circulating serum proteins, including IGF-1. This demonstrates beyond doubt 
that WT1 is also essential for adult tissue homeostasis.  
1.1.3.1 Adult and Ischaemic Heart 
The main population of WT1+ cells in the adult heart are found in the epicardial 
outer layer and vascular WT1 expression in only a small proportion of 
endothelial cells within the large blood vessels (Duim et al., 2015). WT1 
expression is increased in the epicardium in models of myocardial infarction 
(MI) in mice. Epicardial cells post-injury are activated, form epicardium-
derived-cells (EPDCs), migrate inwards from the external epicardial layer and 
differentiate into cardiomyocytes and other cell types through EMT (van Wijk 
et al., 2012). In a number of studies, it has been found that post-MI, EPDCs, 
cardiomyocytes and coronary vascular cells (vascular smooth muscle cells 
(VSMCs) and endothelial cells) proximal to the infarct area express WT1 (K. 
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Wagner et al., 2002; Smart et al., 2011; Duim et al., 2015). Wt1 was also 
activated in the epicardium, EPDCs and cardiomyocytes and in areas of 
fibrosis in cardiac ischaemia reperfusion and in two models of hypertensive 
overload of the heart (constriction of the thoracic aorta and Angiotensin II 
(AngII) infusion) (Braitsch et al., 2013). Furthermore, WT1 regulates adult 
epicardial cell EMT post-MI through direct transcriptional regulation of Snail, 
VCAM-1 and Pdgfrα (Bax and Oorschot, 2011; von Gise et al., 2011; Takeichi 
et al., 2013). WT1 is therefore intrinsic to repair in the adult heart. 
1.1.3.2 Kidney Homeostasis and Repair 
The podocytes of the kidney are found within the glomerular capsule and align 
with endothelial cells of blood vessels, facilitating filtration. WT1 is expressed 
in adult podocytes throughout their life (Mundlos et al., 1993). It is worth noting, 
given the known role of WT1 in EMT and MET, that while podocytes are 
effectively epithelial, they express high levels of a number of mesenchymal 
markers (Miller-Hodges & Hohenstein 2012). WT1 directly regulates the major 
podocyte gene Nephrin (Wagner et al., 2004, 2006) and Podxl (Palmer et al., 
2001) and half the known podocyte-specific genes (Dong, Pietsch and Englert, 
2015; Kann et al., 2015; Lefebvre et al., 2015). Wt1 expression in normal and 
Denys-Drash podocytes inversely correlated with proliferation (Yang, Chen 
and Chen, 2004) and WT1 also appears to influence podocyte cytoskeletal 
architecture (Viney et al., 2007). 
As previously mentioned, (1.1.2.2) Wt1 mutation results in formation of a 
number of developmental renal disorders, however, WT1 is also implicated in 
some acquired kidney diseases: for example in nephrotic syndrome not arising 
from Wt1 mutation (Guan et al., 2003). The mammalian kidney has limited 
regenerative capacity in adults. In contrast, in Danio rerio, which have the 
capacity to renew kidney nephrons throughout adulthood, adult nephron 
forming progenitors also overexpressed Wt1a; one of the two fish Wt1 
orthologues(Arora et al., 2011). In mice, putative NCAM+ renal stem cells 
isolated from the kidney overexpressed Wt1 (Harari-Steinberg, Pleniceanu 
and Dekel, 2011). 
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The adrenal gland, immediately proximal to the kidney has greater 
regenerative capacity than the kidney itself. In development of the adrenal 
gland, formation of mature adrenal cells requires downregulation of WT1, with 
continued expression of WT1 maintaining cells in a progenitor state (Bandiera 
et al., 2013). Indeed, the adrenal gland has a proportion of WT1+ adrenal 
progenitor cells (APCs) in the outer mesenchymal capsule and zona 
glomerulosa, which migrate inwards and differentiate in regeneration of the 
adrenal (Wood and Hammer, 2011; Bandiera et al., 2013). In this respect, 
these APCs and adrenal regeneration have striking similarities with 
regeneration from the epicardium (1.1.3.1). 
1.1.3.3 Liver Regeneration 
The adult mammalian liver has a relatively high regenerative capacity. This is 
primarily attributable to hepatic stellate cells (HSCs). Among other functions, 
HSCs are effectively a liver-resident mesenchymal stem cell (MSC) 
population, activated in damaged liver to initiate regeneration (Kordes et al., 
2014). As previously discussed, WT1 is essential to hepatic development and 
despite only being expressed in HSCs, Wt1 KO livers lack a lobe, 
demonstrating the importance of WT1 in HSCs (Ijpenberg et al., 2008). HSCs 
have similarities to other tissue-resident WT1-expressing cell populations. 
HSCs, podocytes and Sertoli cells have similar functions and roles, as all these 
cells are found in close association with endothelial cells and form a functional 
filtration barrier with blood; HSCs are found in the space of Disse, where they 
associate with vascular endothelial cells and hepatocytes. Like epicardial cells 
and EPDCs, HSCs are activated in injury, become proliferative and stop 
synthesising RA (Ohata et al., 1997; Guadix et al., 2011). 
1.1.3.4 Adult Reproductive Organs 
Sertoli cells of the testis and granulosa cells of the ovaries share a common 
Wt1+/Sox9+ progenitor in the bipotential genital ridge prior to sex determination 
and these two distinct cell types then continue to express WT1 into adulthood 
(Albrecht and Eicher, 2001; Nakamura et al., 2008). WT1 is essential for 
maintaining Sertoli cell identity and function throughout life. This is 
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demonstrated by Wt1 KO in the testis, which results in transition of Sertoli cells 
into Leydig cells; conversely WT1 overexpression in Leydig cells causes them 
to express Sertoli cell markers (Zhang et al., 2015). Wt1 KO in adult Sertoli 
cells was also shown to induce Sertoli cell apoptosis and loss of adherence 
(Rao et al., 2006). As previously mentioned, inhibition of WT1 in female 
reproductive tissues in development impairs fertility and similarly in this adult 
Sertoli cell Wt1 KO, spermatogenesis was impaired and fertility reduced.  
The female reproductive system is unique in mammals, in that it undergoes a 
constant cycle of tissue formation, degradation and regeneration due to 
menstruation. During menstruation there is constant expansion and turnover 
of the endometrial layer. It has been found that WT1 is expressed in the 
endometrial stroma cells throughout this process and is particularly 
upregulated during transition of stroma cells into decidual cells (Zhou, 
Rauscher and Bondy, 1993; Makrigiannakis et al., 2001; Cousins et al., 2014). 
There is a significant contribution of epithelial cell migration and MET to this 
process, with which WT1 was implicated (Cousins et al., 2014). In 
endometriosis (ectopic formation of the endometrial lining of the uterus) WT1 
protein and gene expression is reduced in the stromal cells of the endometrium 
(Matsuzaki et al., 2005, 2006) and upregulated in the associated neurons 
(Coosemans et al., 2009), but with no  notable changes in microvascular WT1 
expression.  
WT1 has been studied extensively in mammary cancers, though to a much 
lesser extent in healthy mammary tissue. It has been noted, however, that 
WT1 is expressed in the breast and it is possible it could co-localise with a 
putative mammary gland progenitor cell niche (Villadsen et al., 2007; Artibani 
et al., 2017). 
1.1.3.5 WT1 in Fat and Bone Marrow 
As previously mentioned (1.1.3), Wt1 KO in adult mice results in significant 
loss of fat and bone tissue (Chau et al., 2011). WT1 expression was found in 
the adult mouse in all visceral fat depots: omental, retroperitoneal, perirenal, 
mesenteric, epididymal, and epicardial (Chau et al., 2014). In the adult, WT1 
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is expressed in a very small proportion (~1%) of all CD34+ haematopoietic 
precursor cells (Hosen et al., 2002). However, this small population clearly has 
an important role, as these isolated cells, following adult Wt1 KO were no 
longer capable of forming red blood cells (Chau et al., 2011); an observation 
which was replicated in vitro (Cunningham et al., 2013). This observation is 
explained by the fact that WT1 transcriptionally activated Erythropoeitin (EPO) 
which is required for red blood cell production (Dame et al., 2006). After 
isolating healthy WT1+ haematopoietic precursor cells it was found they could 
produce red blood cells, white blood cells and granulocytes and are therefore 
probably oligolineage-restricted haematopoietic progenitors (Chau et al., 
2011). In human haematopoietic cell lines, WT1 also appeared to control cell 
cycle progression and cell differentiation (L W Ellisen et al., 2001). 
Normal bone homeostasis relies upon bone synthesis by osteoblasts, which 
originate from MSCs, and bone reabsorption by osteoclasts, which originate 
from haematopoietic cells (Kusumbe, Ramasamy and Adams, 2014). A role 
for WT1 in these two cell types could explain the bone loss observed in adult 
Wt1 KOs. In support of this, in these adult Wt1 KO mice there was increased 
osteoclast formation, though Wt1 KO mesenchymal cells had a reduced 
capacity to generate osteoblasts (Chau et al., 2011). 
In a number of the contexts explored above, it can be seen that WT1 is 
maintained in a small proportion of adult cells and that these cell populations 
often have a degree of pluripotency and a necessity for the regulation of 
EMT/MET. A proportion of these WT1-expressing cells (podocytes, HSCs and 
Sertoli cells) form a filtration barrier between their resident tissues and 
endothelial cells and capillaries. Disruption of WT1 in the populations of WT1-
expressing adult cells has far reaching consequences, beyond effecting these 
WT1-expresing cells alone. Furthermore, these adult cells often have the 
capacity to recapitulate developmental processes to facilitate repair.  
1.1.4 WT1 in Cancer 
Despite its restricted expression in the adult, WT1 is widely expressed 
throughout a range of cancers, and as such, was ranked as the best 
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therapeutic cancer antigen by the National Cancer Institute (US) (Cheever et 
al., 2009). Consequently, there are a number of ongoing Phase I, II and III 
clinical trials, though no commercially available WT1 immunotherapeutic 
agents have been produced as yet (Coosemans et al., 2013; Koido et al., 
2014; Zauderer et al., 2016; Bigalke et al., 2017; Katsuda et al., 2017). The 
relatively low expression of WT1 in adult tissues adds to the attractiveness of 
WT1 as a cancer therapeutic targets, as side effects could be limited. An 
established approach in multiple cancers is to sensitise the host immune 
system to a particular antigen and the majority of anti-WT1 trials have 
attempted this utilising either T-lymphocytes (Makita, Hiraki and Azuma, 2002; 
Oka et al., 2004) or more recently dendritic cells (Coosemans et al., 2013; 
Koido et al., 2014; Takakura et al., 2015; Bigalke et al., 2017; Katsuda et al., 
2017) sensitised to WT1, with some positive outcomes on tumour regression. 
Incredibly, a proportion of CD8+ T-lymphocytes were found to be 
spontaneously activated by the WT1 antigen in the absence of any intervention 
in acute myeloid leukaemia (Scheibenbogen et al., 2002). 
A full review of the role of WT1 in cancer is beyond the scope of this 
introduction. However, a recent meta-analysis of WT1 in human cancer 
patients found that WT1 was expressed in a variety of solid tumours and was 
significantly correlated with poorer prognostic outcome and reduced survival 
(Qi et al., 2015). Intriguingly, WT1 can act as both a tumour suppressor, such 
as in Wilms’ tumour (Call et al., 1990), but as an oncogene in other cancers 
such as leukaemia, lung cancer and breast cancer (Miller-Hodges & 
Hohenstein 2012). As well as being expressed in cancers characteristic of all 
the tissues in which WT1 functions during adulthood and development, WT1 
is also present in cancers of tissues in which WT1 is not normally present 
(reviewed by Sugiyama 2010) (Figure 1.2). First, an overview of the general 
function of WT1 in cancers, then a specific discussion of the role of WT1 in 




Figure 1.2. WT1 expression in a variety of cancers. Figure adapted from Sugiyama 
(2010). Overexpression was determined by WT1 immunohistochemistry and/or RT 
qPCR. Positivity (%) denotes the % of tumours with WT1 overexpression. AML = 
acute myeloid leukaemia, ALL = acute lymphoid leukaemia.  
 
1.1.4.1 The Function of WT1 in Cancer 
WT1 overexpression in cancers is evidently pathological, as WT1 expression 
in development, homeostasis and disease is tightly regulated in a 
spatiotemporal manner. This has proved sufficient to highlight WT1 as a 
therapeutic target, however, it is important to interrogate the role of WT1 in 
different cancers in order to better understand the effect of therapeutically 
targeting WT1, as well as provide a deeper understanding of the function of 
WT1 in general. Simplistically, research to date has shown WT1 in cancer to 
regulate four major processes: cell proliferation, apoptosis, cell migration and 
cell transition (specifically EMT and MET). Misregulation of these processes 




In a number of different cancer types, higher levels of WT1 expression within 
tumour tissue was associated with increased malignancy and worse patient 
outcomes (Miyoshi et al., 2002; Cui et al., 2014; Rauscher et al., 2014). 
However, it should also be noted that in one study of serous ovarian 
carcinoma, high WT1 expression was a positive prognostic predictor of 
outcome (Taube et al., 2016). This duplicity in WT1 action is often observed 
due to its bidirectional regulatory potential, though this could also demonstrate 
differences between different cancer types and how a process which is 
beneficial in one cancer can be detrimental in another.  
Along with generally predicting a worse outcome, increased WT1 expression 
and decreased WT1-anti-sense (WT1-AS) RNA expression were associated 
with increased cell proliferation (Ashiba et al., 2007; Xu et al., 2013; Du et al., 
2015; Atik et al., 2016; Barresi et al., 2016). WT1 has also been shown to 
modulate apoptosis in tumour cells through regulation of p53 and bcl-2 
(Maheswaran et al., 1995; Mayo et al., 1999; Tatsumi et al., 2008) and cell 
migration (Barbolina et al., 2008; Brett, Pandey and Fraizer, 2013a; Wu et al., 
2013; Lin et al., 2016). In one in vitro study of prostate cancer cells, WT1 was 
shown to directly regulate E-Cadherin, consequently promoting EMT and cell 
migration (Brett, Pandey and Fraizer, 2013a). EMT in cancer is known to 
promote tumour growth and metastasis (Kudo-Saito et al., 2009). WT1 target 
genes Snail, Slug, Twist, VEGF and β-Catenin are implicated in EMT in cancer 
(Mak et al., 2010; Li and Zhou, 2011; Haslehurst et al., 2012). 
1.1.4.2 WT1 in Tumour Angiogenesis 
WT1 is widely expressed in the vasculature of tumours and WT1 expression 
has been shown to correlate with increased tumour angiogenesis and 
therefore, greater micro-vessel density within tumours (Dohi et al., 2010; 
Galfione et al., 2014; Katuri et al., 2014; De Palma et al., 2016). WT1 directly 
regulates tumour angiogenesis in these cancer tissues through a number of 
mechanisms. WT1-expressing tumours have higher levels of pro-angiogenic 
factors such as VEGF, MMP9, Ang-1, and Tie-2 (Dohi et al., 2010; Katuri et 
al., 2014). Furthermore, Telomeric repeat binding factor protein 2 (TRF2), a 
direct target of WT1, transcriptionally regulates tumour angiogenesis by 
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activating Pdgfrβ (El Maï et al., 2014, 2015). WT1 is also co-expressed with 
Proliferating cell nuclear antigen (PCNA), Nestin and ETS-1 in tumour 
vasculature (Wagner et al., 2008). Angiogenesis is an essential process in 
establishment and progression of all cancers, as it provides tumour tissue with 
the oxygen and nutrients required. In metastasis, cancer cells use the tumour 
blood supply to disseminate throughout the body. Unsurprisingly then, 
increased WT1 expression in the tumour microvasculature is associated with 
an increased rate of tumour growth, higher recurrence rate and shorter survival 
(Barresi et al., 2015, 2016). As a direct demonstration of the importance of 
WT1 in tumour angiogenesis, endothelial cell-selective Wt1 KO induced 
dramatic regression of tumour vasculature which was sufficient to significantly 
reduce the size of tumours, reduce metastasis and consequently increase 
survival in mice (Wagner et al., 2014).  
1.2 Angiogenesis 
Angiogenesis is the process of new blood vessel formation from existing 
vasculature. It can occur by two main mechanisms; sprouting angiogenesis 
and intussusception. Intussusceptive angiogenesis was first proposed in 1986, 
when electron-scanning microscopy revealed the formation of intraluminal 
pillars within the existing microvasculature with the capacity to induce vascular 
remodelling (Caduff, Fischer and Burri, 1986). Intussusception (reviewed by 
Makanya et al. 2009) is capable of inducing vessel branching, splitting or 
regression relatively rapidly. More recently discovered, a third possible 
process of angiogenesis, which may occur independently or concurrently with 
sprouting and intussusceptive angiogenesis, involves the recruitment of 
circulating endothelial progenitor cells (EPCs) into vessel walls (Asahara et 
al., 1997).  
In developmental contexts, vasculogenesis, de novo formation of vessels from 
precursor cells, and angiogenesis work in tandem to generate the vascular 
network. In the adult, angiogenesis is restricted to only a few specialised 
contexts and tissues, except in pathological circumstances, in which 
angiogenesis can be regenerative or degenerative. In the context of 
cardiovascular disease, arterial occlusion and the resultant downstream 
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hypoxia triggers angiogenesis which remodels the vasculature to resupply 
blood to the ischaemic tissue. This review will primarily cover sprouting 
angiogenesis, which has the greatest potential to reperfuse ischaemic tissues. 
Angiogenesis is initiated in and has the potential to form capillaries, arteries 
and veins (as well as lymph vessels in lymphangiogenesis). To avoid 
unnecessary repetition, description of sprouting angiogenesis will be covered 
from a capillary-centric standpoint, though the mechanisms in all forms of 
blood vessels are broadly the same. The sequential processes dictating 
angiogenesis will be outlined below, with some discussion of the key molecular 
signals required. 
1.2.1 Cellular and Molecular Mechanisms of Angiogenesis 
Sprouting angiogenesis is a complex and highly-regulated, multi-step process 
involving the coordinated action of a number of cell types, cellular processes 
and molecular players. In adult capillaries, quiescent endothelial cells line the 
luminal surface in a monolayer of phalanx shaped cells, interconnected by cell 
junctions and cell adhesion proteins. External to this layer, endothelial cells 
are in contact with pericytes, occasionally with other perivascular cells, 
fibroblasts and inflammatory immune cells, and in veins and arteries, a 
VSMCs. Quiescent endothelial cells and pericytes are attached to a common 
basement membrane. As the primary luminal surface of blood vessels and 
therefore the “tube” component through which blood flows, endothelial cells 
are effectively the functional unit of angiogenesis, though pericytes, smooth 
muscle cells, fibroblasts and immune cells all have an indispensable role. 
Herein is provided an overview of the main processes and players in 
angiogenesis, which should be sufficient to understand the work described in 








Figure 1.3. The cellular and molecular basis of sprouting Angiogenesis. 
Depicted is a cross-sectional representation of a capillary during new vessel formation 
by sprouting angiogenesis. A) A quiescent intact vessel is B) activated by angiogenic 
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factors, as a result of ischaemia, factors released from proximal vessels and signal 
from fibroblasts and inflammatory immune cells. This leads to a number of changes 
in vessel morphology, including prioritisation of an endothelial tip cell which will go on 
to guide the new vessel formation. C) Tip cell progresses, while the endothelial cells 
in the stalk proliferate and form a lumen. D) Eventually, the tip cells and stalk cells 
make contact with another vessel and fuse with it to form a competent vessel, which 
reverts back to a quiescent state. Cell types and components are labelled. Text in 
black denotes processes, while text in blue denotes proteins and genes associated 
with each process. Adapted from Carmeliet & Jain (2011). 
 
1.2.1.1 Initiation of Sprouting Angiogenesis and Tip Cell 
Prioritisation 
Quiescent vessels can be activated by detection of low oxygen levels 
(hypoxia), which brings about transcriptional changes, by external signals 
released by fibroblasts, inflammatory immune cells, or, in the case of tumour 
angiogenesis, by tumour cells. Endothelial cells are sensitive to local oxygen 
levels due to oxygen-sensing proteins such as proxyl hydroxylase domain 
(PHD) proteins. One of the targets of this family of proteins are HIFs, 
considered to be the key transcriptional activators of the response to hypoxia. 
In normoxia, PHDs hydroxylate HIF-1α and HIF-2α, but in hypoxia PHDs are 
inactive and HIFs become active, initiating transcription of a number of genes 
important to regulation of angiogenesis (Berra et al., 2008; Fraisl et al., 2009). 
HIF-1α and HIF-2α both activate transcription of VEGFs, essential proteins for 
the progression of angiogenesis (Nagy, Dvorak and Dvorak, 2007). Other key 
signals for initiation of sprouting angiogenesis include fibroblast growth factors 
(FGFs), Angiopoietins (ANGs) and chemokines (Carmeliet and Jain, 2011).  
Commonly the first cells activated in angiogenesis, pericytes first detach in 
response to ANG-2 released from endothelial cells and proteolytically degrade 
the basement membrane through release of MMPs, including MMP9 (Augustin 
et al., 2009). This occurs focally to allow liberation of endothelial cells from 
their monolayer without completely disrupting the morphology of the vessel. 
ANG-1 released by pericytes activates the Tie-2 receptor in endothelial cells 
(Augustin et al., 2009). Mediated primarily by VEGF, endothelial cells loosen 
both their adherens cell junctions (involving catenins and cadherins such as 
VE-Cadherin) and their tight cell junctions (involving claudins and occludins) 
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(reviewed by Potente et al. 2011). Endothelial cells simultaneously induce 
vasodilation through release of nitric oxide (NO). VEGF and ANGs, also 
activate the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, which 
regulates cell proliferation, adhesion, migration and invasion and, hence, has 
an important role in angiogenesis (Karar and Maity, 2011). The increased 
vascular permeability allows extravasation of plasma proteins, including 
fibrinogen and fibronectin which provide a provision matrix along which cells 
can migrate. 
After these processes have effectively primed the vessel to undergo 
angiogenesis, a fascinating event characteristic of sprouting angiogenesis 
occurs, as an endothelial tip cell is established. In an elegant experiment, it 
was shown that endothelial cells dynamically compete for tip cell position, with 
relative expression levels of Vegfr1 and Vegfr2, in combination with delta-like 
4 (Dll4)–Notch signalling, determining whether cells adopt a tip cell fate, or 
become supporting stalk cells (Jakobsson et al., 2010). Tip cells have a 
distinctive morphology, with numerous extending filipodia and establish 
themselves at the tip of angiogenic outgrowths, with endothelial stalk cells 
comprising the main body of newly forming vessels. Formation of tip cell 
filipodia and associated stress fibres is regulated by the Rho family GTPases 
Cdc42, Rac1 and RhoA (Defilippi et al., 1999; Pollard and Borisy, 2003; De 
Smet et al., 2009). Tip cells have high migratory capacity and low proliferative 
capacity, whereas conversely, stalk cells have low migratory capacity and high 
proliferative capacity. Even with the same signal, VEGF-A binding to VEGFR2 
in stalk cells results in increased endothelial proliferation, while in tip cells, a 
VEGF-A concentration gradient drives guided migration (Gerhardt and 
Betsholtz, 2003).  
1.2.1.2 Angiogenic Vessel Outgrowth and Lumen Formation 
In order for angiogenesis to be effective, angiogenic vessel outgrowths need 
to elongate, follow guidance signals, undergo controlled branching and be 
competent to support blood flow. Tight regulation of this process ensures that 
angiogenic vessels perfuse tissues most in need of an increased blood supply. 
Angiogenic vessel outgrowth progression, led by endothelial tip cell migration 
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and enabled by stalk cell proliferation and pericyte migration, is driven by a 
combination of attraction and repulsion guidance cues. This is demonstrated 
by the Neuropilin-1 receptor (NRP1), expressed in endothelial cells; binding of 
VEGF165 to NRP1 promotes endothelial migration, whereas binding of 
Collapsin-1 or Semaphorin-3 (Sema3) inhibits migration (Miao et al., 1999). 
As previously mentioned, endothelial tip cells migrate along an external VEGF 
concentration gradient; in addition other attraction guidance cues include SDF-
1, CXCL12 and some repulsion cues include Netrin-1 and Robo4 (Potente et 
al. 2011). Semaphorins, Ephrins, Slits, Netrins and some other factors 
important in endothelial cell guidance in angiogenesis are also essential to 
axon guidance, while endothelial tip cells and axon growth cones have a 
number of morphological and functional similarities. This implies a degree of 
overlap in regulatory pathways between the two processes (Klagsbrun and 
Eichmann, 2005; Eilken and Adams, 2010). 
Endothelial tip cells further mediate migration of angiogenic vessels through 
proteolytic degradation of the ECM to generate vascular guidance tunnels 
through which vessels can form. To mediate proteolytic degradation, tip cells 
produce MMP-14 and MMP-2, which are restricted to tip cells and not 
expressed in stalk cells during angiogenesis (Karagiannis and Popel, 2006; 
Yana et al., 2007; Stratman et al., 2009). Due to the dynamic competition for 
tip cell identity, stalk cells can adopt a tip cell fate, as previously described and 
migrate away from the existing angiogenic vessel outgrowth to form a new 
vessel branch. Branching structure is determined by a number of factors, 
including VEGF concentration, VEGF-A regulation of Flt-1/Flk-1signalling, 
Notch/Dll4 signalling, Heparin and ECM interactions (Ruhrberg et al., 2002; 
Suchting et al., 2007; Kappas et al., 2008; Chappell et al., 2016; Ubezio et al., 
2016). 
Pericytes proximal to this forming endothelial vessel outgrowth proliferate and 
migrate onto the primitive vessel outgrowth, acting as structural support 
throughout sprouting angiogenesis. Endothelial cells release Pdgfβ which 
binds to the pericyte Pdgfrβ receptor, promoting pericyte proliferation and 
migration onto the forming endothelial outgrowth (Gaengel et al., 2009). 
Sphingosine-1-phosphate (S1P) and S1P receptor (S1PR) signalling also 
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control endothelial cell and pericyte interactions, regulating cytoskeletal, cell 
adhesion, cell proliferation, migration and survival (Gaengel et al., 2009; Lucke 
and Levkau, 2010). 
In stalk cells, Notch-regulated ankyrin repeat protein (NRARP) and Sirtuin-1 
(SIRT1) act to inactivate Notch, which promotes the increased stalk cell 
proliferation essential to elongation of the angiogenic vessel outgrowth (Phng 
et al., 2009; Guarani et al., 2011). As vessels grow and expand, stalk cells 
begin to form a vessel lumen in order to accommodate blood flow by adjusting 
their shape and rearranging their junctions. The contacts between stalk cells 
are mediated by VE-Cadherin junctions, which act with VEGF-A to recruit 
CD34, Sialomucins, Moesin, F-actin, and Myosin II to the endothelial cell 
surface and define the luminal surface (Strilic et al., 2009). These negatively 
charged glycoproteins act to repel endothelial cells away from the junctions. 
Rho-associated protein kinase (ROCK) and Ras-interacting protein 1 
(RASIP1) induce changes in cell adhesion and rearrange the cytoskeletal 
architecture to expand the endothelial lumen (Bryan et al., 2010; Davis et al., 
2011; Xu et al., 2011; Koo et al., 2016). 
1.2.1.3 Fusion, Perfusion and Maturation 
Anastomosis is the process by which angiogenic vessel outgrowths fuse with 
other vessels and establish perfusion. Apposing vessels initiate tip cell contact 
and consolidate connections through VE-Cadherin junctions (De Smet et al., 
2009). Endothelial cells migrate outwards to form a functional vessel 
connection, extracellular matrix is deposited to generate a coherent basement 
membrane. Pericytes mature into a stable vascular lining through ANG-1/Tie-
2 and TGFβ signalling (Augustin et al., 2009; Pardali, Goumans and ten Dijke, 
2010). Newly formed vessels are then capable of supporting blood flow and 
are shaped by haemodynamic forces. Shear stress of blood flow in the 
endothelial lumen activates the shear stress responsive transcription factor 
Krüppel-like factor 2 (KLF2), which in turn activates the PI3K and MAPK 
survival pathways (Nicoli et al., 2010; Aksamitiene, Kiyatkin and Kholodenko, 
2012; Boras et al., 2014). 
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Evidently, effective tissue perfusion and nutrient delivery is dependent upon, 
not only competent individual vessels, but a well organised vascular network. 
The vascular network is structurally stabilised by pericytes, which deposit ECM 
and form cross-links between new vessel connections. Remodelling of the 
vascular network topology can occur by further sprouting angiogenesis and 
intussusceptive angiogenesis to fine-tune oxygen delivery. In contrast, vessels 
which are superfluous or do not support blood flow are pruned. Visualisation 
of vascular pruning demonstrates that this occurs by coordinated 
intussusception, endothelial cell apoptosis and endothelial cell migration 
(Lenard et al., 2015). This can be mediated by low haemodynamic stress, low 
VEGF levels, FGD5 activation of Cdc42 and a number of Wnt ligands, 
including Wnt5a (Hlushchuk et al., 2011; Cheng et al., 2012; Korn et al., 2014). 
1.2.2 Non-Vascular Cells in Angiogenesis 
Alongside endothelial cells and pericytes which can be thought of as the 
primary players in angiogenesis, it is becoming increasingly clear that a 
number of other cell types play an intrinsic role in regulation of angiogenesis, 
either by direct mediation or release of signals.  
1.2.2.1 Monocytes, Macrophages and Dendritic Cells 
Circulating chemoattractant angiogenic signals activate monocytes, 
macrophages and dendritic cells and recruit them to the site of angiogenesis 
from within the circulation and perivascular space. Among these signals are 
Granulocyte stimulating colony-stimulating factor (G-CSF) (Shojaei et al., 
2009; Schuett et al., 2017), Monocyte chemoattractant protein 1 (MCP-1) 
(Ueno, Toi and Saji, 2000) and β-defensin (Conejo-Garcia et al., 2004) 
released by endothelial cells.  
Macrophages regulate and often initiate angiogenesis through paracrine 
effects and direct interaction with vascular cells. Macrophages secrete VEGF-
A, MMPs, MCP-1, Interleukins, TGF-β and even microRNAs which elicit 
responses in endothelial cells, pericytes and VSMCs (Li et al., 2013; Zajac et 
al., 2013; Jaipersad et al., 2014; Jetten et al., 2014; Okizaki et al., 2015). The 
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PI3K/Akt signalling pathway in macrophages controls their regulation of HIF-
1α and HIF-2α in angiogenesis (Joshi et al., 2014). HIF-1α is one of the factors 
controlling macrophage-endothelial cell-cell contact (Gerri et al., 2017). 
Macrophages attach to endothelial cells by binding of their specific integrin 
receptor, Macrophage adhesion ligand 1 (Mac-1), to endothelial adhesion 
molecules and regulate processes, including ECM degradation and perhaps 
most importantly, anastomosis (reviewed by Jaipersad et al. 2014; Fantin et 
al. 2009; Outtz et al. 2011). There is a diversity of macrophage phenotypes 
and lineages and it has been suggested that anti-inflammatory M2 
macrophages are more pro-angiogenic than pro-inflammatory M1 
macrophages (Jetten et al., 2014; Okizaki et al., 2015). Indeed, endothelial 
cells seem to actively support differentiation of macrophages into an M2 state 
(He et al., 2012).  
Dendritic cells also produce a number of pro- and anti-angiogenic proteins, 
including VEGF-A and respond to angiogenic signals from other cells (Sozzani 
et al., 2007). Immature, VEGFR2-expressing dendritic cells promoted 
angiogenesis in the endometrium, dramatically increasing endothelial cell 
migration (Fainaru et al., 2007).  
Intriguingly, monocytes, macrophages and dendritic cells appear to have 
some capacity to differentiate into endothelial-like cells. In damaged skeletal 
muscle tissue, macrophages were essential for vascular remodelling and 
regulated endothelial-to-mesenchymal transition (EndoMT), which occurred 
aberrantly in the absence of macrophages (Zordan et al., 2014). In another 
study, macrophages treated with the angiogenic factors VEGF, FGFs and IGF-
1 developed a more endothelial phenotype and were capable of forming tube-
like structures (Schmeisser et al., 2001). Accordingly, dendritic cells also 
differentiated into endothelial-like cells on treatment with VEGF-A and could 
form tube like structures in vitro (Pujol et al., 2001).  
1.2.2.2 Neutrophils 
Neutrophils are essential to the inflammatory response, acutely accumulating 
in the early stages of tissue and vascular inflammation (reviewed by Phillipson 
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& Kubes 2011). Similarly, in angiogenesis neutrophils are primarily associated 
with angiogenic vasculature during initial onset of angiogenesis and have been 
implicated in initiating the angiogenic response in a number of contexts; the 
main neutrophil released factors in these contexts are VEGF-A, MMP9, 
macrophage inflammatory protein 1α (MIP-1α) and macrophage inflammatory 
protein 2   (MIP-2) (Nozawa, Chiu and Hanahan, 2006; Ardi et al., 2007; Gong 
and Koh, 2010; Christoffersson et al., 2013).  
1.2.2.3 Mast Cells, Eosinophils and Basophils 
The inflammatory myeloid cells, primarily responsible for allergic reactions, 
eosinophils, basophils and mast cells have a putative, but minimally 
investigated, role in angiogenesis. Through unknown mechanisms, 
eosinophils induce endothelial cell proliferation, upregulation of VEGF and 
induce angiogenesis in vitro and in vivo (Puxeddu, Alian, et al., 2005). Mast 
cells influence angiogenesis to some extent and release angiogenic factors 
including VEGF, bFGF and IL-8 (Reed, Albino and McNutt, 1995; Boesiger et 
al., 1998; Kim et al., 2010). Basophils express the angiogenic factors NRP1, 
NRP2, VEGF-A, VEGF-B and VEGFR2 (de Paulis et al., 2006). In allergic 
diseases such as asthma, and in tumour angiogenesis, eosinophils, basophils 
and mast cells seem to interact and overlap in their roles, resulting in increased 
angiogenesis (Puxeddu, Ribatti, et al., 2005; Crivellato, Travan and Ribatti, 
2010; Marone et al., 2016). 
1.2.2.4 T-Lymphocytes and B-Lymphocytes 
The cells of the adaptive immune system, T- and B-lymphocytes, have been 
implicated in allergy-associated angiogenesis and tumour angiogenesis. It has 
been shown that lymphocyte express IL-17F, STAT3 and IL-25, the latter of 
which induced the PI3K/Akt and Erk/MAPK pathways in endothelial cells 
(Starnes et al., 2001; Corrigan et al., 2011; Yang et al., 2013). This is of 
relevance as these factors have all be implicated in angiogenesis (Starnes et 
al., 2001; Wei et al., 2003; Corrigan et al., 2011; Karar and Maity, 2011). 
However, perhaps due to the normal localisation of lymphocytes in bone 
marrow and the lymph nodes and the necessity for their activation by antigen-
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presenting cells, their role in angiogenesis appears tangential, with no 
evidence to date that disturbing lymphocyte function impairs angiogenesis. 
 
1.2.2.5 Fibroblasts 
Fibroblasts are the primary cell type responsible for extracellular matrix and 
collagen deposition and hence provide extracellular matrix in angiogenesis 
along which endothelial cells migrate during sprout formation. Following 
ablation of fibroblasts in vitro, angiogenic vessel outgrowths fail to form an 
endothelial lumen (Newman et al., 2011). Fibroblasts also regulate 
angiogenesis through p53-mediated expression of Thrombospondin-1 (an 
anti-angiogenic factor) (Dameron et al., 1994). EndoMT is capable of 
generating fibroblasts from endothelial cells. Fibroblasts appear to have a 
degree of native plasticity and also generate endothelial cells through the 
reverse process, mesenchymal-to-endothelial transition (Ubil et al., 2014). 
This p53-regulated fibroblast-to-endothelial transition contributed to cardiac 
repair post-MI attributable to increased neovascularisation of the injured heart 
(Ubil et al., 2014). 
1.2.2.6 Stem Cells and Progenitors 
Angiogenesis is effectively a recapitulation of developmental processes with 
an accompanying reversion towards a more pluripotent phenotype in 
angiogenic cells. It is therefore, intuitive that a number of stem and progenitor 
cell populations have been shown to participate in angiogenesis. As 
established, most immune cells have a degree of involvement in angiogenesis. 
In adults, there is a circulating niche of undifferentiated haematopoietic stem 
cells (HSCs); the progenitors to myeloid cells, lymphocytes, erythrocytes, 
megakaryocytes and platelets. HSCs also increasingly appear to be the origin 
of endothelial progenitor cells. This relationship is reciprocal, as bone marrow 
Notch+/Akt+ endothelial cells maintain HSC self-renewal through paracrine 
release of angiocrine signals (Butler et al., 2010; Kobayashi et al., 2010). 
EPCs have been found to secrete angiogenic growth factors including VEGF, 
Hepatocyte growth factor (HGF), G-CSF and GM-CSF (Rehman et al., 2003). 
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Late, but not early EPCs were also capable of forming tubules and 
incorporating into existing endothelial cell tubules in vitro (Sieveking et al., 
2008). However, EPCs and HSCs synergistically facilitated angiogenesis to a 
greater extent than EPCs or HSCs in isolation (Yoon et al., 2005). 
Another stem cell population in adults is the mesenchymal stem cell (MSC) 
population, which is capable of generating adipose progenitor cells (APCs) 
and osteoblasts, among other cell types (Barclay et al., 2012). Numerous 
studies with MSC implantation into the ischaemic myocardium post-MI have 
shown the angiogenic potential of MSCs to increase angiogenesis and repair 
through release of angiogenic signals and exosomes which influence 
endothelial cell function and transition of MSCs into endothelial-like cells (Silva 
et al., 2005; Wu et al., 2007; Hu et al., 2008; Bian et al., 2014; Anderson et al., 
2016; Gong et al., 2017). APCs are capable of enhancing angiogenesis both 
in vitro and in vivo and like MSCs, release exosomes containing pro- and anti-
angiogenic factors (Lopatina et al., 2014; Bejar et al., 2016; Cheng et al., 
2017). Of clinical relevance, in murine models of diabetes, the APC niche was 
depleted and this contributed to a proportion of the impaired angiogenesis 
observed in diabetes (Rennert et al., 2014). Osteoblasts and the myeloid-
derived cell type osteoclasts are primarily involved in bone formation, however, 
they are also capable of expressing VEGF-A and participating in angiogenesis 
(Tombran-Tink and Barnstable, 2004; Hoogendam et al., 2014). Furthermore, 
osteoblasts enhance the migration of HSCs from the bone marrow and 
mediate the angiogenic activity of EPCs and HSCs (Kusumbe, Ramasamy and 
Adams, 2014; Chen et al., 2017; Tsirkinidis et al., 2017). As angiogenesis is 
essential for bone formation and regeneration, the involvement of osteoblasts 
and osteoclasts in angiogenesis is not counter-intuitive (Stegen, van Gastel 
and Carmeliet, 2015).(D’Alessio et al., 2015) 
1.2.3 Developmental Angiogenesis 
Vasculogenesis is the primary mechanism of embryonic vascular network 
formation. In embryonic vessel formation, vasculogenesis generates a 
primitive vascular plexus by aggregation of angioblasts, which differentiate into 
endothelial cells and form new blood vessels. Angiogenesis occurs to remodel 
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this plexus into a competent vascular network. The mechanism of 
developmental sprouting angiogenesis is broadly similar to that described 
previously (1.2.1) and remodelling also occurs to some extent by 
intussusception and EPC recruitment. Angiogenesis is crucial for development 
of all organs to supply oxygen and nutrients to developing tissues and maintain 
this by remodelling the vasculature as these organs grow and develop.  
1.2.4 Physiological Angiogenesis 
Post-development, angiogenesis is arrested in most organs, except in a few 
discrete contexts. The main site of angiogenesis in the healthy adult organism 
is the female reproductive system, specifically the mammary gland and uterine 
endometrium. Mammalian vertebrates have a regular menstrual cycle, during 
which the endometrial lining of the uterine tract undergoes a formidable cycle 
of tissue expansion, degradation and shedding. This is accompanied by tissue 
neovascularisation by angiogenesis followed by vessel breakdown (Cousins 
et al., 2014). This degree of tissue turnover in any other mammalian tissue 
would cause extensive, irreversible damage, though due to coordinated tissue 
formation and angiogenesis the uterus is capable of undergoing up to 400 
cycles during a woman’s life (Cousins et al., 2014). Vessels in the 
endometrium have an unusual tortuous, spiral morphology (Pijnenborg, 
Vercruysse and Hanssens, 2006). If an ovum embeds in the uterine lining, 
further angiogenesis occurs to support the continued expansion of the 
decidualised endometrium and progesterone secreting corpus luteum during 
establishment of pregnancy and to establish the placenta.  
Unlike in other tissues, progesterone and oestrogen play a crucial role in 
initiating and regulating angiogenesis in the endometrium. These two 
hormones activate angiogenic signals, including VEGF-A, in normal uterine 
physiology and in pregnancy (Greb et al., 1997; Walter, Rogers and Girling, 
2005; Kim et al., 2013; Zhang et al., 2017). The MAPK pathway and Leptin-
activated STAT3 have also been implicated in endometrial angiogenesis (Hu 
and Zhang, 2017; Vargas et al., 2017). Leukocytes play a regulatory role by 
releasing angiogenic factors in the uterus, including Placental growth factor 
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(PGF), essential to angiogenesis in pregnancy and the placenta (Li et al., 
2001; Lima et al., 2014; Rätsep et al., 2014). 
Similarly, the adult mammary gland goes through a physiological, cyclic 
expansion, differentiation and degradation in response to the menstrual cycle 
and more broadly, the oestrus cycle (Andres and Strange, 1999). Therefore, 
the mammary gland also undergoes regular cycles of angiogenesis (Durando 
et al., 2011; Shao and Zhao, 2014). 
1.2.5 Tumour Angiogenesis 
Tumours require a vascular network to grow; angiogenesis is a hallmark of all 
cancers and is even enhanced in leukaemia (Schmidt and Carmeliet, 2011). 
While the majority of pathways and mechanisms of tumour angiogenesis 
overlap with angiogenesis in other contexts, tumour angiogenesis, like 
tumorigenesis in general is a mis-regulated pathological process and 
therefore, results in an abnormal vascular morphology. Tumour angiogenesis 
is generally initiated by VEGF-A overexpression as a result of upregulation of 
HIF-1α and STAT3 in tumour cells (Zhong et al., 1999; Wei et al., 2003; Olsson 
et al., 2006; Nagy, Dvorak and Dvorak, 2007). Consequently, a lack of 
organised angiogenesis results in torturous, serpentine blood vessels, which 
are permeable, prone to bleeding, frequently lack pericytes and may carry 
blood in one direction one moment, only to be perfused in the opposite 
direction the next (Nagy et al., 2009). These vessels are even sometimes 
completely unperfused (Nagy et al., 2009). While tumour angiogenesis is 
essential to provide nutrients and oxygen to the developing tumour, poorly-
regulated angiogenesis is also responsible for areas of tumours becoming 
ischaemic and necrotic as they expand. 
Recognising the importance of angiogenesis in cancer progression, there are 
now a number of anti-angiogenic drugs deployed in combination with 
chemotherapy (reviewed by Vasudev & Reynolds 2014). These include 
inhibitors of VEGF signalling such as Bevacizumab, Sunitinib and Aflibercept 




1.2.6 Pathological Angiogenesis 
The main disease associated with pathological angiogenesis is retinopathy, 
damage to the ocular retina by vessel remodelling and expansion. There are 
broadly two types of retinopathy; non-proliferative retinopathy, as a result of 
hypertension (hypertensive retinopathy) or premature birth (diabetes of 
prematurity) pathologically remodelling or damaging the retinal blood vessels 
and proliferative retinopathy as a result of diabetes (diabetic retinopathy) 
bringing about aberrant angiogenic overgrowth of the vascular network. This 
can ultimately result in blindness. The angiogenesis which occurs in 
proliferative retinopathy is closely linked to inflammatory processes and 
consequently, numerous angiogenic factors and inflammatory cytokines are 
implemented in the progression of retinopathy (Gologorsky, Thanos and 
Vavvas, 2012; Zhou, Wang and Xia, 2012; Simó, Sundstrom and Antonetti, 
2014; Babapoor-Farrokhran et al., 2015). 
Endometriosis is a common gynaecological disease in which endometrial 
tissue arises outside the uterine tract. As with normal endometrial tissue, these 
ectopic endometrial lesions require a dense vascular network to survive and 
proliferate. Consequently, a combination of vasculogenesis and angiogenesis 
occurs to establish and maintain endometrial lesions in angiogenesis. 
Alongside VEGF from epithelial and stromal endometriotic cells, angiogenic 
and inflammatory signalling by immune cells drives pathological angiogenesis 
in endometriosis, particularly VEGF and Interleukin release by peritoneal 
macrophages, neutrophils and lymphocytes (reviewed by Gazvani & 
Templeton 2002; Groothuis 2012). Anti-angiogenic therapy is not routinely 
deployed to treat endometriosis, though experimentally inhibiting 
angiogenesis has been effective in reducing lesion size and impairing growth. 
This suggests that anti-angiogenic drugs could be more routinely deployed in 
endometriosis in the future (Laschke et al., 2006; Laschke and Menger, 2012; 
Edwards et al., 2013). 
1.2.7 Regenerative Angiogenesis 
While angiogenesis in the adult is restricted to a few discrete situations and 
pathological processes, angiogenesis has huge regenerative capacity across 
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a range of diseases, supporting tissue remodelling and formation of new 
tissue. Some of the myriad contexts in which angiogenis is beneficial include, 
wound healing, bone regeneration, liver repair and ischaemic reperfusion in 
renal and cardiovascular disease. Given the cardiovascular focus of this work, 
the regenerative potential of angiogenesis in cardiovascular disease is of 
particular interest.  
Ischaemic cardiovascular diseases include myocardial infarction, peripheral 
vascular disease and stroke. The primary cause of these is arterial occlusion, 
ordinarily the result of atherosclerosis and eventual plaque rupture, which 
restricts downstream blood flow, thereby starving tissues of oxygen. The 
resulting ischaemia causes devastating tissue damage and can lead to 
irreversible degradation and death if blood flow is not re-established. 
Angiogenesis, in tandem with arteriogenesis (redirection of blood flow within 
existing vasculature), is capable of restoring oxygen to ischaemic tissues; 
reducing damage and inducing tissue regeneration. In the heart, following 
myocardial infarction, angiogenesis acts to reperfuse ischaemic myocardium 
and thereby reduces the damage sustained. However, this rarely occurs 
without extensive scarring and damage to the heart. This scarring occurs when 
angiogenesis is unable to reperfuse the infarct area rapidly or extensively 
enough to prevent irreversible cardiomyocyte death. In principle, this also 
applies to the neurons of the brain in stroke and skeletal muscle in peripheral 
vascular disease. As angiogenesis does not consistently occur to a sufficient 
extent to induce complete tissue reperfusion, therapeutically targeting 
ischaemic angiogenesis is of considerable interest to improving patient 
outcomes in cardiovascular disease.  
1.3 WT1 in Angiogenesis 
In contrast to the number of anti-angiogenic drugs currently licenced for 
therapeutic targeting of tumour and pathological angiogenesis, only one pro-
angiogenic drug has, to date, reached the clinic, Beclapermin (Regranex®). 
Beclapermin, approved by the FDA in 1997, is a PDGF-based gel applied for 
the treatment of lower extremity chronic diabetic neuropathic ulcers (Fang and 
Galiano, 2008). While this treatment is effective for increasing angiogenesis 
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into the affected area, it has a localised effect and limited depth of penetration. 
Systemic pro-angiogenic therapeutics, primarily based around targeting VEGF 
or FGF signalling have all failed to pass clinical trials due to limited or no 
beneficial outcome (Simons and Ware, 2003), a case repeated in a recent 
phase III G-CSF and Sitagliptin clinical trial, SITAGRAMI (Brenner et al., 
2016). This demonstrates the unmet clinical need for a targeted pro-
angiogenic therapeutic, not based on generic angiogenic growth factors. 
Indeed, while upregulating angiogenesis is evidently essential for facilitating 
regenerative angiogenesis, increasing new neovascularisation in non-specific 
manner may have no meaningful impact on targeted tissue reperfusion. WT1 
has recently been implicated in angiogenesis and as a transcriptional regulator 
with discrete temporal and spatial expression in angiogenesis and other 
tissues, could be a more effective therapeutic target to enhance regenerative 
angiogenesis.  
WT1 is largely absent from non-regenerating adult vasculature, except 
potentially in the vasa vasori (microvessels in the vessel wall of large vessels) 
which undergo a degree of physiological remodelling and angiogenesis 
(Ritman and Lerman, 2007; Vasuri et al., 2012). However, WT1 is expressed 
in endothelial cells, fibroblasts, pericytes and inflammatory cells in vasculature 
undergoing angiogenesis (McGregor et al. 2014, Katuri et al. 2014; Dohi et al. 
2010). Given the widely accepted role for WT1 as an oncogenic target, it was 
first recognised that WT1 could be a potential transcriptional regulator of 
angiogenesis in cancers, where it is found in vascular cancers and in the 
tumour vasculature of solid cancers (Timár et al., 2005; Wagner et al., 2008, 
2014; Dohi et al., 2010; McCarty, Awad and Loeb, 2011; Trindade et al., 2011; 
Iranparast et al., 2014; Katuri et al., 2014; Barresi et al., 2015, 2016). In 
endometrial cancer, WT1 expression was found to correlate with angiogenesis 
(Dohi et al., 2010). In acute leukaemia, WT1 expression correlated with VEGF 
expression which was pro-angiogenic (Iranparast et al., 2014) whilst in Ewing 
sarcoma not only was WT1 correlated with VEGF expression, but it directly 
regulated its transcription, along with MMP9 (McCarty, Awad and Loeb, 2011; 
Katuri et al., 2014). It was discovered that WT1 regulates angiogenesis in a 
number of tumours, working by transcriptionally activating the ETS-1 
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transcription factor to control endothelial cell migration and proliferation 
(Wagner et al., 2008). Furthermore, induction of Wt1 KO specifically in the 
vascular endothelium of tumours dramatically impaired angiogenesis and 
resulted in reduced tumour growth and increased tumour regression (Wagner 
et al., 2014). 
The role of WT1 in angiogenesis does not, however, appear to be a peculiarity 
of tumour angiogenesis. Following induction of MI in rats, WT1 was found to 
be expressed in endothelial cells and supporting vascular cells of the coronary 
vasculature proximal to the site of infarction and this expression was 
colocalised with PCNA and VEGF (K. Wagner et al., 2002). These 
observations were later replicated in a mouse model of MI (Duim et al., 2015). 
Intriguingly, at least a proportion of these WT1+ endothelial cells post-MI are 
generated from the epicardium and EPDCs (S. Chen et al., 2013). Given the 
known role and widespread expression of WT1 in the developing heart, it is 
likely this represents a reactivation of angiogenesis as seen in development 
(Martínez-estrada et al., 2010; Zhou and Pu, 2012). 
Work in vivo and in vitro has since provided strong evidence that WT1 is 
transcriptionally regulated by HIF-1 binding in hypoxic conditions (Wagner et 
al., 2003) and in turn transcriptionally regulates VEGF (Graham et al. 2006; 
Hosen et al. 2007; Amin et al. 2011; McCarty et al. 2011; Iranparast et al. 
2014). WT1 also appears to directly regulate the pro-angiogenic Interleukin IL-
10 (Sciesielski et al., 2010).  In vitro, hypoxia was shown to induce a ~3 fold 
increase in WT1 expression in HUVECs (Duim et al., 2015). In HUVECs and 
C166 mouse endothelial cells, it was shown that WT1 inhibition impaired cell 
migration and cell proliferation in vitro (Wagner et al., 2008, 2014; Duim et al., 
2015). WT1 knock-down also impaired angiogenic vessel formation in 
endothelial cells in an in vitro 2D tube formation assay (Wagner et al., 2008, 
2014; Duim et al., 2015). In a more complex ex vivo aortic ring assay of 
angiogenesis Tie2CreERT2 Wt1 KO almost completely abolished new vessel 
formation (Wagner et al., 2014). All of this demonstrates that WT1 has an 
important role to play in regenerative cardiovascular angiogenesis, in 
endothelial cells in particular and raises the exciting possibility that WT1 could 
be therapeutically harnessed as a pro-angiogenic target in angiogenesis; 
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moreover, a therapeutic capable of regulating angiogenesis in a controlled, 
coordinated manner as necessary to enhance regeneration.  
1.4 Hypothesis 
Given the developing consensus that WT1 is an important regulator of 
angiogenesis, the main goal of the work described in this thesis is to determine 
the role of WT1 in cardiovascular diseases, specifically in endothelial cells in 
ischaemic angiogenesis. This will be investigated using in vivo and ex vivo 
models of angiogenesis, alongside a mouse model of inducible vascular 
endothelial cell-specific WT1 knockout (KO). Thus, the hypothesis addressed 
in this thesis is that: 
“The expression of Wt1 in vascular endothelial cells is central to the 
angiogenic formation of new vasculature” 
1.5 Aims 
To address this hypothesis, investigations have been designed to: 
1. Determine the expression pattern of WT1 in in vivo and ex vivo models 
of angiogenesis and ischaemia. 
2. Determine whether selective deletion of WT1 from the vascular 
endothelium inhibits angiogenesis in in vivo and in vitro models. 
3. Determine the function of WT1 in the endothelium during angiogenesis. 









Materials and Methods 
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2.1 Experimental Animals 
2.1.1 Vascular Endothelial WT1 KO Mouse (VE-Wt1 KO) 
All mice were bred and caged in line with Home Office conditions at the Little 
France Animal Facility (University of Edinburgh). Licenced procedures were 
carried out in strict accordance with the Home Office Animals (Scientific 
Procedures) Act 1986, under project Licence 60/4523 and personal licence 
I93FA603D. 
Mice expressing tamoxifen-inducible Cre-recombinase under the control of the 
VE-cadherin promoter (VE-Cadherin-CreERT2) (provided by Melissa Cudmore 
(University of Edinburgh)) (Monvoisin et al., 2006) and mice with LoxP flanked 
WT1 gene (WT1 co/co) (provided by Nick Hastie (University of Edinburgh)) 
were crossed to generate vascular endothelial Wt1 conditional knock-out mice 
(VE-Wt1 KO) (Figure 2.1) in which knock-out (KO) of WT1 can be induced 
specifically in VE-Cadherin expressing cells by tamoxifen injection. 
  
Figure 2.1: Three stage breeding strategy for generating a new mouse strain 
from initial VECADcreERT2 and WT1 co/co mouse lines. Genotypes are shown in 
red and Mendelian ratios shown beneath offspring. For tamoxifen-inducible VE-
cadherin Cre, ‘+’ indicates the presence of the VE-cadherin Cre, while ‘-‘ indicates its 
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absence. For WT1 ‘co’ indicates the presence of a floxed WT1 gene, while ‘+’indicates 
a WT1 gene which cannot be conditionally knocked-out. 
 
2.1.2 Tamoxifen injection regime 
VE-Wt1 KO was induced by once daily intraperitoneal injection of tamoxifen 
(33mg/kg in glyceryl tridodecanoate) for 5 days. Cre control (CC) mice also 
received these injections, while vehicle control (VC) mice received the same 
regime of vehicle (glyceryl tridodecanoate) solution injection (Table 2.1) 
(Figure 2.2). 
Experimental Mouse Line Genotype Injection 
VE-Cadherin CreERT2 Wt1 
VE-Wt1 KO Present Wt1Co/Co Tamoxifen 
CC Present Wt1+/+ Tamoxifen 
VC Present Wt1Co/Co Vehicle 
Table 2.1: Experimental mice. The genotype and type of injection received by the 
different experimental mice are shown. All mice have VE-Cadherin CreERT2 present, 
while only vascular endothelial Wt1 KO (VE-Wt1 KO) and vehicle control (VC) mice 
have the homozygous LoxP flanked Wt1 allele (Wt1Co/Co) present (Cre control (CC) 
mice have the homozygous wild-type Wt1 allele (Wt1+/+). VE-WT1 KO and CC mice 
receive tamoxifen injections, while VC mice receive vehicle injections. 
 
 
Figure 2.2: Tamoxifen/vehicle injection regime. Vascular endothelial Wt1 knock-
out (VE-Wt1 KO) and Cre control (CC) mice received once daily intraperitoneal 
injection of tamoxifen (33mg/kg in glyceryl tridodecanoate) for 5 days. Vehicle control 
(VC) mice received the same regime of vehicle (glyceryl tridodecanoate) solution 




A WT1 reporter mouse with a knock-in green fluorescent protein under the 
control of the WT1 promoter (WT1-GFP), generated by Hosen et al. 2007, was 
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used. In this mouse, GFP is expressed in the nucleus of mice upon activation 
of the WT1 promoter and transcription of the WT1 gene, allowing detection of 
WT1 by GFP expression. 
2.1.4 C57Bl/6  
Where mentioned, C57Bl/6 mice used were C57Bl/6J mice. This inbred strain 
is considered to be wild-type (WT). 
 
2.2 Genotyping 
2.2.1 DNA extraction 
DNA for genotyping was extracted from mouse ear clips. Ear clips were 
digested in 75µl digestion solution (25mM NaOH, 0.2mM EDTA, pH=12) per 
sample at 95oC for 45mins to create a crude lysate. Solution was allowed to 
cool, then neutralised with 75µl digestion solution (40mM Tris-HCl, pH=5) per 
sample. 
2.2.2 VE-cadherin-Cre PCR 
For each sample, 4µl of extracted DNA lysate were added to 7.5µl master mix 
(GoTaq G2 Hot Start Green Master Mix 100rxn, C-M7422-X), 3µl distilled 
water (dH2O), 0.75µl forward primer and 0.75µl reverse primer. 
Primer sequences: 
5’- TCGATGCAACGAGTGATGAG -3’ 
5’- AGTGCGTTCGAACGCTAGAG -3’ 
 
 PCR was run under the following conditions: 
- 94oC 5mins 
- 94oC 30s  
- 55oC 30s 
- 72oC 10mins 
- Samples held at 4oC 
2.2.3 WT1 co/co PCR 
For each sample, 5µl of extracted DNA lysate were added to 12.55µl dH2O, 




10342-020), 0.5µl forward primer, 0.5µl reverse primer and 2.5µl dNTPs 
(Invitrogen, 10297-018).  
Primer sequences: 
5’- TGGGTTCCAACCGTACCAAAGA -3’ 
5’- GGGTTATCTCCTCCCATGT -3’ 
 
 PCR was run underthe following conditions: 
- 94oC 2mins 
- 94oC 15s  
- 58oC 30s 
- 72oC 1min 
- 72oC 5mins 
- Samples held at 4oC 
2.2.4 Agarose Gel Electrophoresis 
Agarose gels were made up at 1g/100ml agarose in 1x Tris-acetate-EDTA 
(TAE) buffer (40mM Tris acetate, 1mM EDTA) for Cre and WT1 co/co PCR. 
Gels were run at 100V for ~45mins until bands were sufficiently separated for 
visualisation. Gels were visualised under UV light. For VE-cadherin Cre 
genotyping, a band at 375bp indicated the presence of Cre (Figure 2.2). For 
WT1 co/co genotyping bands were at 196bp and 230bp (Figure 2.3). 
 
 
Figure 2.3: A representative agarose gel electrophoresis gel for Cre genotyping. 
A band at 375bp indicates the presence of a Cre allele. 100 bp DNA ladder is 
represented far left of the image. The two rightmost lanes are negative (-ve) and 








Figure 2.4: A representative agarose gel electrophoresis gel for WT1 co/co 
genotyping. The wild type (+) WT1 allele forms a band at 196 base pairs (bp), while 
the conditional WT1 KO allele (co) forms a band at 230 bp. A key for interpreting the 
gels for different genotypes is shown. 100 bp DNA ladder is represented on the far 




2.3 Isolation of Mouse Aorta 
Mice were killed by asphyxiation in CO2. The ribcage was exposed by 
subcutaneous excision along the ventral midsagittal plane with surgical 
scissors. The diaphragm was pierced and thoracic cavity exposed by cutting 
through the sternum, ribs and diaphragm, as necessary to allow appropriate 
visibility and accessibility. Lung and oesophageal tissue were excised and the 
thoracic aorta was bisected immediately anterior to the diaphragm, using a 
cotton bud to absorb any resulting blood. Fat and adventitia were then cleaned 
from the aorta in situ using fine surgical scissors, from the site of bisection to 
the start of the aortic arch. The aorta is bisected at the aortic arch and the 
section of aorta is removed.  
2.4 Aortic Ring Assay 
Thoracic aortae were isolated as described (Section 2.3). Aortae were cut into 
rings (~0.5mm in length) under a dissecting microscope (Olympus CK40, 
Olympus) using fine surgical spring scissors (Fine Science Tools). In a 96-well 




Key:  co/+       co/co    +/+ 
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(Millipore 08-115), made up to 1 mg/ml in OptiMEM (Gibco, 51985-026) with 
pH equalised by addition of NaOH (~10µl/ml 1M NaOH). Collagen gel was 
then left to set for 15mins at room temperature and 1hr at 37oc. 150 µl of one 
of four media preparations were then added to each well; a) OptiMEM only, b) 
OptiMEM + 5ng/ml VEGF (Peprotech, 450-32), c) OptiMEM + 2% FBS, d) 
OptiMEM + 2% FBS for the first three days and + 5ng/ml VEGF thereafter. 
Vessels were cultured in triplicate at 37oC in a humidified atmosphere at 5% 
CO2.  
Media were changed every 2-3 days and vessel growth was measured at 
intervals up to 12 days post-embedding. Vessel number was counted, blinded 
to treatment and the maximum vessel length was measured. 
2.5 Myography 
Aortae were isolated as described in Section 2.3. Myography was performed 
using(del Campo and Ferrer, 2015) a Multi Myograph Model 610M wire 
myograph and Myo-Interface Model 310A (both Danish Myo Technology) with 
Labchart 8 software (ADInstruments). Prior to mounting vessels, physiological 
saline solution (PSS) (per 1L: 7.2g NaCl, 0.37g KCl, 0.17g CaCl2, 1.8g 
Na2HPO4, pH 7.3) and PSS with 12mM KCl by equimolar substitution with 
NaCl (KPSS) were aerated with carbogen (95% O2, 5% CO2) and warmed to 
37oC in a water bath. Myograph wells were filled with PSS and a section of 
aorta (~2mm in length) was mounted between the jaws of the myograph on 
40µm steel wire wire using a dissecting microscope. If necessary, the luminal 
surface of the vessel was rubbed with a wire to remove the endothelium. 
Vessels were stretched to their optimal resting force; 7.34mN for aortae and 
3.2mN for mesenteric arteries. Vessels were left to equilibrate, adjusting until 
force remained constant.   
KPSS (6ml) was added to each well and maximum contraction response was 
recorded. Wells were thoroughly rinsed with PSS and then 6ml PSS was 
added to each well. Response to noradrenaline (NA), acetylcholine (ACh), 
serotonin (5-HT) and sodium nitroprusside (SNP) was then assessed by 
cumulative addition of each drug so the final concentration in the well 
incrementally increased (Table 2.2). On the day, drugs were diluted in dH2O 
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to make stock solutions of 1x10-6M, 1x10-5M, 1x10-4M and 1x10-3M. For 
aortae, NA was only added up to a concentration of 3x10-6. Prior to 
assessment of relaxant responses to ACh and SNP, vessels were pre-
constricted with NA at a concentration that achieved 50% of their maximum 
contractile response. Wells were rinsed with PSS between each different drug 





6µl 1x10-6 1x10-9M 
12µl 1x10-6 3x10-9M 
42µl 1x10-6 1x10-8M 
12µl 1x10-5 3x10-8M 
42µl 1x10-5 1x10-7M 
12µl 1x10-4 3x10-7M 
42µl 1x10-4 1x10-6M 
12µl 1x10-3 3x10-6M 
42µl 1x10-3 1x10-5M 
120µl 1x10-3 3x10-5M 
 
2.6 Anaesthesia and Analgesia 
Pre-surgery, mice were anaesthetised with inhaled isoflurane (5%) in O2 and 
anaesthesia was maintained thereafter with 3-4% isoflurane in O2. At the site 
of incision, hair was removed exposed with clippers and sterilised with 
Povidone Iodine solution (Videne, 2122828). Vetergesic (buprenorphine) 
(Ceva) was diluted 1:10 in sterile H2O and injected subcutaneously at dose of 
0.05mg/kg body weight. During surgery, 1% lidocaine HCl (Hospira, RL-1045) 
was applied topically to lubricate exposed tissue if necessary. Post-surgery, 
EMLA cream (Astra Zeneca, 00651) was applied topically. All surgery was 
carried out on a heated mat to regulate body temperature under anaesthesia. 
2.7 Subcutaneous Sponge Implantation Model 
A roughly 1.5cm horizontal incision between the scapulae was made and, 
using blunt dissection, this incision was extended subcutaneously to create 
Table 2.2: Myography drug 
treatments. The volume of 
NA, ACh, 5-HT and SNP 
added to each well, along with 
the final concentration 




two tunnels extending caudally over the left and right hindquarters. One sterile 
polyurethane sponge (0.5cm x 0.5cm x 1cm) was inserted into each side and 
the wound was closed using closure clips (1.75mm x 1.75mm; Fine Science 
Tools, 12040-01). Mice were allowed to recover and clips were removed after 
7-10 days. 
Mice were culled by CO2 21 days post-implantation. Sponges were then 
excised, cut in half across the shortest axis and either fixed in 4% zinc formalin 






Figure 2.5: Exposed subcutaneous sponges in situ 21 days after implantation. 
Sponges are indicated by red arrows and the dotted line represents the axis along 
which sponges were cut for processing. 
 
2.7 Hindlimb Ischaemia 
2.7.1 Femoral Artery Ligation 
Protocol was carried out in line with that previously described for the hindlimb 
ischaemia model (Limbourg et al., 2009; Niiyama et al., 2009). Fur was 
removed from the ventral surface of both hindlimbs. Using a laser Doppler 
scanner (Moor Instruments) and Moor LDI software (5.3) (Moor Instruments) 
a pre-operative laser Doppler scan was taken. Mice were placed under the 
scanner and using a laser blood flow in the murine hindlimbs were assessed.  
Then, a 1cm incision was made in the medial thigh, starting at the mid-point of 
the inguinal ligament. The femoral vessels were revealed using blunt 
dissection and the femoral artery was separated from the femoral vein. Two 
double-knotted ligatures were applied to the femoral artery with 5/0 suture silk 
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(Fine Science Tools, 18020-50), proximal to the inguinal ligament and another 
two ~20mm distally. The femoral artery was then bisected along its length in 
situ. The skin was closed with non-absorbable 5/0 monofilament sutures 
(Ethilon, W1618T). Another laser Doppler was performed post-operatively to 
confirm ablation of blood flow and further laser Doppler scans were carried out 
at 3, 7, 14, 21, 28 days. Colour quantification of laser Doppler images was 
analysed by MoorLDI software (5.3) (Moor Instruments) to quantify the extent 
of blood flow, represented by colour spectrum. 
2.7.2 Muscle Isolation 
After 28 days and completion of all laser Doppler scans, mice were killed by 
asphyxiation in CO2. The adductor and gastrocnemius muscles were isolated 
from both the injured and uninjured hindlimbs. Muscles were then cut in half 
across the shortest axis and either fixed in 4% zinc formalin for 24hrs or snap 
frozen on dry ice and stored at -80oC prior to analysis. 
2.8 Murine Models of Arterial Remodelling 
2.8.1 Wire Injury 
Intra-luminal injury was surgically induced in the left femoral artery using a wire 
injury model (Sata et al., 2000). A 1cm incision was made in the medial thigh, 
starting at the mid-point of the inguinal ligament. The femoral vessels were 
revealed using blunt dissection and a small, homemade retractor. The branch 
of the femoral artery was ligated distal to the site of incision and a small incision 
was made to the profunda femoralis at the branch of the femoral artery and 
the profunda femoralis. An angioplasty wire was inserted, in a retrograde 
direction, ~5mm proximally into the common femoral artery. The wire was left 
in place for 30s before removal. Permanent ligatures (Fine Science Tools, 
18020-50) were applied to the profunda femoralis proximal to the site of 
incision. Temporary ligatures were removed and the skin was closed with non-






2.8.2 Optical Projection Tomography  
Following wire injury, vessel were isolated and embedded in 1.5% agarose 
(Invitrogen, 16520050), dehydrated in 100% methanol for 48hrs and then 
suspended in a solution of 1:2 (vol/vol) benzyl alcohol:benzyl benzoate for 
48hrs. Optical projection tomography (OPT) was performed on a Bioptonics 
3001 OPT tomograph. Exposure time was adjusted for each sample to provide 
high resolution images. 3D files were generated from raw images using 
NRecon software (Skyscan). Images were then viewed using CTan software 
(Skyscan). (Kirkby et al., 2011; Zhao et al., 2015). 
2.9 Murine Menstruation Model 
Uterine samples from C57Bl/6 female mice were kindly provided by Philippa 
Saunders and Douglas Gibson (QMRI, University of Edinburgh). This group 
has developed a mouse model of menstruation (Brasted et al., 2003) modified 
to enable non- surgical induction of decidualisation and a longer 
decidualisation period. This is carried out using β-oestradiol, progesterone and 
an intra-uterine injection of sesame oil to induce decidualisation; described in 
full by Cousins et al. (2014). In this model, one uterine horn was decidualised, 
while the other was used as a non-decidualised control. 
2.10 Quantitative PCR 
2.10.1: RNA Extraction 
Frozen sponge tissue was kept on dry ice prior to RNA extraction. 700µl of 
Qiazol (Qiagen) was added to each half sponge which was homogenised 
using an ultra turrax homogeniser (IKA T10 Basic) for ~3mins until smooth. 
Samples were then halved and a further 350µl of Qiazol was added to each 
half, prior to further homogenisation; the sampes were then left to rest for 
5mins on wet ice. 200µl of chloroform was added and samples were mixed 
and left for 2mins at R.T. Samples were then centrifuged at 12,000 G at 4oC 
for 15mins. The aqueous phase was removed and combined from the two 
halves of the same sample. Further RNA purification was carried out using an 
RNeasy Mini Kit (Qiagen) as per manufacturer’s instructions. RNA quality and 
concentration were determined using a Nanodrop ND-1000 (Thermo 
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Scientific) spectrophotometer. RNA integrity was determined by agarose gel 
electrophoresis on a 1% agarose gel made up with TAE and stained with Gel 
Red (Figure 2.5). 
 
Figure 2.7: Representative RNA Integrity analysis. Good RNA integrity is shown 
by clear bands and a roughly 2:1 ratio between 28S and 18S bands, respectively. 
Weaker bands are representative of a lower RNA concentration. 
 
2.10.2 cDNA Synthesis 
cDNA synthesis was carried out using a QuantiTect Reverse Transcription Kit 
(Qiagen) on ice. Using RNA concentration values from the Nanodrop 
spectrophotometer, 500ng of RNA was diluted to a final concentration of 12µl 
in nuclease-free H2O per sample. To this, 2µl of gDNA Wipeout Buffer was 
added and samples were incubated at 42oC for 2mins and then replaced on 
ice. To each sample, 4µl Quantiscript RT Buffer, 1µl RT Primer Mix and 1µl 
Quantiscript Reverse Transcriptase were added. Samples were then 
incubated at 42oC for 15mins, then 95oC for 3mins. As negative controls, one 
sample was prepared with 12µl H2O instead of RNA and one sample per 
experimental group with 1µl H2O instead of Reverse Transcriptase. cDNA was 
stored at -20oC.  
2.10.3 Quantitative Real Time PCR 
Concentrated cDNA was diluted 1/10 or 1/20 in nuclease-free H2O. Standards 
were made up by pooling cDNA from all samples (except negative controls) 
and serially diluting 1/2, 1/4, 1/8, 1/16, 1/32, 1/64, 1/128, 1/256 and 1/512 in 
nuclease-free H2O. All procedures were carried out on wet ice unless 
otherwise stated. Mastermix was prepared as shown (Table 2.2) and was 
distributed on a 96-well plate at 8µl per well with 2µl cDNA. Samples and 





1500rpm for 2mins. 96-well plates were loaded onto a LightCycler 480 
Instrument (Roche) and run on LightCycler 480 software (Roche). All primers 
(Table 2.3), probes and mastermix were from Roche. 
Reagent Volume (µl/well) 
Nuclease-free water 2.7 
Probe Master 5 
Primer (forward) 0.1 






Gene Primer Sequences Probe Used 
WT1 5’- GCACTAGACAAAGTTCACCTGAGA -3’ #95 
5’- CGCTATCCACATCAAAGCAA -3’ 
HIF-1α 5’- GCACTAGACAAAGTTCACCTGAGA -3’ #95 
5’- CGCTATCCACATCAAAGCAA -3’ 
VEGF-A 5’- AAAAACGAAAGCGCAAGAAA -3’ #1 
5’- TTTCTCCGCTCTGAACAAGG -3’ 
CD31 5’- CGGTGTTCAGCGAGATCC -3’ #45 
5’- ACTCGACAGGATGGAAATCAC -3’ 
Snail 5’- CTTGTGTCTGCACGACCTGT -3’ #71 
5’- CAGGAGAATGGCTTCTCACC -3’ 
Slug 5’- CATTGCCTTGTGTCTGCAAG -3’ #71 
5’- AGAAAGGCTTTTCCCCAGTG -3’ 
PDGFR-β 5’- TGATGAAGGTCTCCCAGAGG -3’ #1 
5’- CTGCTTGCTGTGGCTCTTCT -3’ 
Table 2.4: Genes and primer sequences used in RT qPCR along with the probe 
number used for each. Sequences of qPCR probes for each gene and the 







Table 2.3: qRT-PCR Mastermix. The 
volume of each reagent added to create 
8µl mastermix for addition to each 2µl 




2.11 Histological Techniques  
2.11.1 Preparing Slides 
Samples were fixed overnight in 4% zinc formalin and then stored in 
phosphate-buffered saline (PBS) prior to embedding in wax blocks. Wax 
blocks were sectioned at 5µm on a Leica RM2235 Rotary Microtome (Leica 
Biosystem, UK), mounted on slides and dried at 37oC overnight. Slides were 
dewaxed in xylene for 10mins then rehydrated in 100%, 95%, 80% and 70% 
ethanol for 20secs each before washing in H2O. Staining was then carried out 
as per individual protocols. 
2.11.2 Haematoxylin and Eosin 
Slides were submerged in Mayer’s Hematoxylin (Dako, UK) for 5mins, then 
Acid ethanol (1% HCl in 70% EtOH), Scott’s tap water for 20-30secs and Eosin 
for 5-10 secs (Dako). A wash in tap water was carried out between each of the 
above steps. Sections were then dehydrated in 70%, 80% 90% and 100% 
ethanol for 20s each and xylene for 10mins prior to mounting coverslips with 
mounting medium (Pertex, SEA-0104-00A).  
2.11.3 Picrosirius Red 
Picrosirius red staining was carried out by the Histology department (Shared 
University Research Facilities (SURF), University of Edinburgh) at The 
Queen’s Medical Research Insitute, University of Edinburgh.  
2.11.4 Immunoprecipitation Staining 
Antigen retrieval was carried out by submerging slides in 10mM sodium citrate 
buffer and boiling for 5mins in a pressure cooker. Slides were then submerged 
in 0.3% H2O2 solution in dH2O for 30mins and 50mM NH4Cl in PBS (pH7.4) 
for 30mins, rinsing thoroughly in between and after in dH2O. Samples were 
blocked with 10% serum (in PBS) from the animal in which the primary 
antibody was raised, for 1hr at R.T. Samples were incubated with the primary 
antibody overnight at 4oC in a humidified chamber. 
Slides were then thoroughly washed in PBS and incubated with the secondary 
peroxidase-conjugated antibody for 1hr at R.T., rinsing thoroughly after with 
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PBS. DAB staining was then carried out for 10mins using ImmPACT DAB 
Substrate (Vector, UK) as per manufacturer’s instructions. Slides were 
counterstained with Haematoxylin and Scott’s tap water, dehydrated and 
mounted as described in H&E Section. 
2.12 Immunofluorescent Staining 
2.12.1: Paraffin-embedded, Formalin-fixed Tissue 
Slides were prepared as in section 2.9.1. Antigen retrieval was carried out by 
submerging slides in 10mM sodium citrate buffer and boiling for 5mins in a 
pressure cooker. Slides were then submerged in 0.3% H2O2 solution in dH2O 
for 30mins. Samples were blocked with 10% serum in PBS from the animal in 
which the primary antibody was raised for 1hr at R.T.  Samples were then 
incubated with primary antibodies overnight at 4oC in a humidified chamber. 
Slides were then thoroughly washed in PBS and incubated with the 
appropriate secondary antibody for 1hr at R.T., rinsing thoroughly after with 
PBS. Counterstaining with DAPI (1/1000 in PBS) was carried out for 10mins. 
Slides were thoroughly rinsed in PBS and mounted with coverslips using 
PermaFluor (Thermo Scientific). 
2.12.2 Aortic Rings 
Aortic rings were stained in 96-well plates with 50µl /well of all reagents and at 
R.T. unless otherwise stated. Culture medium was removed and wells were 
washed with PBS. Aortic rings were fixed with 4% zinc formalin per well for 
30mins, then thoroughly washed in PBS. 0.25% Triton X-100 in PBS was 
added for 30mins, followed by thorough washing with PBS. Aortic rings were 
blocked with 10% serum in PBS from the animal in which the primary antibody 
was raised for 1hr. Samples were then incubated with primary antibodies 
overnight at 4oC.  
Wells were thoroughly rinsed with PBS + 0.1% (vol/vol) Triton X-100 before 
incubation with secondary antibodies for 1hr. DAPI was then added at 1/1000 
for 10mins, washing with PBS before and after. 
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Each well was refilled with dH2O and collagen gels containing the aortic tissue 
were detached by running a needle around the edge of the well. Gels were 
removed from the bottom of the well using fine forceps and manipulated up 
the side of the well onto a slide. Up to six gels were mounted per slide and 
mounted with coverslips using PermaFluor (Thermo Scientific). 
2.12.3 Tyramide Signal Amplification 
For WT1 immunofluorescence, tyramide signal amplification was carried out 
using TSA™ Plus System (PerkinElmer, USA) conjugated to Fluorescein, 
Cyanide 3 or Cyanide 5 fluorescent proteins. As per the protocol in section 
2.11.14, a peroxidase-conjugated anti-rabbit antibody was added at the 
secondary antibody step for 1hr at R.T. Then, following a thorough rinse with 
PBS, TSA™ Plus tyramide was added at 1/50 in the provided reaction diluent 
for 10mins at R.T. Slides were rinsed again in PBS and the rest of the protocol 
was carried out as for Paraffin-embedded Sections.  
 
2.13 Transcriptomics 
2.13.1 WT1-GFP FACs Sorting 
FACs was carried out by Richard McGregor with the help of the QMRI FACs 
facility. Subcutaneous sponges were implanted in WT1-GFP reporter mice 
as described in section 2.7. Sponges were removed at day 7 or day 21. Cells 
were extracted from sponges and sorted by GFP expression into GFP+ and 
GFP- cells.  
 
2.13.2 Whole Genome RNA Expression Profiling 
Sorted cells from section 2.13.1 were submitted to the Illumina Whole 
Genome Expression Profiling Service (Qiagen). In brief, extracted whole 
genome total RNA was screened for RNA expression on a MouseWG-6 or 
MouseRef-8 v2 Expression BeadChip with Illumina iScan. This provided 





2.13.3 Transcriptomic Data Analysis 
Data from section 2.13.2 was processed with the help of Graeme Grimes and 
the IGMM Bioinformatics Core. Microarray data was read in R using the 
bioconductor package ‘limma’ and raw expression profiles were normalised so 
that the intensities or log-ratios had similar distribution across a set of arrays. 
The raw data was checked using expression distribution and found to be of 
good quality. Probes not expressed in any samples were removed using a 
detection filter of p< 0.01. Differential expression analysis was conducted 
using limma. Genes which had a significantly different levels of gene 
expression between GFP+ and GFP- groups were identified using an FDR cut 
off of q<0.05.  
Processed data were analysed using the online programs GOrilla (Eden et 
al., 2007, 2009), ReviGO (Supek et al., 2011) and DAVID (Huang, Sherman 
and Lempicki, 2008, 2009). 
2.13.4 Identification of Potential WT1 Target Genes 
In order to determine potential genes with which WT1 may interact, the 
location of known motifs to which WT1 binds (identified from previous 
experiments; Table 2.4), was determined within the mouse genome. This was 
performed using two online programs; BLASTN from Ensembl [release 88] 











 WT1-binding sequence Identified by 
1.  5’- GCGGGGGCG -3’  Rauscher et al. 1990 
2.  5’- CGCCCCCGC -3’ Rauscher et al. 1990 
3.  5’- TCCTCCTCCTCCTCTCC -3’  Wang et al. 1993 
4.  5’- GCGTGGGAGT -3’ Nakagama et al. 
1995 
5.  5’- 
GCGTGGGCG(T/G)(G/A/T)(T/G) -
3’ 
Hamilton et al. 1995 
6.  5’- GGAGAGGGAGGATC -3’ Little et al. 1996 
Table 2.6: WT1-binding sequences identified from previous literature. 
Sequences of identified WT1-binding motifs used to identify potential direct WT1-
target genes, along with the paper in which each sequence was originally identified. 
 
BLASTN was used to screen the entire C57Bl/6J mouse genome for the 
location of WT1-binding sequences. Search parameters were confined as 
follows: 
Search Sensitivity:    Short sequences 
Max E-value:     1000 
Word size for seeding assignments: 7  
Filters:     None 
RSAT was used to extract promoter sequences of genes whose expression 
were significantly changed between GFP+ and GFP- groups at both Day 7 and 
Day 21 in data from section 2.13.2. Extracted promoter sequences were then 
screened for the presence and location of WT1-binding sequences in both the 
reverse and forward strands using the RSAT tool “DNA-pattern”, allowing for 
no substitutions in target sequence to reduce the probability of false positive 
hits. Mouse genome release for reference was “Mus Musculus GRCm38”. 
To control for random hits in BLASTN and RSAT, analysis was repeated for 
non-sense control sequences. These randomly generated sequences were 
9bp long with a GC content of 0.5.  
Lists of genes with potential WT1-binding sites were analysed using GOrilla, 




2.14 Statistics and Analysis 
Statistical analysis was carried out using Minitab 16 software (Minitab) and 
Prism 5 software (GraphPad). Prism 5 was used for all graphical analysis. 
Image analysis, including DAB and PSR staining analysis and nuclei counting 
was carried out using Image J. Data was assessed for a normal Gaussian 
distribution and parametric or non-parametric analysis was carried out 
accordingly. Student’s t-test, or Mann-Whitney u-test were carried out for data 
with two groups. For data with more than two groups, one-way ANOVA was 
carried out with post-hoc Bonferroni tests, or a Kruskal-Wallis one-way 
ANOVA. For data with more than two groups and two dependent variables, 
two-way ANOVA was carried out. To determine correlation, linear regression 
was applied. All data was shown as mean +/- s.e. mean. Groups were 























WT1 in Angiogenesis and 




WT1 has been investigated thoroughly in a number of contexts, including 
development, developmental kidney disorders and cancer. However, the role 
of WT1 in the vasculature, specifically in the context of cardiovascular disease 
is much less well-characterised. In order to gain an initial understanding of the 
role of WT1 in the vasculature and endothelial cells, in vitro and ex vivo model 
have often been used. These have a number of advantages over in vivo 
approaches in that, while they are sometimes less representative of 
physiological processes, they are simple, reproducible, easily manipulated, 
readily observable and variables can be more effectively controlled. For these 
reasons, in vitro and ex vivo experimental approaches have often been 
employed to examine the functional role of WT1, either independently or in 
combination with in vivo experiments. This approach was also employed for 
the experiments in this chapter. For context, the work to date on WT1 in vitro 
and ex vivo of relevance to vascular function is outlined below. 
As previously discussed (1.3), WT1 is expressed in vivo in developing 
vasculature and in vasculature undergoing angiogenesis (reviewed by Scholz 
et al. 2009). Work performed in vitro has attempted to elucidate the role of 
WT1 in the vasculature in angiogenesis. The coordinated action of WT1 and 
two major regulators of angiogenesis, HIF-1α and VEGF has been 
demonstrated in vitro and in vivo, in non-vascular cell lines; WT1 directly 
regulates VEGF and is itself transcriptionally regulated by HIF-1α (Wagner et 
al., 2003; Cash et al., 2007; Hanson et al., 2007; McCarty, Awad and Loeb, 
2011). Whilst these relationships have not been proven in endothelial cells, it 
would be surprising if the same transcriptional mechanisms did not occur since 
HIF-1α is widely expressed in endothelial cells in angiogenic vasculature (K. 
Wagner et al., 2002). HIF-1α and other hypoxia-inducible factors are the main 
regulators of the vascular response to hypoxia and concordantly, hypoxia 
induces an increase in WT1 expression (~3 fold) in HUVECs (Duim et al., 
2015). This is of relevance as endothelial cells, VSMCs and pericytes are all 
sensitive to oxygen levels and hypoxia is the main inducer of pathological and 
regenerative angiogenesis (Moeller et al., 2004; Semenza, 2014). 
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On a cellular level, WT1 has previously been demonstrated to play a role in 
cell proliferation, growth, migration, transition, adhesion, survival and 
apoptosis (reviewed by Hastie 2017). In endothelial cells, many of the same 
processes seem to be of relevance. In HUVECs, it was found that WT1+ cells 
had much higher levels of PCNA expression (Duim et al., 2015) and  reducing 
WT1 protein levels by siRNA resulted in reduced proliferative capacity, 
alongside reduced PCNA and BrdU expression, with no significant effect on 
apoptosis (Wagner et al., 2008). Reducing WT1 expression by shRNA in a 
scratch assay significantly reduced cell migration, though interestingly, 
overexpressing C-kit, a direct target of WT1, somewhat restored the migratory 
response (Wagner et al., 2014).  
Perhaps the most commonly deployed in vitro angiogenic assay is the 2D-tube 
formation assay. Here, endothelial cells are plated onto a basement 
membrane and spontaneously form luminal endothelial vessels. This is a 
quantifiable, reproducible assay involving endothelial cell, migration, 
adhesion, ECM degradation and tubule formation (Arnaoutova and Kleinman, 
2010). The role of endothelial WT1 in this 2D-tube formation assay is clear. 
WT1 expression increased vessel formation in this assay for HUVECs cultured 
with Ewing’s sarcoma cell lines (McCarty, Awad and Loeb, 2011), in HUVECs 
silenced with Wt1 siRNA (Wagner et al., 2008) and C166 mouse endothelial 
cells with Wt1 shRNA (Wagner et al., 2014). A more complex, ex vivo 
angiogenic assay involving a number of vascular cell types is the aortic ring 
assay, in which the thoracic aorta is isolated from mice and embedded in 
collagen or Matrigel. Recent results from this assay used a Tie2CreERT2 Wt1 
KO (Wagner et al., 2014). Tie2 is a gene expressed in endothelial cells and a 
proportion of cells of a haematopoietic lineage including macrophages, B- and 
T-lymphocytes, natural killer cells and dendritic cells, so the inducible 
Tie2CreERT2 Wt1 KO will reduce Wt1  expression in all these cells (Constien 
et al., 2001; Kisanuki et al., 2001). In the aortic ring assay, Tie2CreERT2 Wt1 
KO almost entirely abolished angiogenic vessel formation (Wagner et al., 
2014). All of this strongly implicates WT1 in endothelial angiogenesis.  
As WT1 is not expressed in adult quiescent vasculature (McGregor et al.), it 
would not be expected to play a physiological role in most tissues. Therefore, 
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the role of WT1 in regulation of vascular tone has not been directly 
investigated, despite long having been known that WT1 mutation in Denys-
Drash syndrome and other WT1-associated glomerulopathies can manifest 
with hypertension (Little et al., 1993; Wagner et al., 2008; Lipska et al., 2014). 
In congenital obstructive nephropathy, Wt1 is downregulated resulting in 
apoptosis, however nitric oxide (NO)/Hsp70 expression reduces this apoptosis 
and in kidney cells NO regulates Wt1 mRNA expression (Mazzei et al., 2010). 
NO-mediated regulation of Wt1 transcription was also observed in lung 
epithelial cells and lymphocytes (Marcet-Palacios, Davoine, et al., 2007; 
Marcet-Palacios, Ulanova, et al., 2007). This is of particular interest because 
NO, as a potent vasodilator, is essential for maintenance of endothelial cell 
function and vascular tone. Intriguingly, as well as NO influencing Wt1 
transcription, WT1 is capable of directly regulating inducible nitric oxide 
synthase (iNOS), which in turn synthesises NO (Johannesen et al., 2003; 
Mazzei et al., 2010). The inextricable link between vasodilation and 
angiogenesis is a paradigm well accepted in the case of VEGFs and NO also 
has a dual role in these entwined processes, as a target of VEGF (Coletta et 
al., 2012).  
Therefore, while some interesting insights into the role of WT1 in vascular 
function have arisen from in vitro and ex vivo experiments, there remains much 
that has been either completely neglected or remains partially investigated. It 
is clear there is a role for WT1 in regulating angiogenic function of the 
endothelium in the 2D-tube formation assay, but it is unclear through what 
mechanism. For example, while a number of groups have suggested WT1 is 
important in in vitro/ex vivo angiogenesis, none have examined its expression 
during this process. The work herein will attempt to provide more clarity to this 
situation by further investigating the role of WT1 in endothelial cell function 
and angiogenesis. 
3.1.2 Hypothesis  
Given the previous implication of WT1 in angiogenesis in vitro, the work 
described in this chapter addressed the hypothesis that: 
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“As Wt1 is intrinsically involved in angiogenesis in endothelial cells, Wt1 
KO in the vascular endothelium will impair ex vivo angiogenesis.” 
3.1.3 Aims 
1. Introduce the VE-WT1 KO model of inducible endothelial-selective WT1 
deletion to Edinburgh. 
2. Determine whether selective deletion of WT1 from endothelial cells 
(VE-WT1 KO) alters endothelium-dependent relaxation. 
3. Characterise and optimise the ex vivo aortic ring angiogenesis assay. 
4. Determine whether selective deletion of WT1 from endothelial cells 
(VE-WT1 KO) inhibits ex vivo angiogenesis. 
This VE-Wt1 KO mouse under the control of VE-Cadherin Cre is 
advantageous in comparison to the Tie2 Cre  mouse for investigating 
endothelial WT1, as in contrast to Tie2 Cre, it only knocks-out Wt1 in adult 





3.2 Materials and Methods 
For full materials and methods refer to Chapter 2. 
3.2.2 VE-Wt1 KO Mouse 
In order to confirm the KO of Wt1, female VE-Wt1 KO mice, 16-18 weeks were 
used. Cre control (CC) and VE-Wt1 KO were used in this experiment (n=5). 
I.P. tamoxifen injections were carried out as described in 2.1.1. Uterine and 
mammary tissue were harvested 1 week after finishing injections, fixed in 10% 
formalin and wax embedded prior to staining as described (2.12.2).  
Immunohistochemistry using antibodies against CD31/αSMA/WT1/DAPI was 
carried out on uterine tissue. Rabbit v mouse anti-CD31 was used at 1/500 
(ab28364, Abcam), with secondary donkey v rabbit Alexa 488 (1/200) 
(Invitrogen, A21206); Rabbit v mouse anti-WT1 (1/500) (Abcam, ab89901) 
with secondary peroxidase IgG (1/200) (Vector, PI-1000) and TSA Tyramide 
Cy3 (PerkinElmer, SAT705A001EA); Rabbit v mouse anti-αSMA (1/500) 
(C6198, Sigma); DAPI (1/1000) (D9542, Sigma). 
This staining was quantified in two ways: as the proportion of CD31+ vessels 
which have any WT1+ endothelial cells compared with those vessels with no 
WT1+ endothelial cells and as the proportion of CD31+ endothelial cells 
(identified by DAPI+ nuclei) which were WT1+. 
Male VE-Wt1 KO mice, 11-19 weeks old were culled 4 weeks after the last 
injection of tamoxifen and heart, liver, spleen, kidney, kidney and testes were 
harvested fixed in 10% formalin and wax embedded as described (2.12.2). All 
these tissues were H&E stained. Testes, epididymal fat and seminal vesicles 
were harvested and weighed.  
3.2.1 Myography 
Myography was initially carried out on aortae from C57Bl/6 male mice, 12-16 
weeks of age (n=3-5), in order to optimise the protocol and characterise the 
normal response of vasculature to NA, 5-HT, ACh and SNP.  
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To assess the effect of VE-Wt1 KO on vascular function, aortae from VE-Wt1 
KO male mice, 11-16 weeks of age (n=7-8) were subjected to myography (see 
section 2.4, for full protocol). 
3.2.2 Aortic Ring Assay 
The murinethoracic aorta was isolated from mice and embedded in 1mg/ml 
collagen type 1 gel (Millipore 08-115). See section 2.5 for full details. 
Characterisation and optimisation of the aortic ring model was initially carried 
out in C57Bl/6 male mice, 12-20 weeks of age (n=5-6). Vessel outgrowths 
were quantified as shown in Figure 3.2.1.  
For quantification of the effect of endothelial cell-selective Wt1 KO on 
angiogenesis in the aortic ring assay, VE-Wt1 KO male mice 12-19 weeks of 
age were used (n=8). VE-Wt1 KO was induced by I.P. tamoxifen injection over 
5 days as described in section 2.1.1. Aortic tissue was harvest 1-4 weeks after 
finishing the tamoxifen injection regimen. 
For imaging WT1 in the angiogenic vessel outgrowths of the aortic ring assay, 
aortic section from a WT1-GFP (see section 2.1.2) male mouse 10 weeks of 
age was used (n=1). GFP was induced by including 4-OH Tamoxifen in the 
aortic ring media at a concentration of 1µM for the duration of the experiment.  
 
Histological staining of aortic rings was carried out as described in section 
2.12.2. The antibodies used for individual staining and the concentrations they 






6 Max. vessel length 
8 
9 10 
11 Figure 3.2.1 Quantification of 
angiogenic outgrowths from aortic 
rings. Outgrowths were counted at 
each new branch point, as shown, with 
the maximum vessel length quantified 




1o Antibody 2o Antibody 
Rabbit v mouse anti-CD31 (1/500) 
(Abcam, ab28364) 
Goat v rabbit Alexa 488 (1/200) 
(Molecular Probes, GAR-A488) 
Isolectin-B4 (1/500) 
(Invitrogen, 1110271) 
Streptavidin - Alexa 488 (1/200) 
(Invitrogen, A-32354) 
Rabbit v mouse anti-αSMA (1/500) 
(C6198, Sigma) 
Directly conjugated to Cy3  
Rabbit anti-GFP (1/200) 
(Abcam, ab6556) 
Goat v rabbit peroxidase IgG (1/100) 
(Vector, PI-1000) 
TSA Tyramide Cy5 (1/50) 




Table 3.2.1: Antibodies used for aortic ring immunohistochemistry. Primary 
antibodies are provided with the relevant secondary antibodies used in the adjacent 
column. Antibody description/name, concentration used, provider and catalogue 








3.3.1 The VE-Wt1 KO Mouse Model 
3.3.1.1 Confirmation of WT1 KO 
Uterine tissue from VE-Wt1 KO mice was assessed and quantified from 
WT1/CD31/DAPI IHC. In CC (Figure 3.3.1 A-C) and VE-Wt1 KO (Figure 3.3.1 
D-F) a proportion of vascular endothelial cells in some vessels were WT1+, 
though the strength of staining for WT1 was lower than in the surrounding 
stromal cells, which were highly WT1+. In VE-Wt1 KO tissue, a smaller 
proportion vessels had WT1+ endothelial cells than in CC vessels (p<0.05, 
unpaired t-test) (Figure 3.3.1G). The total number of WT1+ vascular 
endothelial cells was also quantified and had a trend towards being lower in 
VE-Wt1 KO in comparison to CC (p=0.051) (Figure 3.3.1H).  
A number of organs isolated from VE-Wt1 KO male mice were H&E stained. 
General morphology of these tissues was assessed by a pathologist (Tim 
Aitman, University of Edinburgh) to determine whether there was any overt 
phenotypic different between VE-Wt1 KO, CC and VC mice. It was determined 
that there was no evident difference in morphology of the heart, liver, spleen 






Figure 3.3.1: Vascular endothelial Wt1 knock-out (VE-Wt1 KO) uterine tissue 
has less WT1+ endothelial vessels than in Cre control (CC). CD31 (green), WT1 
(red) and DAPI (blue) IHC was carried out on uterine tract tissue from A-C) CC and 
D-F) VE-Wt1 KO female mice. Endothelial WT1 staining (arrows), was noted in a 
proportion of vessels and endothelial cells in CC and VE-Wt1 KO, with less WT1+ 
endothelial cells in VE-Wt1 KO. From this staining was quantified the proportion (%) 
of G) vessels with any WT1+ endothelial cells and H) WT1+ endothelial cells of total 
endothelial cells. There were significantly less WT1+ vessels in VE-Wt1 KO v CC. 
Vessels outlined in white. Scale bars = 50µm. Columns represent mean + s.e.mean. 
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Figure 3.3.2: No morphological changes induced by vascular endothelial Wt1 
knock-out (VE-Wt1 KO) in a number of organs. H&E staining was carried out on 
extracted tissues 4 weeks after induction of VE-Wt1 KO in VE-Wt1 KO, vehicle control 
(VC) and Cre control (CC) mice on A-C) kidney, D-F) liver, G-I) heart and J-L) spleen. 
No gross morphological differences were noted in any of these tissues between 
groups. Representative images from n=5. VC = vehicle control, CC = Cre control, VE-
Wt1 KO = vascular endothelial WT1 KO. Scale bars - 100µm. 
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3.3.1.2 VE-Wt1 KO Mice Have Enlarged Gonads, but Reduced 
Testis Weight 
In VE-Wt1 KO mice, it was evident that the male gonad was visibly enlarged 
in comparison to CC and VC mice, which progressed with time after induction 
of VE-Wt1 KO. 4 weeks post-induction the weights of the epididymis, seminal 
vesicles and testis were recorded; it was found that there was a small, but 
robust reduction in male testis weight in VE-Wt1 KO  in comparison to CC 
testis (p<0.05) (Figure 3.3.3 A-C).  
With CD31/WT1/DAPI immunofluorescent staining, it was found that WT1 was 
expressed in the endothelium in a large proportion of vessels in the testis, in 






Figure 3.3.3: Vascular endothelial Wt1 knock-out (VE-Wt1 KO) induces gross 
changes in gonad morphology due to reduction of endothelial testis 
expression. Gonad morphology in A) Cre control (CC) and B) VE-Wt1 KO. C) Testis 
weight was lower in VE-Wt1 KO than in Cre control four weeks post-induction with 
33mg/kg tamoxifen. Weights of the epididymal fat (Epi), or seminal vesicles (SV) were 
not different. CD31/WT1/DAPI IHC in D-F) CC and G-I) VE-Wt1 KO testis. This 
reveals endothelial WT1 staining in CC testis in vascular endothelial cells. Scale bars 
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3.3.2 Myography in C57Bl/6 Mice 
Myography was carried out on arteries from C57Bl/6 mice to establish the 
baseline responses of different vessels in response to contractile and relaxant 
drugs. Aortae and mesenteric arteries were used, either intact, or with the 
endothelium removed (denuded). These were assessed for viability by 
exposure to high (125mM) K+ in physiological salt solution (KPSS). The type 
of artery and whether or not it was denuded had a significant effect on the 
contractile response (p<0.05, 2-way ANOVA) to KPSS (Figure 3.3.4 A). The 
responses to noradrenaline (NA) (Figure 3.3.4 B) and acetylcholine (ACh) 
(Figure 3.3.4 C) were assessed in intact and denuded aortae and mesenteric 
arteries and the response to sodium nitroprusside (SNP) (Figure 3.3.4 D) was 
assessed in intact and denuded aortae.  
Both denuded and intact aortae were more sensitive to NA than intact 
mesenteric arteries and denuded mesenteric arteries and, hence, had higher 
PD2 values for NA (p<0.05 denuded, p<0.001 intact, one-way ANOVA with 
Bonferroni post-hoc tests) (Table 3.3.1). Intact mesenteric arteries had a 
significantly greater maximum contractile response (Emax) to NA than intact 
















































































































































Figure 3.3.4: Analysis of normal vasoconstriction and vasodilation of C57Bl/6 
arteries. Myography was carried out with C57Bl/6 aortae and mesenteric arteries, in 
vessels manually denuded to remove the endothelium alongside intact vessels. 
Vasoconstrictory response to A) KPSS and B) increasing concentrations of 
noradrenaline was assessed (normalised to KPSS response). Vessels were 
preconstricted with noradrenaline and then assessed for the vasodilatory response to 
acetylcholine and sodium nitroprusside, expressed as C, D) normalised to KPSS 
response and E, F) normalised to KPSS and expressed as % relaxation. n=5-7 for 
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Table 3.3.1: Sensitivity (PD2) and maximum contractile response (Emax) of 
C57Bl/6 aortae and mesenteric arteries. The Emax (%KPSS) (for NA only) and PD2 
(-log conc.) have been calculated for denuded (D) and non-denuded (ND) aortae and 
mesenteric arteries in response to NA, Ach and SNP. *p<0.05, **p<0.01, ***p<0.001, 
one-way ANOVA with Bonferroni post-hoc tests (differences between boxes of same 
colour). n=3-5, mesenteric, n=7, aortae. NA = noradrenaline, Ach = acetylcholine, 
SNP = sodium nitroprusside.  
3.3.3 VE-Wt1 KO Results in Increased Vasoconstriction  
Myography was carried out to assess the effect of VE-Wt1 KO on general 
vascular function, vasoconstriction and vasodilation. There was no significant 
difference in contraction to KPSS between aortae from VE-Wt1 KO, VC and 
CC mice (Figure 3.3.5 A-B). Aortae from VE-Wt1 KO exhibited greater 
contraction in response to NA in intact, but not denuded aortae (Figure 3.3.5 
A-B). VE-Wt1 KO aortae had a greater contractile response to NA (Figure 
3.3.5 C) 5HT in intact aortae (Figure 3.3.5 E). Denuded VE-Wt1 KO aortae 
showed a trend toward having a greater contractile response to NA and 5HT, 
though this was not significant (Figure 3.3.5 D and F, respectively). There was 
no difference in the sensitivity between groups of aortae to NA or 5HT, as 
evident by a lack of difference in the PD2 values, however, denuded VE-Wt1 
KO aortae had a greater maximum contractile response (Emax) to 5HT in 






































































































































































Figure 3.3.5: VE-Wt1 KO increases aortic vasoconstriction. Myography was 
carried out with VE-Wt1 KO, CC & VC aortae, in intact vessels and those manually 
denuded to remove the endothelium. There was no difference between groups in 
contractile response to KPSS in A) intact or B) denuded vessels. The contractile 
response to increasing concentrations of noradrenaline (normalised to KPSS 
response) was increased in C) intact, but not D) denuded VE-Wt1 KO aortae in 
comparison to CC and VC. The contractile response to increasing concentrations of 5HT 
(normalised to KPSS response) was also increased in E) intact VE-Wt1 KO aortae, 
but not F) denuded. *p<0.05, **p<0.01, VE-Wt1 KO v CC and VC, 1-way ANOVA with 
Bonferonni post-hoc test. n=7-8. VC = Vehicle control, CC = Cre control, VE-Wt1 KO 








The vasodilatory response of VE-Wt1 KO aortae were then assessed in 
response to Ach and SNP in the same vessels. There was no difference in the 
vasodilatory response of denuded or non-denuded VE-Wt1 KO aortae in 
response to Ach (Figure 3.3.6 A & B) or SNP (Figure 3.3.6 C & D) in 
comparison to VC and CC aortae. There was no difference between groups in 











































































































































Figure 3.3.6: VE-Wt1 KO increases aortic vasoconstriction. Myography was 
carried out with VE-Wt1 KO, CC & VC aortae, in intact vessels and those manually 
denuded to remove the endothelium. There was no difference between groups in 
vasodilatory response to acetylcholine or sodium nitroprusside. Aortae were first pre-
constricted with noradrenaline. Then vasodilatory responses to increasing 
concentrations of acetylcholine were assessed in A) intact aortae and B) denuded 
aortae and sodium nitroprusside in C) intact aortae and D) denuded aortae. 
Responses are normalised to KPSS and then shown as the % relaxation from starting 
vascular tone. There were no significant differences between groups. 1-way ANOVA 
with Bonferonni post-hoc test. n=7-8. VC = Vehicle control, CC = Cre control, VE-Wt1 









  VC CC VE-Wt1 KO 




73.91 134.04 70.78 138.90 96.24 175.16 
PD2: 
(-log conc.) 
















8.06 8.21 8.06 8.00 8.07 8.00 
Table 3.3.2: VE-Wt1 KO aortae have an increased Emax response to 5HT when 
denuded of endothelium. The Emax (%KPSS) (for vasoconstrictory drugs only) and 
PD2 (-log conc.) have been calculated for VC, CC and VE-Wt1 KO denuded (D) and 
non-denuded (ND) aortae. VE-Wt1 KO denuded aortae have a greater Emax than 
VC and CC denuded aortae. No values for denuded aortae in response to Ach, due 
to lack of response. **p<0.01, VE-Wt1 KO, v VC and CC, 1-way ANOVA with 
Bonferroni post-hoc tests. n=6-8. NA = noradrenaline, 5HT = 5-hydroxytryptamine, 
Ach = acetylcholine, SNP = sodium nitroprusside. VC = vehicle control, CC = Cre 
control, VE-Wt1 KO = vascular endothelial WT1 KO. 
 
3.3.4 Ex Vivo Angiogenesis in the Aortic Ring Assay 
3.3.4.1 Quantification of Vessel Outgrowth 
The aortic ring model was used as an ex vivo model of angiogenesis. Aortic 
rings isolated from C57Bl/6 mice were embedded in collagen and cultured in 
one of five different media; OptiMEM, +VEGF, +FCS, +FCS +VEGF or <3 FCS 
>3VEGF. In all media, multiple vessel outgrowths formed from the surface of 
the aortic tissue (Figure 3.3.7). From visual analysis, at Day 3 post-embedding 
outgrowth of cells was evident. These began to form into connected vessel 
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outgrowths at Day 5 and Day 7 and then continued to grow and branch up until 




Figure 3.3.7: Angiogenesis in the aortic ring assay. Brightfield images of aortic 
rings from C57Bl/6 mice embedded in collagen and treated with A-E) 
unsupplemented OptiMEM medium, F-J) medium + 5ng/ml FCS, K-O) medium + 2% 
FCS and P-T) medium + 5ng/ml VEGF + 2% FCS. Images shown are at Day 3, Day 
5, Day 7, Day 10 and Day 12, by row chronologically from the top to bottom. Scale 
bars = 200µm, representative images from n=6. 
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Cell and vessel outgrowth at Day 3, Day 5 and Day 7 were quantified for 
different media by counting under brightfield light microscopy (Figure 3.3.8). 
Cell outgrowths were determined as cells visible under the microscope which 
were evidently originating from, and still in contact with, the aortic tissue. 
Addition of FCS to media resulted in an increase (~75%) in the number of 
cellular outgrowths at Day 3 in the +FCS- and the +VEGF +FCS-treated tissue, 
in comparison to OptiMEM alone (p<0.001) (Figure 3.3.8 A). There was no 
significant difference at Day 3 between any of the other treatments. Culturing 
in +VEGF +FCS media resulted in the greatest number of vessel growths by 
Day 5 and all media had a significantly greater number of vessels by Day 7 in 
comparison to OptiMEM (+FCS & +VEGF +FCS: p<0.05, +VEGF & <3 FCS 
>3 VEGF: P<0.001). The maximum vessel length (used as a measure of the 
maximum vascularised distance) at Day 7 was also increased in all media in 
comparison to OptiMEM (+FCS: p<0.05, +VEGF & +VEGF +FCS: P<0.001) 
(Figure 3.3.8 C). 
 In +VEGF and <3 FCS >3 VEGF treatments vessel number continued to 
increase from Day 5 to Day 7, whereas in all other treatments, vessel number 
reduced from Day 5 to Day 7 (Figure 3.3.8 B). Vessel elongation appeared to 
have a biphasic growth pattern, with rapid increase in vessel length from Day 
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Figure 3.3.8: The effect of medium supplementation on tube-like structure 
formation in the aortic ring assay. Quantification of vessel outgrowth in the aortic 
ring assay, with different medium supplementation, assessed by brightfield 
microscopy. A) Number of vessel outgrowths/ ring at Day 3. Columns represent mean 
+ s.e.mean. B) Number of vessel outgrowths/ ring at Day 5 & 7. C) Maximum vessel 
length/ ring at Day 3, 5 & 7. Symbols represent mean ± s.e.mean; l data from C57Bl/6 
mice (n=5 for all graphs). Abbreviations: OptiMEM = unsupplemented OptiMEM 
medium;  +VEGF = medium + 5ng/ml FCS;  +FCS = medium + 2% FCS;  +VEGF 
+FCS = medium + 5ng/ml VEGF + 2% FCS;  <3 FCS >3 VEGF = medium + 2% FCS 
up to Day 3, then medium + 5ng/ml VEGF*p<0.05, **p<0.01, ***p<0.001, all vs 
















3.3.4.2 Formation of Complex Multicellular Angiogenic 
Outgrowths 
Rings of aortic tissue from C57Bl/6 mice were embedded in culture for up to 7 
days with OptiMEM medium + 5ng/ml VEGF. Spontaneous angiogenic vessel 
outgrowth occurred over this time period, with immunostaining revealing two 
components to these vessels; CD31+/Isolectin-B4+ multicellular endothelial 
tubes, with a supporting αSMA+ perivascular component (Figure 3.3.9). These 
vessels formed branching structures radiating out from the aortic ring (Figure 
3.3.9 A), with αSMA+ cells forming a network of connections between 
proximate vessels Figure 3.3.9 B).  
While some endothelial cells in these vessels also express αSMA in the 
cytoplasm, the strong cytoskeletal and cell membrane αSMA staining evident 
in perivascular cells is not evident (Figure 3.3.10) From this respect, two 
different cell populations comprising vessels can be classified for each 
staining. With regard to CD31; CD31+/αSMA+ cells and CD31-/αSMA+, but not 
CD31+/αSMA- cells. With regard to Isolectin-β4; Isolectin-β4+/αSMA+ cells and 
Isolectin-β4-/αSMA+, but not Isolectin-β4+/αSMA- cells. Isolectin-β4 or αSMA 
































Figure 3.3.9: Immunofluorescent staining of angiogenic outgrowths in culture. 
Immunostaining for endothelial and perivascular markers revealed an endothelial 
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the aortic ring assay. Vessels were cultured with 5ng/ml VEGF. A, B, C) 


















Figure 3.3.10: Endothelial cells express αSMA during ex vivo angiogenesis. Co-
immunostaining of αSMA with A) Isolectin-B4 and B) CD31 shows endothelial cells 
have limited cytoplasmic αSMA expression during ex vivo angiogenesis, though 
seemingly perivascular cells do not express endothelial markers. n=6-9. Vessels were 
cultured with 5ng/ml VEGF. 
 
 
3.3.4.3 WT1 is Expressed in Some Angiogenic Vessels 
The aortic ring model has been demonstrated to be an effective model of 
angiogenesis, with multi-cellular angiogenic vessel formation occurring over a 
relatively short period of time. In order to visualise WT1 in this process, ex vivo 
aortic rings were cultured from WT1-GFP reporter mice, with GFP knock-in 
under the same promoter as WT1, such that GFP is synthesised upon WT1 
expression (WT1+/GFP). In preliminary experiments (n=1) nuclear GFP was 
ubiquitously present in Isolectin-B4+ and αSMA+ cells of certain vessel 
outgrowths at Day 7 (Figure 3.3.11 A) and entirely absent in others at the same 
time-point (Figure 3.3.11 B).  
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Figure 3.3.11: GFP expression is ubiquitously present in some angiogenic 
vessels and ubiquitously absent from others. Immunostaining against GFP in the 
WT1-GFP reporter mouse revealed nuclear GFP expression co-localising with DAPI 
in endothelial and perivascular cells of ex vivo angiogenic vessels (A), though 


















3.3.4.4 VE-Wt1 KO Transiently Inhibits Angiogenesis 
Given the early vascular expression of WT1 in angiogenic vessels, the effect 
of WT1 KO in endothelial cells was investigated to determine whether WT1 
has a functional role in angiogenesis. Quantification of the aortic ring assay in 
VE-Wt1 KO mice and relevant controls revealed that KO of WT1 in endothelial 
cells reduced the number of vessel outgrowths present at Day 5, though there 
was no difference between groups by Day 7 (Figure 3.3.12 A). The lack of 
difference at Day 7 is attributable to a concurrent increase in vessel number in 
the VE-Wt1 KO group from Day 5-7 and a reduction in vessel number in the 
control groups over the same time period. However, when cultured in VEGF 
(Figure 3.3.12) or FCS for 3 days, then VEGF (Figure 3.3.12), VE-Wt1 KO had 
no effect on vessel number. 
Figure 3.3.12 VE-Wt1 KO transiently impairs angiogenesis in the aortic ring 
assay, though VEGF counteracts this effect. Vessel counts at Day 5 and Day 7 in 
A) Un-supplemented medium, B) medium + 5ng/ml VEGF and C) medium + 2% FCS 
<Day 3, +5ng/ml VEGF <Day 3. Symbols repent mean ± s.e.mean; *p<0.05, VE-Wt1 
KO v CC & VC, 1-way ANOVA with Bonferroni post-hoc tests. n=5-8. VC = Vehicle 
control, CC = Cre control, VE-Wt1 KO = vascular endothelial Wt1 KO. 
FCS + VEGF




































































The experiments in this chapter investigated the role of WT1 in vascular 
endothelial cells, specifically, in the context of vascular function, maintenance 
of vascular tone and angiogenesis. Use of the ex vivo aortic ring angiogenesis 
assay supported the hypothesis that WT1 is intrinsically involved in 
angiogenesis in endothelial cells; WT1 was expressed in vessel outgrowths in 
the aortic ring assay and selective deletion of WT1 from the endothelium (VE-
Wt1 KO) transiently impaired angiogenesis. Alongside these findings, a 
number of intriguing and novel insights were obtained. VE-Wt1 KO increased 
vasoconstriction in response to NA and 5HT and while VE-Wt1 KO did not 
have an evident basal phenotype, it did induce testicular hypertrophy, through 
an unknown mechanism, with concurrent enlargement of the gonad. 
3.4.1 Ex Vivo Angiogenesis 
The ex vivo aortic ring assay is an elegant model for characterising sprouting 
angiogenesis, as by necessity, all new angiogenic outgrowths in culture must 
have originated from the vascular aortic tissue and the resident cells. 
Characterisation of vessel-like outgrowths in this model show that a number 
of typical processes associated with sprouting angiogenesis occur; a number 
of vascular outgrowths are formed and become elongated and branched, with 
pruning of vessels as angiogenesis progresses. This pruning was concurrent 
with rapid elongation of the remaining outgrowths.  
Immunofluorescent staining of aortic ring outgrowths has been carried out 
previously, demonstrating two cellular components to vessel-like angiogenic 
outgrowths; a central endothelial structure, with supporting mural αSMA+ cells 
(Zhu and Nicosia, 2002; Zhu et al., 2003; Baker et al., 2012). In addition to this 
prior work, the experiments herein confirm the presence of these two cell 
populations and provide a more detailed picture of the morphology of 
angiogenic outgrowths. The conventional view is that endothelial cells drive 
angiogenesis, with pericytes and other mural cells subsequently recruited to 
endothelium-derived angiogenic outgrowths to provide structural support 
(reviewed by Carmeliet & Jain 2011). IHC staining in the aortic ring assay 
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confirms this to some extent, showing endothelial cells, with the filipodia and 
branching structure characteristic of tip cells (Jakobsson et al., 2010) guiding 
the endothelial tube-like structures. However, contrary to this accepted 
wisdom, αSMA+ pericyte-like cells are present right up to the tip of these 
endothelial structures, wrapping around them, encapsulating them and often 
guiding expansion of angiogenic outgrowths alongside endothelial cells.  
One possible function these pericyte-like cells could be facilitating is 
proteolysis of the extracellular matrix, which both endothelial tip cells and 
pericytes engage in (Karagiannis and Popel, 2006; Yana et al., 2007; Augustin 
et al., 2009; Stratman et al., 2009). Given the dense collagen extracellular 
matrix in this assay, it is possible that pericytes are required alongside tip cells 
to create guidance tunnels through the matrix and this morphology is, 
therefore, unique to this assay. However, given the complex cross-signalling 
which occurs between endothelial cells and pericytes in angiogenesis 
(Augustin et al., 2009; Gaengel et al., 2009), it seems logical that pericytes 
would be involved throughout the process and facilitate endothelial tip cell 
function. It would be interesting to know whether these pericyte-like cells 
identified at the tip of the endothelial outgrowths have a unique function and 
expression profile in comparison to those further away from the tip; analogous 
to the unique role of endothelial tip cells are unique in their function. The 
histological techniques optimised in this chapter alongside FACs would be 
useful for investigating this relationship in the future. 
Another interesting observation in the aortic ring assay is that the endothelial 
cells comprising the angiogenic vessel-like outgrowths express the endothelial 
markers CD31 and Isolectin-B4, but also express the mesenchymal marker 
αSMA (which is more commonly associated with mural cells and not 
expressed in quiescent vascular endothelial cells). Endothelial tip cells are 
known to have a number of properties more characteristic of mesenchymal 
cell types, including their high migratory capacity and proteolytic function 
(Jakobsson et al., 2010). EMT involves transition of cells into a mesenchymal 
type, dissociation from other associated cells and increased migration (Kalluri 
and Weinberg, 2009); however, many cells are also capable of partial EMT 
(Revenu and Gilmour, 2009). There is preliminary evidence for EndoMT in 
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angiogenesis, with a number of regulators of EMT (including Snail, Slug and 
TGF-β; all activated by or transcriptionally activating MMP-2 and MMP-9) also 
apparently regulating angiogenesis  (Yu and Stamenkovic, 2000; Ma et al., 
2007; Welch-Reardon et al., 2014). However, as endothelial cells maintain 
cell-cell contact as outgrowths form, it has been hypothesised that a partial 
EndoMT occurs (Welch-Reardon, Wu and Hughes, 2015).  
3.4.1 Endothelial WT1 KO Impairs Ex Vivo Angiogenesis 
WT1 has been shown to be expressed in angiogenic vasculature in 
development (Duim et al., 2016), cancer (Dohi et al., 2010; Katuri et al., 2014; 
Wagner et al., 2014) and regenerative (Duim et al., 2015) contexts. Use of the 
WT1-GFP reporter mouse in the aortic ring assay showed that WT1 was 
discretely expressed in endothelial cells and αSMA+ cells of angiogenic vessel 
outgrowths. This confirms preliminary observation of WT1 in aortic ring 
outgrowths (McGregor et al.). Interestingly, WT1 expression was widespread 
in some outgrowths but completely absent from others, perhaps implying a 
different origin or function of these WT1+ outgrowths in comparison to WT1- 
outgrowths. It is also possible WT1+ outgrowths are at a different stage of the 
angiogenic process to those that are WT1- and that, therefore, this reflects 
temporal WT1 expression. In fact, this was seen in the adult myocardium post-
MI in which WT1 was only expressed acutely after injury (Duim et al., 2015). 
The WT1 expression in αSMA+ cells is also a point of interest, as previous 
studies on WT1 in angiogenesis have focused on endothelial WT1 expression. 
These results show that if WT1 is important an important factor in 
angiogenesis, it may not be solely endothelial WT1 regulation which is 
responsible. 
Unfortunately, due to the limited availability of WT1-GFP mice and the fragility 
of the newly formed angiogenic outgrowths during staining, images were only 
obtained from one mouse, limiting interpretation of these results. It would be 
interesting to reproduce these experiments and stain aortic ring outgrowths at 
different time points following the initiation of angiogenesis to assess how WT1 
expression changes over time. Furthermore, lineage tracing experiments for 
WT1 in this model would be fascinating to determine whether WT1+ vessels 
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have the same origins as WT1- vessels and whether WT1+ endothelial cells 
are capable of transitioning into mesenchymal cells (and vice-versa); an 
element which is yet to be investigated in the aortic ring assay.  
Knockdown of WT1 in the vascular endothelium (VE-WT1 KO) (confirmed to 
reduce endothelial WT1 expression by ~4 fold in the uterus) led to an 
impairment of ex vivo angiogenesis in the aortic ring after 5 days of culture in 
collagen. This demonstrates that WT1 expressed in the endothelium does 
indeed have a role in the angiogenic process. However, angiogenesis was not 
completely impaired and by day 7 vessel outgrowth number had recovered to 
normal levels in the VE-WT1 KO. This is interesting as outgrowths from control 
aortic rings exhibited pruning from day 5, whereas those from VE-WT1 KO did 
not; suggesting the dynamics of the angiogenic response are delayed or 
altered when Wt1 expression is reduced in endothelial cells. In line with the 
acute expression of WT1 in the endothelium post-MI (Duim et al., 2015), 
impairment of ex vivo angiogenesis in the VE-WT1 KO implies that endothelial 
WT1 is playing an intrinsic, though non-essential, role in initiation and/or early 
stages of angiogenesis.  
WT1 regulates Snail and Slug (Martínez-Estrada et al., 2010; Takeichi et al., 
2013), two of the factors implicated in EndMT in angiogenesis (Yu and 
Stamenkovic, 2000; Ma et al., 2007; Welch-Reardon et al., 2014). If the 
hypothesis that partial EndoMT is essential to angiogenesis (Welch-Reardon, 
Wu and Hughes, 2015) proves to be true, it is possible this could explain the 
delayed angiogenesis observed in aortic rings from the VE-Wt1 KO. In this 
case, delayed or reduced EndoMT could hamper degradation of the basement 
membrane and ECM and thus, impede endothelial cell progression. It is also 
worth noting that αSMA+ cells in this model expressed WT1 and that this 
expression may be sufficient to facilitate normal endothelial function through 
release of WT1-regulated factors from αSMA+ cells into endothelial cells. 
Alternatively and perhaps, controversially, αSMA+ cells may become 
endothelial cells through mesenchymal-to-endothelial transition. Additionally, 
the VE-Wt1 KO did not induce complete deletion of WT1 from endothelial cells 
and this could also explain the remaining capacity of endothelial cells to 
undergo angiogenesis.  
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It is worth noting that addition of VEGF to the assay was sufficient to overcome 
the suppression of angiogenesis induced by VE-WT1 KO in aortic rings. WT1 
is known to regulate VEGF (Graham et al., 2006; Amin et al., 2011; McCarty, 
Awad and Loeb, 2011; Iranparast et al., 2014) and the recovery of function on 
addition of VEGF suggests the impairment of angiogenesis seen in the VE-
Wt1 KO is, at least in part, as a result of disruption to VEGF signalling. 
However, two alternative hypotheses are also possible; firstly, that addition of 
VEGF is sufficient to provide optimal angiogenic conditions and drive 
angiogenesis, regardless of WT1 deletion and secondly, that VEGF is 
activating a number of downstream targets of WT1, independently of the WT1 
protein. In order to clarify the mechanism involved, the levels of VEGF protein 
and mRNA could be determined in VE-Wt1 KO aortic ring assays and an 
endothelium-selective, inducible VEGF or VEGFR KO could be used in this 
aortic ring model to determine whether this deletion produces a similar effect 
to the VE-Wt1 KO. As with WT1 KO mice, VEGF KO mice die mid-gestation 
(Kreidberg et al., 1993; Tammela et al., 2005). Given that both VEGF and WT1 
are major transcriptional regulators activated by HIF-1, it would seem 
somewhat redundant if they were playing the same role in angiogenesis 
(Wagner et al., 2003; Tammela et al., 2005). 
WT1 has been previously investigated in the aortic ring assay, using a 
Tie2CreERT2 Wt1 KO (Wagner et al., 2014). In agreement with the results 
described in this chapter using the VE-Wt1 KO mouse (Wt1 KO under the 
control of a VE-CadherinCreERT2), the Tie2 WT1 KO also impaired ex vivo 
angiogenesis, though the inhibition seen with the Tie2 Wt1 KO was more 
dramatic, with an almost complete inhibition of outgrowth formation (Wagner 
et al., 2014). Alongside endothelial cells, Tie2 is expressed in cells of a 
haematopoietic lineage including macrophages, B- and T-lymphocytes, 
natural killer cells and dendritic cells (Constien et al., 2001; Kisanuki et al., 
2001). The greater inhibition of angiogenesis in this less selective Wt1 KO 
suggests that WT1 in one or all of these other cell types is important for 
regulation of angiogenesis. To clarify this role, the aortic ring assay could be 
carried out with a ubiquitous inducible Wt1 KO to see if the result is the same, 
as well as inducible Wt1 KOs in macrophages and pericytes. All of this would 
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help determine the specific cell types in which WT1 expression influences 
angiogenesis. 
The aortic ring assay has considerable unexplored potential for investigating 
the processes involved in sprouting angiogenesis and the role WT1 plays in 
these. From a pure angiogenesis line of investigation, as well as in relation to 
WT1, it would be interesting to stain for other cell types in this model to 
determine how different cellular components arising from the aorta are 
involved in angiogenesis and which of these are expressing WT1. Cell types 
that could be interesting, due to their known involvement in angiogenesis and 
their documented WT1 expression are monocyte-derived macrophages and 
dendritic cells (L W Ellisen et al., 2001; Fainaru et al., 2007; Jaipersad et al., 
2014; Li et al., 2016), fibroblasts (Braitsch et al., 2013; Ubil et al., 2014), MSCs 
(Chau et al., 2011; Gong et al., 2017), HSCs (L W Ellisen et al., 2001; Butler 
et al., 2010) and APCs (Chau et al., 2014; Cheng et al., 2017). EPCs have not 
been shown to have WT1 expression, although, as with many WT1-expressing 
cells they undergo a TGF-β mediated EMT (Díez et al., 2010). Regardless, 
investigating EPCs in the aortic ring assay could add further weight to the 
hypothesis of a resident vascular EPC niche involved in angiogenesis 
(Zammaretti and Zisch, 2005). 
Finally, my group has optimised a protocol allowing RNA extraction and qPCR 
to be carried out in the aortic ring assay (Morgan et al. unpublished data). In 
order to provide greater insight into the mechanism underlying the function of 
WT1 in angiogenesis, qPCR should be carried out in the aortic ring assay with 
VE-Wt1 KO and ubiquitous Wt1 KO. 
3.4.2 Vasoconstriction is Altered by Endothelial WT1 KO 
Myography was carried out to determine whether endothelial function was 
impaired by VE-Wt1 KO. WT1 is not known to be expressed in healthy adult 
vasculature (Chau et al., 2011), so it was not envisioned that WT1 deletion 
would affect vascular function in non-pathological circumstances. Consistent 
with this hypothesis, the contractile response of aortae to potassium, was not 
affected by VE-Wt1 KO, suggesting calcium-mediated contraction of VSMCs. 
93 
 
However, surprisingly, aortae from VE-Wt1 KO mice exhibited an increased 
contractile response to two vasoconstrictors, 5HT (serotonin) and NA 
(noradrenaline). This is the first time WT1 has been shown to have any 
influence on vasoconstriction. This could prove to be a novel and exciting area 
of investigation. At this point, it is worth noting that the effect of VE-Wt1 KO 
was restricted to vasoconstriction, with no effect on vasodilation in response 
to the two drugs assessed (ACh and SNP). There are a number of factors to 
consider in relation to these novel findings.  
Serotonin binds to 5HT receptors in the endothelium and VSMCs, with 
counterbalancing effects. In the endothelium, binding of serotonin to 5HT1B, 
5HT1D and 5HT2B receptors induces vasodilation, which is in part NO-
dependent, while binding of serotonin to 5HT receptors in VSMCs induces 
vasoconstriction (Nagatomo et al., 2004; Watts and Davis, 2011). 
Noradrenaline binds to the α- and β-adrenergic receptors in endothelial cells 
and VSMCs, to induce vasoconstriction, though it also has the potential to 
induce EDRF-dependent endothelial relaxation (Chotani et al., 2000; Tanoue 
et al., 2002; Dessy et al., 2004). The simplest explanation for the increased 
contractile response seen in VE-Wt1 KO aortae to these drugs is that VE-Wt1 
KO has affected the number of 5HT and adrenergic receptors in the 
vasculature and that WT1 normally plays a role in modulating these receptors. 
As the maximum contractile response to 5HT is increased in denuded VE-Wt1 
KO aortae, this suggests changes in receptors both in the endothelium and 
VSMCs. If WT1 is expressed at low levels in some endothelial cells and 
therefore, VE-Wt1 KO affected serotonin and noradrenaline signalling post-
induction of KO, it is possible these receptor changes could occur as a 
compensatory response to physiological changes induced by VE-Wt1 KO. 
Transcription factors, such as WT1, are capable of producing surprisingly rapid 
transcriptional changes in response to stimuli (Kahlert et al., 2000) and so, 
alternatively, as WT1 is not thought to be ordinarily expressed in the 
endothelium the differences seen could reflect a rapid transcriptional response 
by WT1 in the endothelium. A final, explanation is that VE-Wt1 KO could 
produce systemic effects that alter NA and 5-HT-mediated signalling; 
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concordantly, the levels of circulating NA and 5-HT could be measured in 
these mice. 
A role of WT1 in vasoconstriction would be very relevant to cardiovascular 
disease in which hypertension increases risk of myocardial infarction, stroke 
and heart failure. In Denys-Drash syndrome and some other glomerulopathies 
resulting from Wt1 mutations hypertension is evident (Little et al., 1993; 
Wagner et al., 2008; Lipska et al., 2014). The increased vasoconstriction in 
VE-Wt1 KO observed here raises the possibility that WT1 could be important 
in regulating vascular tone and that WT1 mutations are causative of 
hypertension. This is further supported by previous observations that WT1 
regulates NO signalling (Johannesen et al., 2003; Mazzei et al., 2010). 
However, selective endothelial KO of WT1 does not inhibit endothelium-
dependent (ACh-mediated) relaxation, which suggests that impaired 
angiogenesis in this model is not due to a generalised impairment in the 
endothelial cell NO pathway. In order to further investigate the possible role of 
Wt1 in vascular tone, the blood pressure of VE-Wt1 KO mice should be 
assessed in vivo to determine if they are hypertensive and are therefore, 
predisposed to cardiovascular disease. 
Furthermore, regulation of vascular tone is connected with angiogenesis and 
some factors can influence both processes (Coletta et al., 2012). In fact, 
serotonin and noradrenaline signalling are intertwined; in sympathetic nerves, 
activation of the 5HT1D receptor (also present in endothelial cells) inhibited 
release of noradrenaline (Molderings et al., 1990). Excitingly, given the focus 
of this thesis on angiogenesis, serotonin and noradrenaline signalling 
influence angiogenesis. Serotonin has been shown to be pro-angiogenic, 
inducing endothelial cell proliferation and migration and in vitro 2D-tube 
formation and also promoting angiogenesis in vivo  by reducing 
Thrombospondin-1 levels (Qin et al., 2013).  In a colon cancer model, 
serotonin deficiency affected MMP-12 release by macrophages and hence, 
reduced angiogenesis and tumour growth (Nocito et al., 2008). Moreover, in a 
murine ischaemic limb model, stimulation of endothelial 5HT1B by inhibiting 
VSMC 5HT2A, activated the eNOS/Akt pathway and increased in vivo 
angiogenesis (Iwabayashi et al., 2012). Similarly, the β3-adrenergic receptor 
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was shown to influence retinal endothelial cell proliferation and migration with 
potential involvement of MMP-2, MMP-9, PI3K and MEK (Steinle et al., 2003). 
Furthermore, in vivo noradrenaline upregulated VEGF, MMP-2 and MMP-9 
(Yang et al., 2006). This all raises the exciting possibility that WT1 may be 
controlling vascular tone and angiogenesis simultaneously through regulation 
of noradrenaline and serotonin signalling pathways, though the mechanism is, 
as yet, unclear. 
 
3.4.3 Endothelial WT1 has a Role in the Adult Testis and Male 
Gonad 
Histological assessment of a number of organs was carried out in the VE-Wt1 
KO mouse and found to be grossly normal. As a result, it was initially assumed 
that the VE-Wt1 KO mouse had no phenotype, which was to be expected, 
given the assumed absence of endothelial WT1 expression in the adult (except 
in vessels of the uterine wall and mammary glands). However, following 
induction of VE-Wt1 KO, it was observed that the male gonad became visibly 
enlarged. This was shown to occur despite a reduction in testis weight and 
with no change in the weight of the epididymal fat or seminal vesicles. 
Immunofluorescent staining in the testis revealed a large number of 
endothelial WT1+ vessels in the testis of adult CC mice; this staining appeared 
to be reduced in VE-Wt1 KO mice, consistent with the reduction in WT1 
expression in the vessels of the uterus in this line. This is the first time a role 
for endothelial WT1 in the testis has been shown has been shown and it should 
henceforth be assumed that WT1 is normally expressed in the vascular 
endothelium of the adult testis.  
In relation to WT1 in the testis, endothelial WT1 expression should be 
assessed in completely wildtype mice, however, to confirm this is not specific 
to these mice and in mice of different ages to confirm this is not specific to our 
examined time point or the age of these mice. While it is possible that WT1 
expression in the testis is induced by the activation of VE-Cadherin Cre in 
these mice, the fact that the gonadal enlargement was seen in VE-Wt1 KO 
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and not CC means it is not likely this is just a Cre effect. As the testis continues 
to grow in mice throughout early adulthood (Sharpe et al., 2003) it is not clear 
from our results whether the reduced testis size is a result of impaired 
testicular growth, testicular atrophy, or a combination of the two. Induction of 
VE-Wt1 KO in older mice should be carried out and the change in testis weight 
assessed over time post-induction of VE-Wt1 KO to determine if they reduce 
in size or have impaired growth. How VE-Wt1 KO is specifically affecting 
testicular morphology could be assessed by histology to determine if there is 
any structural alterations in Leydig or Sertoli cells. 
The visible enlargement of the gonad cannot be attributed to increased size of 
the testis, epididymal fat or seminiferous vesicles, as these were ruled out. 
Therefore, two possible hypotheses for the enlarged gonad are that it is 
occurring as a result of inflammation, or of fluid accumulation. It appears 
unlikely to be due to inflammation, as this would likely result in the components 
of the gonad becoming enlarged and inflamed themselves. When WT1 was 
ubiquitously deleted in adult mice, it rapidly resulted in generalised oedema 
and atrophy of the spleen and pancreas (Chau et al., 2011). It would appear 
this is occurring locally to the testis in the VE-Wt1 KO mouse. The endothelial 
WT1 observed in testicular vessels of CC mice, make it reasonable to assume 
this is attributable to a reduction in endothelial WT1 expression in the testicular 
vasculature. This may result in poorer perfusion of the testis and increased 
permeability of the vasculature, in turn leading to fluid leaking into the 
surrounding tissue and localised oedema. WT1 regulates VEGF in the 
endothelium (Wagner et al., 2003) and VEGF has an essential role in 
regulation of vascular permeability (Nagy, Dvorak and Dvorak, 2007). The 
reduction in testis size is in line with the reduction in tumour size observed 
following Tie2 Cre Wt1 KO, attributable to impaired tumour angiogenesis 
(Wagner et al., 2014). If a similar mechanism is occurring in the testis, the 
reduced size observed may be as a result of impaired angiogenesis limiting 





The experiments contained in this chapter provided greater insight into the role 
of WT1 in the vascular endothelium ex vivo. This supported the previously 
accepted paradigm and our hypothesis that WT1 is intrinsically involved in 
angiogenesis in endothelial cells. However, it is also clear that WT1 is also 
expressed in other vascular cells in angiogenesis and that endothelial WT1 is 
not indispensable to the progression of angiogenesis. There were also a 
number of novel and exciting findings in relation to the vascular function of 
endothelial WT1 outside of the context of angiogenesis; namely that 
endothelial WT1 influences vasoconstriction and potentially vascular 
permeability alongside angiogenesis in the adult testis. This raises the 




























Cardiovascular disease (CVD) is still the leading cause of death worldwide; in 
2013 17.3 million people died of CVD, equivalent to 31.5% of all deaths 
(Naghavi et al., 2015). Ominously, unlike the majority of other preventable 
diseases, deaths from CVD have risen over the last 20 years or so, as the 
global population moves towards a more sedentary, lifestyle and increasingly 
unhealthy diet (Naghavi et al., 2015). In Europe, the picture is somewhat 
brighter, with deaths from CVD steadily dropping (Townsend et al., 2016) and 
in 2012, for the first time, cancer overtook CVD as the leading cause of death 
for men in the UK (Bhatnagar et al., 2015). First amongst these CVDs for 
fatality was coronary heart disease, which can result in heart attack 
(myocardial infarction), with cerebrovascular stroke the second most common 
cause of death (Bhatnagar et al., 2015). In the case of critical limb ischaemia, 
while there is no appropriate treatment for some patients, it rarely results in 
death. It is worth considering that even sub-lethal cardiovascular events, such 
as often occur with critical limb ischaemia, can have debilitating long term 
impact on patient health and welfare. Given the persistent global burden of 
CVD, further incremental advances in our treatment of CVD will be necessary 
if we are to continue to reduce its impact. The work in this chapter addresses 
the role of WT1 in vivo in relation to CVD, particularly regenerative, ischaemic 
angiogenesis and to the potential of WT1 as a therapeutic target in CVD. 
In ischaemic cardiovascular diseases such as myocardial infarction, stroke 
and critical limb ischaemia /peripheral arterial disease, damage is induced in 
tissues by deprivation of oxygen as a result of disruption to normal blood flow. 
Most commonly, ischaemia is induced as a result of plaque build-up in the 
arterial wall, also known as atherosclerosis. In atherosclerosis, accumulation 
of lipids in the arterial wall forms an atherosclerotic plaque, which narrows the 
lumen of the artery and reduces downstream blood flow (reviewed by Lusis 
2000). This can be sufficient to induce ischaemia in affected tissues; however, 
acute ischaemic attacks are induced when the atherosclerotic plaque 
becomes unstable and ruptures, accompanied by thrombosis, blocking 
proximal arteries and capillaries. Which vessels are affected determine which 
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tissues become ischaemic and, hence, the symptoms that develop; blockage 
of the coronary arteries results in coronary artery disease and myocardial 
infarction, blockage of the cerebral microvasculature induces stroke, and 
blockage of the peripheral limb microvasculature results in peripheral artery 
disease which can progress into critical limb ischaemia. Atherosclerosis is 
accompanied, and worsened, by endothelial cell dysfunction, wherein the 
normal anti-inflammatory and anti-thrombotic function of the vascular 
endothelial cells becomes impaired. In addition there is dysregulation of 
vascular tone and permeability (in part due to decreased NO), and increased 
expression of adhesion molecules by the endothelium (Sitia et al., 2010).  
While the symptoms atherosclerosis depend on the site of lesion formation, 
the underlying pathophysiology is broadly similar; ischaemic pathophysiology 
in myocardial infarction, stroke and critical limb ischaemia has been reviewed 
by Buja (2005), Durukan & Tatlisumak (2007), and Varu et al. (2010), 
respectively. Initial ischaemic damage occurs as a result of oxygen deprivation 
and, hence, energy deprivation as mitochondria are unable to generate 
sufficient ATP. This progresses particularly rapidly in tissues such as the brain 
and heart which have a high-energy demand. The damage in ischaemic cells, 
including endothelial cells and inflammatory cells (such as leukocytes), results 
in increased free radical formation and increased cytosolic Ca2+. The 
endothelial cell dysfunction seen in an atherosclerotic milieu is also observed 
in ischaemic tissues, in which endothelial dysfunction also occurs (Viehman et 
al., 1991; Sitia et al., 2010). Ischaemia induces upregulation of a number of 
pro-inflammatory factors and cytokines, such as MCP-1, NF-kB, TNF-α, 
interleukins, and the complement pathway, which results in recruitment of 
inflammatory cells and induction of an inflammatory response (Frangogiannis, 
Smith and Entman, 2002). Neutrophils rapidly migrate to the affected tissue, 
with macrophages, mast cells and leukocytes then recruited, with seemingly 
both beneficial and detrimental effects (Frangogiannis, Smith and Entman, 
2002).  
Fibrosis also occurs in myocardial infarction and peripheral artery disease, 
driven by resident and recruited fibroblasts. While fibrosis can often be 
detrimental, in these diseases fibroblasts also have a regenerative and 
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reparatory role. Post-myocardial infarction, fibroblasts deposit extracellular 
matrix and collagen to maintain structural integrity in the infarct area as 
myocardial cells die-off (Shinde and Frangogiannis, 2014). They also interact 
with inflammatory cells by secreting pro-inflammatory cytokines and release 
pro-angiogenic factors (van Nieuwenhoven and Turner, 2013). Both the heart 
and skeletal muscle have resident progenitor populations capable of 
regenerating muscle, or epicardial cells and satellite cells, respectively. 
Interestingly, in skeletal muscle regeneration, fibroblasts and inflammatory 
cells regulate proliferation and differentiation of satellite cells into mature 
myocytes (Murphy et al., 2011; Wang and Rudnicki, 2011). In the heart, 
cardiac fibroblasts are generated from the epicardium post-MI (Braitsch et al., 
2013; Ellison et al., 2013) and appear to have the capacity to generate 
myocardial cells (Jayawardena et al., 2012; Qian et al., 2012). 
If ischaemia is maintained, its deleterious impact can become irreversible with 
widespread cell apoptosis;  however, activation of angiogenesis occurs early 
after onset of ischaemia in myocardial infarction, stroke and peripheral artery 
disease and has the potential to re-perfuse damaged tissues to induce repair 
and regeneration (Carmeliet and Jain, 2011). In all of these contexts, 
angiogenesis and arteriogenesis simultaneously occur to increase the extent 
of reperfusion. Interventions which increase in vivo angiogenesis have been 
shown to improve function post-ischaemia in animal models of stroke (Wang 
et al., 2004; Fan et al., 2010; Jin et al., 2014), MI (Hao et al., 2007; Garbern et 
al., 2011; Meloni et al., 2013) and critical limb ischaemia (Emanueli et al., 
2002; Iwase et al., 2005). 
In the context of CVD, WT1 has primarily been investigated in vivo in 
myocardial infarction. As previously mentioned, the outer layer of the heart, 
the epicardium, has the capacity to partially regenerate the heart post-MI and, 
while all other cell populations in the heart lose WT1 expression in adulthood, 
epicardial cells are WT1+ and Wt1 is overexpressed in the murine epicardium 
post-MI (Duim et al., 2015). After injury, activated epicardial cells generate 
epicardial-derived-cells (EPDCs) which differentiate into cardiomyocytes and 
other cell types through EMT (van Wijk et al., 2012). In fact, post-MI, EPDCs, 
cardiomyocytes, VSMCs and endothelial cells proximal to the infarct area all 
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express WT1 (K. Wagner et al., 2002; Smart et al., 2011; Duim et al., 2015). 
In other models of cardiac injury, including ischaemia-reperfusion, WT1 was 
also expressed in areas of fibrosis (Braitsch et al., 2013). In these in vivo 
models, WT1 directly regulated adult epicardial cell EMT through direct 
transcriptional regulation of Snail, VCAM-1 and Pdgfrα (Braitsch et al., 2013).  
WT1 is known to play a role in developmental angiogenesis in the heart 
(Martínez-estrada et al., 2010; Zhou and Pu, 2012) and this is replicated post-
MI where WT1 is expressed in the vascular endothelial cells and supporting 
cells of vessels proximal to the infarct area, co-localising with VEGF and PCNA 
(K. Wagner et al., 2002; Duim et al., 2015). In line with the important role of 
WT1 in the epicardium, a proportion of WT1+ vascular endothelial cells arise 
from the epicardium and EPDCs (S. Chen et al., 2013). Finally, in the 
subcutaneous sponge implantation model of in vivo angiogenesis, preliminary 
data suggested that induction of vascular endothelial Wt1 KO, under the 
control of VE-Cadherin Cre, resulted in a ~8 fold reduction in blood vessel 
formation (McGregor et al. 2014, Wagner et al. unpublished data). 
As it has long been evident that WT1 is involved in the response to ischaemia 
in cardiovascular disease and could, through angiogenesis and other 
beneficial processes, have regenerative potential, it is surprising it has not 
been investigated more thoroughly in this context. Given the immense global 
burden of CVD and that modern medicine is currently incapable of averting 
ischaemic damage, new regenerative treatments are necessary. WT1 appears 
to be a promising candidate given its potential role in ischaemic angiogenesis, 
though in vivo experiments are thought ultimately necessary in order to 
effectively determine this. 
4.1.2 Hypothesis  
This chapter aims to address the hypothesis that: 
“Wt1, particularly Wt1 in endothelial cells, is key to ischaemic 





The specific aims addressed in this chapter were to determine: 
1. The expression of WT1 in vascular and non-vascular cells in two 
models of in vivo angiogenesis.  
2. Whether VE-Wt1 KO inhibits angiogenesis in the subcutaneous sponge 
implantation model. 
3. Whether VE-Wt1 KO inhibits angiogenesis in the hindlimb ischaemia 
model. 
First, the expression of WT1 in normal C57Bl/6 mice will be determined in two 
murine models of in vivo angiogenesis; the subcutaneous sponge implantation 
model and the hindlimb ischaemia (HLI) model of critical limb ischaemia. This 
will provide a greater insight into the role of WT1 in angiogenesis and 
ischaemia, as the role of WT1 has not been only minimally investigated in the 
sponge model and not at all in the hindlimb ischaemia model. 
Then, in both these models, Wt1 will be knocked-out in the vascular 
endothelium using the VE-Wt1 KO mouse (Monvoisin et al., 2006; Wagner et 
al., 2014) and angiogenesis assessed, to determine the role of endothelial 




4.2 Materials and Methods 
For full materials and methods refer to Chapter 2. 
4.2.1 Animals 
4.2.1.1 C57Bl/6 Mice 
C57Bl/6 mice were used as wildtype controls in both the subcutaneous sponge 
implantation (SSI) and hindlimb ischaemia (HLI) models, to characterise the 
models and determine the role of WT1 in control mice. All C57Bl/6 mice were 
C57Bl/6J males, 10-18 weeks of age at the start of experiments.  
4.2.1.2 Endothelial WT1-KO Mouse 
The endothelial WT1-KO mouse was generated by Kay-Dietrich Wagner and 
Nicole Wagner (Université de Nice) and SSI was carried out in this model at 
Université de Nice by this group in mice treated with tamoxifen (KO) or vehicle 
(VE-Wt1 KO). This mouse used the Cre-Lox system to induce an inducible, 
endothelial specific, WT1-KO with VE-Cadherin Cre. This mouse is analogous 
to the VE-Wt1 KO mouse (Section 2.1.1) and work with this mouse line has 
been previously published (Wagner et al., 2014). Sponges were extracted 21 
days post-implantation for histology and RT-qPCR and samples were kindly 
provided by Kay-Dietrich Wagner and Nicole Wagner (Université de Nice). All 
mice used were male and 12-18 weeks of age at start of experiments (n=6).  
4.2.1.3 Vascular Endothelial Wt1-KO (VE-Wt1 KO) Mouse  
The generation and genotype of the VE-Wt1 KO mouse is described in full in 
Section 2.1.1. This mouse was generated at The University of Edinburgh and 
is analogous to the mice generated in Nice (Section 4.2.1.2). Tamoxifen 
injection was carried out as previously described (Section 2.1.1). Controls 
used were; vehicle controls (VC), with identical genotype to VE-Wt1 KOs, 
injected with oil only and Cre controls (CC), with only VE-Cadherin CreERT2  
in the absence of Wt1lox/lox, injected with tamoxifen to control for the effect of 
tamoxifen and Cre.  
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Subcutaneous sponge implantation (SSI): 
VE-Wt1 KO, VC and CC mice used were all male and 11-16 weeks at start of 
experiment (n=8). Sponges were extracted 21 days post-implantation, then 
either fixed in 10% formalin and wax embedded prior to staining, or snap 
frozen on dry ice and stored at -80oC prior to RNA extraction and qPCR 
(Section 2.10).  
Hindlimb ischaemia (HLI): 
VE-Wt1 KO, VC and CC mice used were all male and 11-16 weeks at start of 
experiment (n=8). Gastrocnemius muscle of ischaemic (ligated) and non-
ischaemic (contralateral, non-ligated) limbs were extracted 28 days post-
implantation, then either fixed in 10% formalin and wax embedded prior to 
staining, or snap frozen on dry ice and stored at -80oC prior to RNA extraction 
and qPCR (Section 2.10).  
4.2.2 Histology 
All histological staining was carried out using the techniques outlined in 
Sections 2.11 & 2.12. The details of antibodies used for immunofluorescent 
staining and their concentrations are given below (Table 4.2.1) where not 
previously provided in Section 2.11 & 2.12. 
H&E (Section 2.11.2) and PSR staining (Section 2.11.3) were carried out as 
previously described. Immunoprecipitation staining of CD31 (rabbit v mouse 
anti-CD31 (1/300) (Abcam, ab28364)) and WT1 (rabbit v mouse anti-WT1 
(1/300) (Abcam, ab28364)) were carried out as per the protocol in Section 
2.11.4. Immunoprecipitation staining of F4.80 (rat v mouse anti-F4.80 (1/300) 
(eBioscience, 14-4801) was carried out by the Histology department (Shared 
University Research Facilities (SURF), University of Edinburgh) at The 






1o Antibody 2o Antibody 
Rabbit v mouse anti-WT1 (1/300) 
(Abcam, ab28364) 
Goat v rabbit IgG Peroxidase (1/200) 
(Vector, PI-1000) 
TSA Tyramide Fluorescein or Cy3 or 
Cy5 (1/50) 
(PerkinElmer, NEL701A001KT or 
SAT704A001EA or SAT705A001EA) 
Rabbit v mouse anti-CD31 (1/300) 
(Abcam, ab28364) 
Goat v rabbit Alexa 488 (1/200) 
(Molecular Probes, GAR-A488) 
Isolectin-B4 (1/500) 
(Invitrogen, 1110271) 
Streptavidin - Alexa 488 (1/400) 
(Invitrogen, A-32354) 
Rabbit v mouse anti-αSMA (1/500) 
(C6198, Sigma) 
Directly conjugated to Cy3  
Goat v mouse anti-SNAIL (1/300) 
(Abcam, ab53519) 
Donkey v goat Alexa 555 (1/200) 
Molecular probes (A11056)  
Goat v mouse anti-PCNA (1/300) 
(Santa Cruz, sc-9857) 
Donkey v goat Alexa 555 (1/200) 
Molecular probes (A11056)  
Goat v mouse anti-VEGFR2 (KDR) 
(1/300) 
(Abcam, ab10972) 
Donkey v goat Alexa 555 (1/200) 




Table 4.2.1: Antibodies used for immunofluorescent staining. Primary antibodies 
are provided with the relevant secondary antibodies used in the adjacent column. 
Antibody description/name, concentration used, provider and catalogue number are 
all provided. 
4.2.3 Quantification of Histology 
For quantification, images were taken on an Axioscan Z1 slide scanner (Zeiss) 
and four random regions of interest (ROIs) 500µm x 500µm were selected on 
Zen 2012 Blue software (Zeiss). Images were extracted and analysed using 
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Image J software (V1.47, National Institute of Health, USA). The mean of the 
values for these four regions of interest was then calculated. 
For sponges, due to the sponges being more vascularised and cellularised 
around the periphery, alongside selecting ROIs at random (referred to as 
‘Total’), ROIs were also randomly selected from the outer circumference of 
sponge up to a depth of 1000µm from the edge (referred to as ‘Outer’) and the 
centre of the sponge (referred to as ‘Inner’) (Figure 4.2.1).  
 
Figure 4.2.1: Quantification of histology in sponge sections. The Total cross 
sectional area of the sponge was broken up for quantification of histology into a 
section comprising the outer 1000µm (Outer) and the remaining central area of the 
sponge (Inner). This was necessary due to the uneven vascular and cellular infiltration 
into the sponge.  
4.2.3.1 Vessel Density 
Vessels were identified by luminal structures with a CD31+ endothelial layer 
and counted within the selection ROIs. This was quantified as vessel density 
by vessel number divided by area. 
4.2.3.2 WT1 Positive Nuclei 
Nuclei were identified by DAPI staining. The number of WT1+ nuclei within 
each ROI was counted and expressed as the number of WT1+/DAPI+ nuclei 
divided by the total number of DAPI+ nuclei. 
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4.2.3.3 Percentage Positive Area 
ROIs were thresholded by colour in Image J to convert them to black and 
white images such that the stain of interest was converted to black pixels and 
the rest of the image was converted to white pixels. The percentage positive 
area (for the stain of interest) was then calculated as the number of black 
pixels divided by the total number of pixels in the ROI (black pixels + white 
pixels). The same parameters were used to threshold each ROI. 
Immunoperoxidase (DAB):  PSR: 
Hue:    0-40     220-255 
Saturation:   50-255    0-255 
Brightness:   0-255     0-255 
4.2.4 RT-qPCR 
RNA extraction, CDNA synthesis and RT-qPCR was carried out as described 










4.3.1 The Subcutaneous Sponge Implantation (SSI) Model of 
Angiogenesis 
In wildtype control (C57Bl/6) mice, numerous cell types infiltrated into 
implanted sponges, along with angiogenesis providing a blood supply into the 
sponge matrix through new blood vessel formation (Figure 4.3.1). There was 
a visible difference in sponge appearance at Day 3 (Figure 4.3.1A) compared 
with Day 21 (Figure 4.3.1B), with the colour of sponges changing as cells and 
vessels infiltrated. It was also evident that cutaneous vessels had been 
recruited to, and grown into, the sponges to provide them their own blood 
supply (Figure 4.3.1B). However, H&E staining revealed cells and blood 
vessels only infiltrated a limited distance into the sponges by Day 21, with the 
majority of the sponge still largely uncolonised (Figure 4.3.1C).  
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Figure 4.3.1: Cell and vessel infiltration in the subcutaneous sponge model. 
Subcutaneous sponge implantation was carried out in C57Bl/6 mice. Subcutaneous 
sponges in situ at A) Day 3 and B) Day 21, post-implantation (blood vessels indicated 
with black arrows). C) A cross-section through an H&E stained sponge at Day 21, 
shows the depth of cell infiltration into the sponge. D, E) Representative H&E images 
at Day 21 (50x magnification). F, G) Representative H&E images at Day 21 (100x & 
200x magnification, respectively), with blood vessels clearly visible (black arrows) and 
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4.3.2 WT1 Expression in the Subcutaneous Sponge Model 
(SSI) 
C57Bl/6 mice, were examined for WT1 expression in normal mice in response 
to subcutaneous sponge implantation. Isolectin-B4/WT1/DAPI IF IHC staining 
was carried out on these tissues to visualise WT1 expression and determine 
if there was vascular WT1 expression. Isolectin-B4 stained the cytoplasm of 
vascular endothelial cells of vessels. There were also a large number of cells 
within the sponges that expressed Isolectin-B4 that were not associated with 
blood vessels and other non-vascular cells which did not express Isolectin-B4. 
WT1 staining was observed in sponges; a proportion of this was due to 
expression in cells of the vascular wall but some was also evident in non-
vascular cells proximal to vessels and some was in other non-vascular cells. 
Whilst many blood vessels had no WT1+ cells, WT1 staining was present in a 
proportion of Isolectin-B4+ endothelial cells of newly formed blood vessels, 
with staining occurring in a granular distribution within the nucleus (Figure 
4.3.2 C-E). Many non-vascular Isolectin-B4+ cells and Isolectin-B4- cells also 
expressed nuclear WT1 (Figure 4.3.2). 
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Figure 4.3.2: WT1 is widely expressed in vascular and non-vascular cells of 
the subcutaneous sponge implantation model. Representative images from 
Isolectin-β4 (green), WT1 (red) and DAPI (blue) staining in sponges from the SSI 
model from C57Bl/6 mice. Isolectin-β4 is expressed in a large proportion of cells in 







vascular-associated endothelial cells (white arrows). Representative images from 
n=3.  
 
4.3.3 Endothelial WT1 KO in the Subcutaneous Sponge 
Implantation Model 
Sections from sponges implanted (21 days) in mice with endothelium-selective 
WT1 KO mice were kindly provided by Drs Kai & Nicole Wagner (University of 
Nice). This KO was generated using a VE-Cadherin Cre system as described 
in Section 2.1.1 and is analogous to the VE-Wt1 KO mouse described 
previously and used in aortic ring models (Section 3.3.4.4). However, as the 
generation of the KO and the surgeries were carried out in Nice, and there is 
only a vehicle control (no Cre control), these will be referred to separately to 
avoid confusion. Preliminary data from this work has been published (Wagner 
et al. 2014, McGregor et al. unplublished data). 
4.3.3.1 Endothelial WT1 KO Has No Effect on Vessel Density in 
SSI 
Sections of sponges provided by the Wagner group were stained to determine 
whether angiogenic vessel growth was altered by selective deletion of WT1 
from endothelial cells. Sections were assessed using three histological 
approaches: H&E; CD31 IP IHC; and CD31/αSMA/DAPI IF. Vessel density 
was not altered in mice with selective deletion of WT1 from the endothelium 
(Figure 4.3.3 & 4.3.4). The extent of CD31 positivity (IP (Figure 4.3.3)) and 





























Figure 4.3.3: Vessel density is not affected by endothelial WT1 KO in SSI. 
Vessels were visualised using CD31 and H&E histological staining in endothelial WT1 
KO mice (KO) and vehicle controls (VC). A) Representative CD31 IP IHC in VC 
sponge (examples of CD31+ vessels indicated with arrows). B) Manual quantification 
of CD31+ vessels. Quantification of CD31 expression C) across the whole cross-
section of the sponge (cellularised and non-cellularised area) and D) in the outer 
1000µm of the sponges (cellularised area only). E) Representative H&E staining in 
VC sponge (examples of vessels indicated with arrows). F) Manual quantification of 
vessels from H&E staining. VC = vehicle control, KO = endothelial WT1 KO. All data 





































































































Figure 4.4: Vessel density is not affected by endothelial WT1 KO in SSI. Vessels 
were visualised using CD31/αSMA/DAPI IF IHC. Representative staining in A) VC 
and B) KO sponges (green = Isolectin-B4, red = WT1, blue = DAPI). Quantification of 
C-E) vessel density and F-G) total vessel number. Mean fluorescence intensity of 
staining for I-K) CD31, L-N) αSMA and O-Q) DAPI. Outer= outer 1000µm of the 
sponges (cellularised area only), Inner = central section of sponge excluding outer 
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(cellularised and non-cellularised area). VC = vehicle control, KO = endothelial WT1 
KO. All data mean +/-s.e. mean. p>0.05, unpaired Student’s t-test. n=5.  
 
 
4.3.3.2 Endothelial WT1 KO Has No Effect on WT1 Expression 
in SSI 
WT1 staining in VC and KO sponges from SSI was visualised by WT1 IP IHC. 
This revealed WT1 expression in a number of the cells which had infiltrated 
into the sponge in VC and KO sponges (Figure 4.3.5). From what could be 
identified as vessels, while there appeared to be some vascular cells which 
were WT1+, the majority of WT1+ cells were non-vascular. WT1+ cells were 
present around the periphery of implanted sponges and in the less densely 
colonised area at the centre of sponges. WT1+ cells occasionally seemed to 
be infiltrating into the sponge between skeletal muscle cells present at the 
periphery of the sponges (Figure 4.3.5 A). 
WT1 staining in sponges was quantified in VC and KO sponges as the number 
of WT1+ nuclei (Figure 4.3.5 F) and the total area stained positive for WT1 
(Figure 4.3.5 G). There was a trend towards a reduction in WT1 staining when 
quantified by both of these measures (15.80% vs 4.57%, p=0.073 and 2.25% 








         































Figure 4.3.5: Total WT1 expression is not significantly affected by endothelial 
WT1 KO in SSI. A-C) Representative WT1 IP IHC in VC sponges (sponge boundary 
indicated by dashed line). D) Kidney tissue, positive control for WT1 staining and E) 
Negative control IgG. F) Manual quantification of WT1+ nuclei in VC and KO. G) 
Quantification of WT1 expression in VC and KO. VC = vehicle control, KO = 
endothelial WT1 KO. All data mean +/-s.e. mean. P-values shown, unpaired Student’s 
t-test. n=5.  
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4.3.3.3 Increased Macrophage & Collagen Infiltration in 
Endothelial WT1 KO Sponges 
To determine the effect of endothelial WT1 KO on in vivo fibrosis and 
inflammation, collagen deposition (PSR) and macrophage infiltration (F4.80) 
was assessed by histology. Images were thresholded and the % area of 
staining quantified. There were no significant differences in macrophage 
(Figure 4.3.6) or collagen (Figure 4.3.7) density in sponges from WT and KO 
groups. However, endothelial-specific WT1 KO sponges had a greater mean 
depth of collagen infiltration than controls (3088µm vs 1806µm (p<0.005)) and, 
concurrently, a greater mean depth of macrophage infiltration (3219µm vs 
1746µm (p<0.0005)). Increased depth of cell migration into sponges was also 
evident with CD31/αSMA/DAPI staining (Figure 4.3.8). This revealed a pattern 
of sponge colonisation where αSMA+ cells had infiltrated deepest into the 
sponge, with CD31+ cells adjacent distally; this was the same between 
genotypes. 
   
Figure 4.3.6: Depth of macrophage infiltration, but not macrophage density, 
increased in sponges from endothelial-specific WT1 KO mice. Sponges were 
stained for the macrophage marker F4.80. Representative F4.80 images from A, D) 
VC and B, E) KO sponges. C) Quantification of F4.80 staining, for F4.80 positivity by 
area. F) Quantification of maximum depth of macrophage infiltration revealed 
A B C 
D E F 
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significantly greater depth of macrophage infiltration in KOs. VC = vehicle control, KO 




Figure 4.3.7: Depth of collagen infiltration, but not collagen deposition 
increased in endothelial WT1 KO sponges. Sponges were stained using PSR to 
visualise collagen. Representative PSR images from A, D) VC and B, E) KO sponges. 
C) Quantification of PSR staining, for PSR positivity by area. F) Quantification of 
maximum depth of collagen infiltration revealed greater depth of collagen infiltration 
in KOs. VC = vehicle control, KO = endothelial WT1 KO. All data mean +/-s.e. mean. 
**p<0.01, unpaired Student’s t-test. n=5. 
 
 
          
Figure 4.3.8: Endothelial WT1 KO sponges have greater depth of cellular 
infiltration. CD31/αSMA/DAPI IF IHC revealed a greater depth of cellular infiltration 
in B) KOs compared to A) VCs. αSMA+ cells have visibly infiltrated more deeply than 
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4.3.3.4 Endothelial WT1 KO Has No Effect on Expression of 
Genes Associated with Angiogenesis or EMT  
RNA was extracted from sponges and gene expression was quantified by RT-
qPCR for selected genes associated with angiogenesis (HIF-1a, VEGF-A) or 
EMT (Snail, Slug). First, ‘housekeeper’ genes were selected, to which the 
expression of all other genes were normalised. β-Actin and GAPDH were 
selected, as while linear regression of β-Actin v GAPDH was not significantly 
non-zero, their expression was not different between groups (Figure 4.3.9 A-
D). 
After normalising to β-Actin and GAPDH, expression of HIF-1a, VEGF-A, Snail 








































Figure 4.3.9: Endothelial WT1 KO does not affect global gene expression of 
angiogenic or EMT genes. Global gene expression was assessed by RT-qPCR in 
extracted sponge tissue. β-Actin and GAPDH were chosen as housekeeper genes as 
A, B, C) expression did not differ significantly between groups and D) Linear 
regression of β-Actin v GAPDH in all samples was not significantly non-zero. All other 
genes were normalised to β-Actin and GAPDH expression. E) Expression of HIF-1a, 
VEGF-A, Snail and Slug in VC and KO sponge tissue as assessed by RT-qPCR. 
There was no difference between groups in expression of these.VC = vehicle control, 
KO = endothelial WT1 KO. All data mean +/-s.e. mean. P-values shown, 2-way 
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4.3.4 VE-Wt1 KO in the Subcutaneous Sponge Model 
Demonstrating the effect of endothelial WT1 KO on in vivo angiogenesis and 
other processes in sponges obtained from experiments performed in France 
(Section 4.3.3) was limited by the absence of a Cre control (CC). Therefore, 
this experiment was repeated to control for the potential effects of Cre and 
ensure any differences between VC and KO groups was not solely due to the 
action of Cre. In the following section, an inducible endothelial WT1 KO (VE-
Wt1 KO) was generated and the subcutaneous sponge implantation model 
was applied to it, alongside VC and CC groups. Sponges from SSI were 
removed from the mice after 21 days and assessed by IHC and RT-qPCR. 
4.3.4.1 VE-Wt1 KO Does Not Reduce Vascular Density 
Angiogenesis in the SSI model was assessed by IHC for CD31 and VE-
Cadherin. No significant difference was found between VC, CC and VE-Wt1 
KO for CD31 positivity as measured by percentage area immunopositive for 
CD31 (Figure 4.3.10 A, B). Concurrently, vessel number was quantified in 
sponges from VE-Wt1 KO, CC and CC mice and there was no significant 
difference between groups in CD31+ (Figure 4.3.10 C, D) or VE-Cadherin+ 
(Figure 4.3.10 E, F) vessel density.  
4.3.4.2 VE-Wt1 KO Does Not Affect Cell Infiltration 
VC, CC and VE-Wt1 KO sponges were H&E stained. There were no evident 
differences in sponge morphology between groups. Cell infiltration into 
sponges was quantified and there was found to be no effect of VE-Wt1 KO on 
depth of cell infiltration in sponges when measured by maximum depth of cell 
infiltration, area of cell infiltration and area of cell infiltration as a percentage of 



























Figure 4.3.10: Vascular endothelial Wt1 knock-out (VE-Wt1 KO) has no effect on 
vascular density in SSI. Vascular density was quantified in VE-Wt1 KO, Cre control 
(CC) and vehicle control (VC) sponges from SSI at 21 days post-implantation. It was 
found that VE-Wt1 KO had no effect on vascular density. A) Representative CD31 IP 
IHC staining in VC and B) quantification of CD31 positivity from thresholding this 
staining. C) Representative CD31/αSMA/DAPI staining in VC and D) quantification of 
CD31+ vessel density. E) Representative VE-Cadherin IP IHC staining in VC and F) 
quantification of VE-Cadherin+ vessel density. VC = vehicle control, CC = Cre control, 
VE-Wt1 KO = vascular endothelial WT1 KO. Arrows indicate examples of vessels. All 







































































































Figure 4.3.11: Vascular endothelial Wt1 knock-out (VE-Wt1 KO) has no effect on 
cell infiltration in SSI. At Day 21 post-implantation sponges were removed and 
depth of cell infiltration was determined by thresholding images from H&E staining to 
visualise all cells. A, C, D) Representative H&E images demonstrating depth of cell 
infiltration into sponges in vehicle control (VC), Cre control (CC) & VE-Wt1 KO, 
respectively. Limit of cell infiltration indicated by dashed line. Cell infiltration was 
assessed by B) maximum depth of cell infiltration, D) cross-sectional area of total cell 
infiltration and F) cross-sectional area of cell infiltration as a percentage of the total 
cross-sectional area of the sponge. There was no significant difference between 
groups in any of these parameters. VC = vehicle control, CC = Cre control, VE-Wt1 
KO = vascular endothelial WT1 KO. All data mean +/-s.e. mean. P>0.05, 1-way 









4.3.4.3 VE-Wt1 KO Does Not Affect Macrophage or Collagen 
Infiltration 
To determine the effect of VE-Wt1 KO on in vivo fibrosis and inflammation, 
collagen deposition (PSR) and macrophage infiltration (F4.80) was assessed 
by histology. The pattern of PSR and F4.80 staining was broadly comparable 
to that observed in the sponges provided by our collaborators in Nice (Section 
4.3.3; Figures 4.3.5 & 4.3.7). Images were thresholded and the percentage 
area of staining quantified. There was increased F4.80 staining in sponges 
from VE-Wt1 KO mice vs VC mice, but not vs CC mice which had a trend 
towards increased F4.80 staining vs VC (VC = 4.72%, CC = 8.58%, VE-Wt1 
KO = 10.52%, p<0.01 VE-Wt1 KO vs VC, 1-way ANOVA with Bonferroni post-
hoc tests) (Figure 4.3.12). There was no difference collagen (Figure 4.3.13) 
























































Figure 4.3.12: Macrophage infiltration into sponges is increased by vascular 
endothelial Wt1 knock-out (VE-Wt1 KO). Sponges were stained for the 
macrophage marker F4.80. A, B, C) Representative F4.80 images from vehicle 
control (VC), Cre control (CC) and VE-Wt1 KO, respectively. D) Quantification of 
F4.80 staining, for F4.80 positivity by area, revealed greater macrophage infiltration 
in VE-Wt1 KO vs VC, but not vs CC. VC = vehicle control, CC = Cre control, VE-Wt1 
KO = vascular endothelial WT1 KO. **p<0.01, 1-way ANOVA with Bonferroni post-


















































































Figure 4.3.13: Collagen deposition within sponges is not affected by vascular 
endothelial Wt1 knock-out (VE-Wt1 KO). Collagen in sponges was visualised by 
PSR staining. A, B, C) Representative PSR images from vehicle control (VC), Cre 
control (CC) and VE-Wt1 KO, respectively. D) Quantification of PSR staining, for PSR 
positivity by area, revealed no significant difference between groups. VC = vehicle 
control, CC = Cre control, VE-Wt1 KO = vascular endothelial WT1 KO. 1-way ANOVA 




4.3.4.4 VE-Wt1 KO Has No Effect on Vascular, Angiogenic or 
EMT Gene Expression 
RNA was extracted from sponge tissue and gene expression was quantified 
by RT-qPCR for selected vascular cell markers (CD31, αSMA, VE-Cadherin, 
PDGFRβ), genes associated with angiogenesis (HIF-1a, VEGF-A) and genes 




































to which the expression of all other genes were normalised. β-Actin and 
GAPDH were selected, as their expression did not differ significantly between 
groups and there was a significant correlation between their expression values 
(p<0.0001, linear regression) (Figure 4.3.14A-D).  
After normalising to β-Actin and GAPDH, expression of CD31, αSMA, VE-
Cadherin, PDGFRβ, HIF-1a, VEGF-A, Snail and Slug did not significantly differ 
between VE-Wt1 KO, VC and CC tissue (Figure 4.3.14). While the mean 
expression of CD31 was lower in VE-Wt1 KO tissue, this was not significant 
due to the large variation in CD31 expression in VC and CC tissue (p=0.699, 
































Figure 4.3.14: Vascular endothelial Wt1 knock-out (VE-Wt1 KO) does not affect 
global gene expression of vascular, angiogenic or EMT genes. Global gene 
expression was assessed by RT-qPCR in RNA extracted from sponge tissue from 
vehicle control (VC), Cre control (CC) and VE-Wt1 KO mice. β-Actin and GAPDH 
were chosen as housekeeper genes as A, B, C) expression did not differ significantly 
between groups and D) there was a good correlation between their expression (linear 













































































































































































expression. E) Expression of CD31, αSMA, VE-Cadherin, PDGFRβ, HIF-1a, VEGF-
A, Snail and Slug in VE-Wt1 KO, CC and VC sponge tissue was assessed by RT-
qPCR. There was no difference between groups in expression of these. VC = vehicle 
control, CC = Cre control, VE-Wt1 KO = vascular endothelial WT1 KO. All data mean 
+/- s.e. mean. P>0.05, unpaired Student’s t-test and 1-way ANOVA with Bonferroni 
post-hoc tests. n=8. 
4.3.5 The Hindlimb Ischaemia (HLI) Model of Angiogenesis 
Having examined WT1 in a simple model of in vivo angiogenesis, the hindlimb 
ischaemia (HLI) model was employed as a model which simulates critical limb 
ischaemia seen in humans(Limbourg et al., 2009). This allowed study of the 
role of WT1 in vivo in a more pathophysiological model of cardiovascular 
disease involving ischaemia and angiogenesis. In C57Bl/6 mice, initial 
characterisation of this model was carried out prior to examining the role of 
WT1 in these disease conditions. 
4.3.5.1 Blood Flow Reperfusion Following Femoral Artery 
Ligation 
Following induction of HLI by proximal and distal ligation of a length of femoral 
artery (Section 2.7), partial ablation of arterial blood flow, alongside a degree 
of vascular remodelling was visible at day 28 post-ligation (Figure 4.3.15). 
Assessment of hindlimb blood flow by laser Doppler revealed almost complete 
ablation of blood flow in the distal hindlimb immediately following ligation, with 
a degree of reactive hyperaemia in the non-surgical limb (Figure 4.3.16 A & 
B). However, laser Doppler visualisation from day 3-28 showed a steady and 







































Figure 4.3.15: Vascular architecture in the surgical (ischaemic) and non-
surgical (non-ischaemic) hindlimb. Images of surgical (ischaemic) and non-
surgical (non-ischaemic) hindlimb at day 28 in the HLI model in C57Bl/6 mice. A) 
Normal vascular architecture. FN = femoral nerve, FA = femoral artery, FV = femoral 
vein. B) Non-ischaemic hindlimb at day 28. C) Ischaemic hindlimb at day 28. 
Ligatures applied to the femoral artery are visible, with the section of femoral artery 
in which blood flow was ablated indicated (dashed line). A degree of vascular 
remodelling is visible in the areas close to the ligature, with perfusion of small blood 
























Figure 4.3.16: Reperfusion in the HLI model. Visualisation of blood flow in the 
C57Bl/6 hindlimb over time, on a colourimetric scale, where red is high blood flow and 
blue is low blood flow. Images were generated by laser Doppler imaging of murine 
hindlimbs over the course of recovery from hindlimb ischaemia surgery. A) day 0, pre-
op, B) day 0, post-op, C) day 3, post-Op, D) day 7, post-op, E) day 14, post-op, F) 
day 21 post-op and G) day 28, post-op. SL = surgical limb, NSL = surgical limb.  
 
Quantification of laser Doppler images using MoorLDI software confirmed a 
significant reduction in blood flow in the ischaemic hindlimb, immediately 
following femoral artery ligation (p<0.05) (Figure 4.3.17). In the ischaemic 
hindlimb, a biphasic reperfusion response was evident, with an initial relatively 
rapid recovery of blood flow between day 0 and day 7 and a slower recovery 
of blood flow from day 21 onwards. In the non-ischaemic hindlimb, there was 
a small, but non-significant increase in blood flow immediately following 
femoral artery ligation, which decreased by day 3 and remained relatively 
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Figure 4.3.17: Femoral artery ligation in the HLI model results in a rapid 
decrease in hindlimb blood flow, followed by a biphasic reperfusion response. 
Quantification of laser Doppler images from HLI model immediately pre-op, 
immediately post-op and at days 3, 7, 14, 21 and 28 post-op. A) pre-op and post-op 
blood flow in the ischaemic (surgical) hindlimb, showing a significant reduction in 
blood flow immediately post-op (unpaired t-test). B) Blood flow quantified up to 28 
days post-op in the ischaemic hindlimb, showing a biphasic reperfusion response. C) 
pre-op and post-op blood flow in the non-ischaemic (control) hindlimb. D) Blood flow 
quantified up to 28 days post-op in the non-ischaemic hindlimb, showing blood flow 
decreased and remained steady from day 3. All data mean +/- s.e. mean. *p<0.05, 
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4.3.6 WT1 Expression in the HLI Model 
Femoral artery ligation to induce HLI was carried out in C57Bl/6 mice and 
tissues were harvested at different time points in order to examine the role of 
WT1 in the response of normal, healthy mice to ischaemia.  
4.3.6.1 Vascular WT1 Expression Following Induction of 
Ischaemia 
C57Bl/6 HLI ischaemic and non-ischaemic gastrocnemius was isolated at day 
3, day 7 and day 28 post-op. Isolectin-B4/WT1/DAPI immunofluorescent 
staining was carried out on these tissues to visualise vascular WT1 
expression. As Isolectin-B4 stains endothelial cells, it is possible to identify 
arteries and veins as large luminal structures with an inner Isolectin-B4+ layer. 
Capillaries are smaller, Isolectin-B4+ luminal structures. As it is not consistently 
possible to distinguish capillaries from other, non-vascular Isolectin-B4+ cells 
WT1 expression was initially examined in arteries and veins. 
 In gastrocnemius from non-operated C57Bl/6 mice, there was no evident 
WT1staining in vessel associated cells. However, at day 3, day 7 and day 28 
following femoral artery ligation, the majority of Isolectin-B4+ vessels had no 
WT1+ cells associated with them, though there were vessels with Isolectin-
B4+/WT1+ and Isolectin-B4-/WT1+ cells. Vessels were also visible with only 
Isolectin-B4+/WT1+ or only Isolectin-B4-/WT1+ cells (Figure 4.3.18 A-H). The 
localisation of vascular associated Isolectin-B4-/WT1+ cells external to the 
endothelial layer suggests they are either smooth muscle or perivascular cells. 
In a few cases, there were Wt1+ cells associated with the vasculature external 
to the endothelial layer which were Isolectin-B4+ and had a morphology 
suggestive of some type of immune cell (Figure 4.3.18 F). 
Single WT1 staining in the same tissues confirmed that there were no WT1+ 
vascular cells in completely uninjured, C57Bl/6 gastrocnemius, in ischaemic 
gastrocnemius, vessels with WT1+ endothelial cells and vessels without any 
WT1+ cells were present at day 3, day 7 and Day28 (Figure 4.3.18 I-O). In 
these tissues, visualisation of WT1 by both methods suggested there were 
more WT1+ vessels at day 3 and day 7 in comparison to at day 28, though this 
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was not quantified due to the relatively small proportion of vessels with WT1 
expressing cells. All WT1 staining was nuclear and in a granular pattern, 
similar to that observed in sponges (Section 4.3.2). 
In C57Bl/6 ischaemic gastrocnemius WT1+ and WT1- vascular endothelial 
cells and the vessels they comprised often had noticeably different 
morphologies, as revealed by Isolectin-B4/αSMA/WT1/DAPI. In Figure 4.3.19, 
two examples are shown. Here, in comparison to WT1- cells (Figure 4.3.19 B, 
C), WT1+ endothelial cells (Figure 4.3.19 D, E) have a more cuboidal shape, 
as opposed to their normal squamous morphology and are seemingly more 
numerous and tightly packed. There is also an interesting Isolectin-B4- WT1+ 
cell of unknown identity within the lumen of the vessel, integrated into the 
endothelial layer. Further, the vessel itself, exhibits disruption of the 
endothelial and smooth muscle layer (also seen in Figure 4.3.18 C, F), with 
Isolectin-B4+ cells passing though and integrated into the αSMA+ layer. 
Apelin staining was carried out following previous observations that the 
expression of Apelin in vascular cells may denote these vessels are 
undergoing angiogenesis and distinguish them from non-angiogenic vessel in 
the same tissue (Liu et al., 2015). This was carried out in sections of 
gastrocnemius taken 3, 7 or 28 days following femoral artery ligation and from 
non-ischaemic, non-operated controls (Figure 4.3.20). However, the staining 
showed Apelin in the majority of vessels in both ischaemic and non-ischaemic 
tissue and stained a large number of non-vascular cells, including the majority 
of skeletal myocyte nuclei. It was therefore decided that it was not a useful 
marker of angiogenesis and further co-staining for Apelin and WT1 was not 
carried out.   
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Figure 4.3.18: WT1 is expressed in endothelial and non-endothelial cells of 
vessels in ischaemic gastrocnemius in vivo. IHC revealed that, in the HLI model, 
WT1 was expressed in a proportion of vessels in vivo in the ischaemic gastrocnemius. 
Representative images of Isolectin-β4 (green), WT1 (red) and DAPI (blue) staining in 
A) positive control kidney tissue and C57Bl/6 ischaemic gastrocnemius at B, F) day 
3, C, G) day 7 and D, H) Day 28 (white arrows show non-endothelial, vascular WT1+ 
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cell nuclei). E) Completely uninjured C57Bl/6 gastrocnemius. Representative WT1 IP 
IHC images from C57Bl/6 ischaemic gastrocnemius at I) day 3, J) day 7 and K, L) 
day 28 showing WT1+ vessels and (dashed lines) and WT1+ endothelial cells 
(examples indicated with arrows) and at M) day 3, N) day 7 and O) day 28 showing 




















Figure 4.3.19: WT1+ vessels are morphologically distinct from WT1- vessels. IF 
IHC for Isolectin-B4/αSMA/WT1/DAPI in C57Bl/6 ischaemic gastrocnemius. A) 
Negative control with IgG antibody (red) instead of anti-WT1 antibody demonstrating 
background WT1 staining of endothelial basement membrane of large vessels. 
Representative image of a WT1- vessel stained for DAPI (blue), Isolectin-B4 (green) 
and B) WT1 (red) or C) αSMA (red). Representative image of a WT1+ vessel from the 
same tissue stained for DAPI (blue), Isolectin-B4 (green) and D) WT1 (red) or E) 






















Figure 4.3.20: Apelin staining in C57Bl/6 ischaemic and non-ischaemic 
gastrocnemius. Apelin stains the majority of vessels in ischaemic and non-
ischaemic tissue and a number of other cell types. Apelin IP IHC staining in C57Bl/6 
ischaemic gastrocnemius at A) day 3, B) day 7, C) day 28 and non-ischaemic 
gastrocnemius at D) day 3, E) day 7, F) day 28. G) Negative control with IgG antibody 
instead of anti-Apelin antibody. Scale bars = 100µm. n=3-4. 
 
4.3.6.2 Non-Vascular WT1 Expression Following Induction of 
Ischaemia 
While there was vascular endothelial and non-endothelial WT1 expression, the 
majority of WT1 expression in ischaemia was observed in cells not visibly 
associated with vascular structures. In completely uninjured, C57Bl/6 
gastrocnemius there were non-vascular WT1+ nuclei (Figure 4.3.21A). 
Quantification of immunofluorescent staining of ischaemic and contralateral 
non-ischaemic gastrocnemius revealed that WT1 expression was elevated at 
day 3 post-op in ischaemic tissue, in comparison to (p<0.01, one-way ANOVA 
with Bonferroni post-hoc tests vs uninjured non-operated gastrocnemius) 
(Figure 4.3.21 I). WT1 expression at day 7 and day 28 was not significantly 
higher than expression in uninjured, non-operated gastrocnemius. WT1 
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expression in the contralateral, non-ischaemic gastrocnemius was not 
significantly higher than uninjured at day 3, day7 or day 28 (Figure 4.3.21 H).  
However, Isolectin-B4/WT1/DAPI immunofluorescent staining revealed that 
while the highest levels of tissue WT1 expression in ischaemic gastrocnemius 
was at day 3, there was still visibly elevated WT1 expression in ischaemic 
gastrocnemius at day 7 and day 28 in relation to uninjured gastrocnemius. At 
day 3 there was infiltration of a large number of Isolectin-B4+ cells into the 
interstitial space between skeletal myocytes. These persisted to some extent 
at day 7, but only a small population was still present by day 28. Many of these 
Isolectin-B4+ cells, as well as some Isolectin-B4- interstitial cells expressed 
WT1 (Figure 4.3.21 B-D).  
At day 3, day 7 and day 28 skeletal myocytes were found to express nuclear 
WT1 (4.3.21 E-G). Nuclear WT1 was almost always expressed in smaller 
myocytes with at least one (often multiple) central nuclei and to a lesser extent 
in larger myocytes with peripheral nuclei. These WT1+ myocytes with central 
nuclei occurred in distinct patches. Within these areas, there was an evident 
increase in the Isolectin-B4+ capillaries and larger vessels and this vasculature 
frequently had WT1+ endothelial cells.  
Undamaged skeletal muscle has a resident population of satellite cells which 
are activated in damaged muscle to facilitate repair (Wang and Rudnicki, 2011; 
Berberoglu et al., 2017). Cells expressing WT1 were co-stained with Pax7 (a 
marker of satellite cells) in completely uninjured gastrocnemius and 
gastrocnemius at day 7 post-op (Figure 4.3.22). The anti-Pax7 antibody 
produced a high degree of background staining, particularly in injured muscle, 
but lack of background in the negative control suggests this is likely due to off 
target anti-Pax7 antibody binding. As previously described, there was sporadic 
nuclear WT1 staining in uninjured gastrocnemius muscle tissue and it 
appeared that the majority of these WT1+ nuclei co-expressed Pax7. At day 7 
in the HLI model damaged myofibres with central nuclei appeared to express 

































Figure 4.3.21: WT1 is expressed in infiltrating cells and skeletal myocytes in 
ischaemia. WT1 is expressed in a number of non-vascular cells in ischaemic muscle 
tissue, in a time dependent manner. Isolectin-B4/WT1/DAPI immunofluorescent 
staining in C57Bl/6 gastrocnemius in A) completely uninjured tissue and in HLI at B, 
E) day 3, C, F) day 7 and D, G) Day 28 following femoral artery ligation. WT1 is 
expressed in infiltrating Isolectin-B4+ cells, endothelial and non-endothelial vascular 
cells and skeletal muscle with central nuclei. Arrows indicate examples of vessels 
expressing WT1. Quantification of WT1 staining by percentage area over time at 
different time points in comparison to control (completely uninjured) tissue in H) the 
non-ischaemic contralateral limb and I) ischaemic gastrocnemius. **p<0.05, unpaired 
























































































   
Figure 4.3.22: WT1 and Pax7 appear to partially overlap in preliminary IHC. 
Immunostaining for WT1 (red), Pax7 (green) and DAPI (blue) in A) C57Bl/6 
gastrocnemius Day 7 post HLI and B) uninjured gastrocnemius. WT1/Pax7 co-




4.3.6.3 WT1 Co-expresses with Snail in the HLI model 
IF IHC was carried out in ischaemic gastrocnemius from C57Bl/6 28 days 
following femoral artery ligation to examine the extent to which WT1 was co-
expressed with VEGFR2, PCNA and Snail. There was found to be no overlap 
between WT1 and VEGFR2 expression which were both expressed discretely 
in nuclei of different cells (Figure 4.3.23 A-C). However, there was some co-
expression of WT1 and PCNA which are both expressed in cell nuclei, though 
WT1+/PCNA- and PCNA+/WT1- nuclei were also present (Figure 4.3.23 D-F). 
As expected, anti-Snail staining was predominately cytoplasmic and, while 
there were Snail+/WT1- cells, almost all WT1+ cells also expressed Snail 
(Figure 4.3.23 G-I). The identity of WT1+/PCNA+ and WT1+/Snail+ cells was 




A MERGE Pax7 WT1 DAPI 
B MERGE Pax7 WT1 DAPI 



























Figure 4.3.23: WT1 co-expresses with snail and to a lesser extent PCNA, but not 
with VEGFR2. IF IHC staining for WT1 (red), DAPI (blue) and A, B) VEGFR2 (green), 
D, E) PCNA (green) and G, H) Snail (green). Arrows indicate co-staining. Negative 
controls for anti-WT1 and C) anti-VEGFR2, F) anti-PCNA and I) anti-Snail. Scale bars 






























4.3.7 VE-Wt1 KO in the HLI Model 
Having observed increased WT1 expression in ischaemic tissue following 
induction of HLI, including in endothelial cells of the ischaemic vasculature 
(Section 4.3.6), the effect of WT1 in angiogenesis and other processes of 
relevance was investigated. In order to examine the role of endothelial WT1, 
the VE-Wt1 KO mouse described previously, was subjected to HLI and tissues 
harvested after 28 days were assessed for any effect of VE-Wt1 KO. 
4.3.7.1 VE-Wt1 KO has no Effect on Reperfusion Following 
Femoral Artery Ligation 
Femoral artery ligation resulted in visible hyperaemia in the ischaemic hindlimb 
and reactive hyperaemia in the non-ischaemic hindlimb in all groups (VC, CC 
& VE-Wt1 KO) (Figure 4.3.24). Pre-op blood flow in both limbs was not the 
same between groups. As seen by laser Doppler imaging, over 28 days 
progressive, incremental reperfusion occurred in the ischaemic hindlimb, 
similarly to the response seen following HLI in C57Bl/6 mice (4.3.5). There 
was no visible difference in the extent or pattern of reperfusion between 
groups.  
Quantification of these laser Doppler images revealed ablation of blood flow in 
the ischaemic hindlimb and increase in blood flow in the non-ischaemic 
hindlimb following femoral artery ligation. HLI surgery was as effective in VC, 
CC and VE-Wt1 KO and there was no difference in pre- or post-op blood flow 
between groups. Blood flow in the non-ischaemic limb had recovered to 
approximately pre-op levels by day 7 in all groups and remained constant. 
There was no difference in non-ischaemic hindlimb blood flow over 28 days 
between groups. 
Quantification of reperfusion in the ischaemic hindlimb revealed that VE-Wt1 
KO perfusion was not lower at any time points, though there was a trend 
towards reduced blood flow at day 7 in the VE-Wt1 KO. There was no 
difference in the perfusion of the ischaemic hindlimb between VC, CC or VE-




























Figure 4.3.24: Vascular endothelial Wt1 knock-out (VE-Wt1 KO) has no effect on 
hindlimb reperfusion following femoral artery ligation. Visualisation and 
quantification of laser Doppler images from the HLI model showed no difference 
between vehicle control (VC), Cre control (CC) and VE-Wt1 KO in hindlimb 
reperfusion. Quantification of hindlimb perfusion immediately pre- and post-op in A) 
the ischaemic and B) non-ischaemic hindlimb. Quantification of perfusion in the C) 





















































































































































tail perfusion. F) Representative laser Doppler images (from left to right) immediately 
pre- and post- op, at day 3, 7, 14, 21 and 28. VC = vehicle control, CC = Cre control, 
VE-Wt1 KO = vascular endothelial WT1 KO. All data means +/- s.e. mean. **p<0.005, 
***p<0.0005, pre-op v post-op perfusion, paired Student’s t-test. n=8. 
 
4.3.7.2 VE-Wt1 KO has no Effect on Vessel Density at Day 28 
in HLI 
Hindlimb reperfusion in the HLI model is a result of angiogenesis and 
arteriogenesis. In order to isolate the effect of VE-Wt1 KO on angiogenesis, 
gastrocnemius muscle from HLI day 28 was isolated and vascularisation was 
quantified from histological staining of blood vessels.  
CD31 IP IHC effectively stained arteries, veins and capillaries in all groups 
(Figure 4.3.25 A-C). Quantification of CD31 expression by percentage area of 
staining in ischaemic gastrocnemius revealed significantly less CD31 
expression in VE-Wt1 KO than VC, but not CC, which had slightly reduced 
CD31 expression in comparison to VC (Figure 4.3.25 D). This is suggestive of 
a Cre effect. However, there was no significant difference in CD31+ vessel 
density between groups (Figure 4.3.25 E). VE-Cadherin IP IHC appeared to 
primarily stain larger vessel rather than capillaries (Figure 4.3.25 G-I). It was 
not practical to assess the extent of VE-Cadherin staining due to high 
background staining. Quantification of VE-Cadherin+ vessel density showed 






























Figure 4.3.25: Vascular endothelial Wt1 knock-out VE-Wt1 KO had no effect on 
vessel density in HLI at day 28. Representative images of CD31 IP IHC in A) vehicle 
control (VC), B) Cre control (CC) and C) VE-Wt1 KO. D)  Quantification of CD31 
expression (% area). *p<0.05, unpaired t-test, VC v VE-Wt1 KO. E) Quantification of 
CD31+ vessel density. F) Quantification of VE-Cadherin expression (% area). 
Representative images of VE-Cadherin IP IHC in A) VC, B) CC and C) VE-Wt1 KO. 
VC = vehicle control, CC = Cre control, VE-Wt1 KO = vascular endothelial WT1 KO. 
All data means +/- s.e. mean. *p<0.05 1-way ANOVA with Bonferroni post-hoc tests. 
Scale bars = 50µm. n=8. 
 
4.3.7.3 VE-Wt1 KO has no Effect on Whole Tissue WT1 
Expression in HLI at Day 28 
As previously shown (Sections 4.3.6.1 & 4.3.6.2), endothelial WT1 expression 
makes up a small proportion of WT1 expression in the ischaemic hindlimb in 
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HLI. Concurrently, quantification of WT1 staining in ischaemic gastrocnemius 
at HLI day 28 revealed that deletion of WT1 from the endothelium did not 
reduce the total WT1 staining or the number of WT1 positive cells in the 
gastrocnemius (Figure 4.3.26).  
 
Figure 4.3.26: Vascular endothelial Wt1 knock-out (VE-Wt1 KO) had no effect 
on total WT1 expression in HLI at day 28. Representative images of WT1 IP IHC 
in A) vehicle control (VC), B) Cre control (CC) and C) VE-Wt1 KO. D) Quantification 
of WT1 staining (% area) in VC, CC and VE-Wt1 KO. Nuclear WT1 staining is visible 
as brown nuclei. VC = vehicle control, CC = Cre control, VE-Wt1 KO = vascular 







































4.3.7.4 VE-Wt1 KO has no Effect on Collagen Deposition in 
HLI  
PSR staining in ischaemic gastrocnemius at HLI day 28 was carried out to 
visualise fibrosis in the HLI model. PSR staining revealed collagen localised 
primarily between myofibres (Figure 4.3.27 A-C). VE-Wt1 KO tissues had 
significantly less collagen than VC tissues and appeared to have less than CC, 
though this did not reach significance (Figure 4.3.27 D). As seen with CD31 
(4.3.7.2), this is again suggestive of a Cre effect in this model.  
 
Figure 4.3.27: Vascular endothelial Wt1 knock-out VE-Wt1 KO had no effect on 
collagen in HLI at day 28. Representative images of PSR staining in A) vehicle 
control (VC), B) Cre control (CC) and C) VE-Wt1 KO. D) Quantification of PSR 
staining (% area) in VC, CC and VE-Wt1 KO. VC = vehicle control, CC = Cre control, 
VE-Wt1 KO = vascular endothelial WT1 KO. All data means +/- s.e. mean. *p<0.05, 







































4.3.7.4 VE-Wt1 KO has no Effect on Macrophage Density in 
HLI  
F4.80 staining in ischaemic gastrocnemius at HLI day 28 was carried out to 
visualise macrophages in the HLI model. There was very little F4.80 positivity 
in any samples, due to a very low density of macrophages at day 28 (Figure 
4.3.28 A-C). There was no significant difference in macrophage density 
between groups, as quantified by percentage area of F4.80 staining (Figure 
4.3.28 D). 
 
Figure 4.3.28: Vascular endothelial Wt1 knock-out VE-Wt1 KO had no effect on 
macrophage density in HLI at day 28. Representative images of F4.80 staining in 
A) vehivle control (VC), B) Cre control (CC) and C) VE-Wt1 KO. D) Quantification of 
F4.80 staining (% area) in VC, CC and VE-Wt1 KO. Representative F4.80+ 
macrophages indicated with arrows. VC = vehicle control, CC = Cre control, VE-Wt1 
KO = vascular endothelial WT1 KO. All data means +/- s.e. mean. P>0.05, 1-way 





































4.3.7.5 VE-Wt1 KO has no Effect on Muscle Damage in HLI  
While no significant difference was found between VE-Wt1 KO and CC in any 
parameters assessed, it is possible that VE-Wt1 KO had a detrimental effect 
on the response to damage in HLI and repair. To quantify this, general muscle 
structure was visualised by H&E and assessed. As seen in C57Bl/6 muscle in 
HLI (Section 4.3.6.2), there were visible areas of damaged muscle. Random 
regions of interest were selected, the muscle damage in those areas was 
scored on a semi-quantitative scale (Figure 4.3.29A) and the mean cross-
sectional myofibre area was measured (Figure 4.3.29B). Neither of these 










Figure 4.3.29: Vascular endothelial Wt1 knock-out (VE-Wt1 KO) had no effect 
on skeletal muscle damage in HLI at day 28. Muscle damage was quantified in the 
ischaemic gastrocnemius from VE-Wt1 KO, vehicle control (VC) and Cre control (CC) 
mice, 28 days after femoral artery ligation. A) H&E images were quantified on a semi-
quantitative scale for muscle damage. B) The area of myofibres was quantified. There 
was no difference in either of these parameters between groups. VC = vehicle control, 
CC = Cre control, VE-Wt1 KO = vascular endothelial WT1 KO. All data means +/- s.e. 





























































4.3.7.6 VE-Wt1 KO Has No Effect on Vascular, Angiogenic or 
EMT Gene Expression in HLI 
To assess potential changes in gene expression following VE-Wt1 KO, 
ischaemic muscle tissue was extracted and gene expression was quantified 
by RT-qPCR for selected vascular cell markers (CD31, αSMA), genes 
associated with angiogenesis (HIF-1a, VEGF-A) and genes associated with 
EMT (Snail, Slug). First, ‘housekeeper’ genes were selected, to which the 
expression of all other genes were normalised. β-Actin and GAPDH were 
selected, as their expression did not differ significantly between groups and 
there was a significant correlation between their expression values (p<0.0001, 
linear regression) (Figure 4.3.30 A-D).  
After normalising to β-Actin and GAPDH, expression of CD31, αSMA, HIF-1a, 
VEGF-A, Snail and Slug did not significantly differ between VE-Wt1 KO, VC 
and CC tissue (Figure 4.3.30 E). RT-qPCR was carried out for VE-Cadherin 
and PDGFR-β, but for unknown reasons, unlike in sponges (Section 4.3.4.4 & 
Figure 4.3.14), it was not possible to effectively detect expression levels of 



























Figure 4.3.30: Vascular endothelial Wt1 knock-out (VE-Wt1 KO) does not affect 
global gene expression of vascular, angiogenic or EMT genes in HLI. Global 
gene expression was assessed by RT-qPCR in extracted ischaemic gastrocnemius 
tissue at day 28. β-Actin and GAPDH were chosen as housekeeper genes as A, B, 
C) expression of all genes did not differ significantly between groups and D) there 
was a good correlation between their expression (non-linear regression (p<0.05)). All 








































































































































































CD31, αSMA, VE-Cadherin, PDGFRβ, HIF-1a, VEGF-A, Snail and Slug in VE-Wt1 
KO, CC and VC muscle tissue as assessed by RT-qPCR. There was no difference 
between groups in expression of these. VC = vehicle control, CC = Cre control, VE-






The experiments in this chapter were designed to investigate the role of WT1, 
specifically in the vascular endothelium, in angiogenesis in vivo. This was 
addressed using the subcutaneous sponge implantation model, a model of in 
vivo angiogenesis, and hindlimb ischaemia, a murine model of critical limb 
ischaemia, which stimulates pathophysiological ischaemic angiogenesis. This 
is the first time WT1 has been investigated in the context of critical limb 
ischaemia. Staining for WT1 in these models confirmed that WT1 was 
activated in endothelial cells and VSMCs of the vasculature, suggesting WT1 
may be involved in angiogenesis. However, KO of WT1 selectively in the 
vascular endothelium had no effect on angiogenesis in vivo. Despite this, 
endothelial cell-selective WT1 KO did have some unexpected effects on 
macrophage infiltration (and general cell infiltration) into sponges. 
Furthermore, considerable non-vascular expression of WT1 was identified in 
ischaemic tissues, demonstrating that WT1 has a wider function than just in 
the vascular endothelium during tissue repair. 
The original hypothesis for this chapter was that WT1 regulates angiogenesis 
in endothelial cells and hence, VE-Wt1 KO will impair in vivo angiogenesis. 
These experiments show VE-Wt1 KO does not significantly impair 
angiogenesis in vivo, though they do provide further novel and intriguing 
insights into the role of WT1 in angiogenesis and beyond. 
4.4.1 Endothelial cell-selective Wt1 KO does not impair 
Angiogenesis In Vivo 
The potential for WT1 as an important factor in cardiovascular disease is a 
relatively new concept and is not completely understood. It is clear that WT1 
is key to tumour angiogenesis, and in cardiovascular disease it has been 
shown that WT1 is expressed in ischaemic angiogenic tissue following 
induction of MI (K. Wagner et al., 2002; Duim et al., 2015). In the previous 
chapter it was demonstrated that vascular endothelial cell-selective Wt1 KO 
impairs ex vivo angiogenesis; however, in this chapter, there was no evidence 
that endothelial cell-selective Wt1 KO significantly affects angiogenesis in 
vivo. In the subcutaneous sponge implantation model, endothelial cell Wt1 KO 
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had no effect on vessel infiltration into the sponges in samples provided by our 
collaborators in France, or in sampLes generated from experiments conducted 
in Edinburgh. In the hindlimb ischaemia model, endothelial cell Wt1 KO had 
no effect on reperfusion of ischaemic tissue (as measured by laser Doppler) 
or on vessel density, with no difference in tissue damage. This suggests that 
either WT1 is not important in in vivo angiogenesis, or that endothelial cell Wt1 
KO was not sufficient to produce a physiologically relevant inhibition of 
angiogenesis. 
It is worth noting that there was a significant reduction in CD31 expression in 
the HLI model in comparison to the vehicle control, but not the Cre control 
which had an intermediate level of expression. This is indicative of a potential 
Cre effect in vivo. Cre is known to have potentially toxic effects, even when it 
is inducible; as in the VE-Cadherin CreERT2 used here (Loonstra et al., 2001; 
Hameyer et al., 2007; Naiche and Papaioannou, 2007). However, as these 
experiments have a Cre and a vehicle control this should not adversely impact 
the interpretability of the results. The fact that there is a potential small 
difference in CD31 staining, but not in vessel density, could be due to 
endothelial cell Wt1 KO reducing the number of endothelial cells, rather than 
fully-formed vessels; for example by affecting non-vascular endothelial cells. 
In fact, Wt1 has been shown to regulate endothelial cell apoptosis (Morrison, 
English and Licht, 2005; Ito et al., 2006; Lv et al., 2015) and proliferation in 
vitro and in vivo (Wagner et al., 2008; Duim et al., 2015), disruption of which 
could reduce endothelial cell number. Concurrently, as has been previously 
demonstrated in murine MI, Wt1 co-expressed with PCNA in a proportion of 
Wt1+ cells in HLI (K. Wagner et al., 2002). 
The reduction in CD31 expression with endothelial cell Wt1 KO described 
above was not observed when CD31 gene expression was quantified by 
qPCR. In fact, there was no difference in any of the markers (CD31, VE-
Cadherin, Snail, Slug, VEGF-A and HIF1α) measured by qPCR in either in 
vivo model. If WT1 was playing a role in angiogenesis, it might have been 
expected that expression of CD31 and VE-Cadherin would have reduced in 
the whole tissue; however, no difference in in vivo angiogenesis was observed, 
so this is understandable. Given previous work showing that Wt1 has a role in 
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regulating, markers of EMT Snail and Slug (Martínez-estrada et al., 2010; 
Braitsch et al., 2013; Takeichi et al., 2013) and markers of angiogenesis VEGF 
and HIF-1 (Wagner et al., 2003; Graham et al., 2006), it would be expected 
that expression of these markers would drop in endothelial cells following Wt1 
expression. However, as endothelial cells represent a relatively small 
proportion of the total cells in the sponges or gastrocnemius muscle, it is not 
surprising that no overall drop in expression of these markers was observed. 
This could be confirmed by FACs sorting for endothelial cells and then 
assessing gene expression in these Wt1 KO endothelial cells to determine 
which genes and, hence, which processes are affected by endothelial cell Wt1 
KO. 
Quantification of blood vessel density in these models was performed a 
relatively long time (21 days in sponges and 28 days in HLI) after induction of 
the initial surgery. Furthermore, reperfusion in the HLI model is attributable to 
both arteriogenesis and angiogenesis and cannot be considered a direct 
measurement of angiogenesis. Initial reperfusion is primarily attributable to 
arteriogenesis, with angiogenesis then contributing to reperfusion measurable 
by laser Doppler (Wu et al. unpublished data). Endothelial cell Wt1 KO in the 
aortic ring model, presented in the previous chapter, showed that deletion of 
WT1 from the endothelium had a relatively acute effect on angiogenesis ex 
vivo. Therefore, it is possible that, similarly, endothelial cell Wt1 KO acutely 
impairs angiogenesis but that this acts only to delay new vessel formation, or 
has a relatively minor effect on overall angiogenesis. Angiogenesis could be 
quantified in these models at earlier time points; however, it is not practical to 
quantify vessel density immediately following sponge implantation or femoral 
artery ligation due to the presence of very few quantifiable, competent vessels. 
It would perhaps be more effective, if attempting to confirm a role for WT1 in 
angiogenesis to use a broader vascular Wt1 KO in endothelial cells, mural 
cells and vascular-associated inflammatory cells simultaneously to determine 
if this results in a measurable inhibition of in vivo angiogenesis. It would be 
particularly interesting to determine if complete vascular Wt1 KO completely 
inhibits angiogenesis or not, hence revealing whether Wt1 is essential to 
angiogenesis.   
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Previous work, in cancer in particular, has shown that endothelial WT1 is 
intrinsic to angiogenesis. Endothelial cell-selective Wt1 deletion was sufficient 
to impair tumour angiogenesis,  considerably reducing vascular density in 
tumours and, hence, reduce their growth, or even inducing regression 
(Wagner et al., 2014). Preliminary work with sponges from the endothelial cell 
Wt1 KO mouse from our collaborators in France showed a roughly 8 fold 
reduction in vessel density in these sponges in the endothelial Wt1 KO mouse 
(McGregor et al. 2014). However, this was not replicated by analysis of these 
samples in Edinburgh, or by experiments with endothelial cell Wt1 KO mouse 
(which should, theoretically be genetically identical) performed in Edinburgh. 
The reason for the discrepancy between these results and previous work is 
unclear, however, it does question the extent to which endothelial cells are the 
main players in Wt1-regulated angiogenesis. This was evident in that the effect 
of Wt1 KO on tumour angiogenesis was dramatically greater when it was 
affected under the control of Tie2 Cre, which is also expressed in some 
haematopoietic and immune cells, as opposed to the more endothelial cell-
selective VE-Cadherin Cre, which is also used in the experiments in this 
chapter. The role of WT1 in endothelial and non-endothelial cells was also 
revealed by visualisation of WT1 in these models by histology.  
4.4.2 WT1 Does Have a Role in Angiogenic Vasculature 
WT1 expression was only assessed in sponges 21 days post-implantation, 
whereas in ischaemic gastrocnemius it was assessed at 3, 7 and 28 days post-
induction. Therefore, the majority of observations relate to the role of WT1 in 
the more pathophysiologically-relevant HLI model. Analysis of WT1 
expression in both the sponge and hindlimb ischaemia models revealed that 
WT1 was expressed in the vasculature. This is of particular relevance as 
previous work from our group has shown that WT1 is not expressed in healthy 
adult tissue in the vasculature or other cells, except for specific cell populations 
(McGregor et al. 2014). Therefore, WT1 expression must have been 
reactivated in vascular cells in these contexts and associated with a specific 
vascular response. Indeed, in the case of the sponge model, all vessels 
present in the sponges after implantation must have arisen by angiogenesis. 
The majority of endothelial and vascular WT1 observed was expressed acutely 
158 
 
after induction of ischaemia in HLI, with vascular WT1 decreasing over time. 
It would not be unreasonable to assume that WT1 is acutely activated in 
angiogenic vessels to bring about cellular changes that facilitate initiation or 
progression of angiogenesis.  
The concept of WT1 regulating initiation of angiogenesis is supported by the 
fact that, in some vessels with endothelial WT1 expression, there was clear 
disruption of the endothelial and VSMC layers, with what appeared to be 
endothelial cells migrating outwards. This is consistent with the cellular 
processes occurring early in angiogenesis as an endothelial vessel sprout is 
established (Carmeliet and Jain, 2011). It has been proposed that a partial 
EndMT is required in endothelial cells during angiogenesis to increase their 
migratory potential (Welch-Reardon et al., 2014; Welch-Reardon, Wu and 
Hughes, 2015). Given the known role of WT1 in EMT (Miller-hodges and 
Hohenstein, 2012), it could well be that at least one function of WT1 in 
endothelial cells is to activate EndMT to enable initiation of angiogenesis. 
Supporting this hypothesis, endothelial cells expressing WT1 had an unusual 
columnar morphology, more characteristic of mesenchymal than endothelial 
cells (Mendez, Kojima and Goldman, 2010) and Wt1 was co-expressed with 
Snail in ischaemic gastrocnemius. 
Within the vasculature, WT1 was expressed in endothelial cells, but also in 
VSMCs/pericytes to much the same extent. In a few cases WT1 was present 
in what appeared to be vessel-associated immune cells. It should be confirmed 
whether Wt1 is expressed in vessel-associated immune cells with the cell type 
determined by co-staining with different cell markers. At no time point 
observed were all vessels or all vascular endothelial cells WT1+; however, in 
vessels which had some WT1 expression, Wt1 was often identified in 
numerous cells proximal to each other. This implies that WT1 is discretely 
activated by some local cues and that the activation of Wt1 in one cell may 
bring about transcriptional changes that result in release of molecular signals 
from one cell which correspondingly activate Wt1 in other proximal cells. The 
nature of the signals which may activate Wt1 in this context are unknown, 
though in hypoxia HIF-1 is known to transcriptionally regulate Wt1 (Wagner et 
al., 2003).  
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4.4.3 The Pathophysiological Function of WT1 is Not 
Restricted to the Vasculature 
While endothelial cell Wt1 KO did not significantly impair angiogenesis, it did 
have some unexpected effects in other cell types. These effects were all in 
comparison to vehicle controls, but not to Cre controls, suggestive of a Cre 
effect. In sponges from France, endothelial cell Wt1 KO resulted in an 
increased depth of cell infiltration into sponges, though this was not evident in 
sponges implanted in endothelial cell Wt1 KO mice in Edinburgh. WT1 is 
known to influence cell migration, in endothelial and non-endothelial cells 
(Wagner et al., 2008; Brett, Pandey and Fraizer, 2013b), though it is interesting 
that endothelial cell Wt1 KO seemingly increased infiltration of non-endothelial 
cells as well, with increased depth of collagen and macrophage infiltration into 
sponges. As there was no increase in the density of collagen or macrophages, 
this is most likely attributable to increased cell infiltration rather than to fibrosis 
or inflammation.  
Endothelial Wt1 KO did, however, increase macrophage density in sponges 
from experiments performed in Edinburgh and reduced collagen density in the 
ischaemic gastrocnemius. The idea of Wt1 regulating fibrosis and 
inflammation is not an entirely new concept; for one thing, Wt1 is activated in 
cells responsible for inflammation and fibrosis in a number of diseases 
(McGregor et al. 2014, Hastie 2017). WT1 is expressed in areas of fibrosis 
post-MI (Braitsch et al., 2013), and EMT, which WT1 is known to regulate, 
often contributes to fibrosis in disease (Zeisberg et al., 2007; Liu, 2010). In the 
context of inflammation, WT1 directly regulates a number of inflammatory 
factors (reviewed by Toska & Roberts 2014). Furthermore, staining revealed 
WT1 expression in inflammatory cells in the sponge and HLI models. The 
highest level of WT1 expression occurred three days after induction of 
ischaemia in gastrocnemius, which is in accord with an acute, substantial influx 
of inflammatory immune cells. Altered endothelial cell function and endo-MT 
can increase pathogenic fibrosis and inflammation in disease (Goumans, van 
Zonneveld and ten Dijke, 2008; Goligorsky, 2015), which may in part explain 
the changes as a result of endothelial Wt1 KO. These findings are particularly 
novel and exciting as they suggest endothelial Wt1 KO is sufficient to induce 
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changes in associated cells and that, therefore, WT1+ endothelial cells may 
ordinarily interact with mesenchymal cells and immune cells. In order to 
investigate this further, there are a number of fibrotic and inflammatory murine 
disease models which could be applied to the endothelial WT KO mouse 
model used herein. 
Finally, and perhaps most-excitingly, in the HLI model we discovered an 
entirely new potential role for WT1 in cardiovascular diseases, which demands 
further investigation. Unexpectedly, most of the WT1 expression in the 
ischaemic gastrocnemius over time was in the nuclei of skeletal myocytes. 
Due to the induction of ischaemia by femoral artery ligation and consequent 
arteriogenesis, certain areas of gastrocnemius muscle experience a greater 
extent of ischaemia than others. Simultaneously, and presumably as a result 
of this heterogeneity, there appears to be more muscle damage in some areas 
than in others; as identifiable by smaller myocytes with central nuclei. In these 
areas of increased muscle damage, WT1 was strongly expressed in these 
myocytes, in comparison to relatively uninjured areas where expression was 
lower. Moreover, this expression persisted throughout recovery, suggesting 
the activation of Wt1 in skeletal muscle is not just as a result of hypoxia, but is 
reflective of a role for WT1 in muscle repair following damage.  
As this is a novel observation, there is little to give context to this finding; 
however, WT1 has recently been found to be strongly expressed in developing 
human skeletal muscle tissue (Parenti et al., 2013; Magro et al., 2015). This 
implicates WT1 in myogenesis; a recapitulation of which may well be occurring 
in skeletal muscle tissue as seen here. In the heart, a predominantly muscular 
organ, WT1 expression is maintained in the epicardium, which post-MI 
generates a small population of transiently WT1+ cardiomyocytes (van Wijk et 
al., 2012; Braitsch et al., 2013). Mirroring this situation, skeletal muscle also 
has its own resident stem cell population, the satellite cell, which along with 
signals from macrophages and fibroblasts, is able to induce much more 
extensive muscle repair than induced in the myocardium (reviewed by Wang 
& Rudnicki 2011). These stem cells are dispersed at low density throughout 
the myocardium. Intriguingly then, not only was WT1 expressed in muscle in 
ischaemia, but at very low density in uninjured tissue consistent with WT1 
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being expressed physiologically in satellite cells. Preliminary staining for the 
satellite cell marker Pax7 seemed to show that WT1 co-expressed with Pax7 
in muscle in non-ischaemic and ischaemic tissue, though this needs to be 
optimised further. This leads to generation of a working hypothesis that WT1 
is expressed in the skeletal muscle satellite cells and these are activated in 
damaged tissue, in which they contribute to WT1-regulated regenerative 
myogenesis. 
This needs to be investigated further, initially by FACs on ischaemic and non-
ischaemic muscle tissue to isolate satellite cells and to assess whether or not 
they express WT1. The role of WT1 in muscle repair could then be investigated 
in vitro with skeletal muscle cells and satellite cells, using a number of 
functional assays, then inhibiting Wt1. These findings, if promising, could then 
be moved into in vivo models of muscle injury. If WT1 is found to have a role, 
in muscle repair, it could be applied therapeutically in cardiovascular diseases, 
as well as in myopathies such as muscular dystrophy and myositis. 
4.4.4 Conclusions 
In conclusion, these investigations demonstrated that WT1 is induced during 
tissue repair in vivo, but that endothelial Wt1 KO was not sufficient to 
significantly impair new blood vessel formation. In concordance with the 
results from examining Wt1 in vitro, WT1 was largely expressed acutely in 
vasculature and also had a role in non-endothelial vascular cells. All of this 
may explain why endothelial WT1 has no effect on angiogenesis and WT1-
expressing non-endothelial cells may increase WT1 expression to 
compensate, or even transition into endothelial cells themselves. WT1 also 
appeared to have a role in cell migration, cell transition, fibrosis and 
inflammation in vivo; much of which could be explained if WT1 is regulating 
endMT. Intriguingly, WT1 appeared to be involved in regenerative 
myogenesis; a novel role for this transcription factor. WT1 appears to be 
important in angiogenesis though certainly, WT1 has a broader scope of 























The Gene Expression Profile of 




Determining the function of any gene or protein is a complicated process, 
requiring determination of the molecular pathways involved and how these in 
turn effect cellular processes. In the case of transcription factors, there is an 
added level of complexity, as their influence can be both direct and indirect 
through transcriptional activation of other genes. WT1 is an unusual 
transcription factor in that it is capable of transcriptionally activating and 
repressing factors on a DNA and RNA level. While WT1 has been studied now 
for more than twenty five years (Call et al., 1990; Gessler et al., 1990) and its 
diverse functions have slowly been elucidated, the molecular mechanisms of 
this multi-functional protein are still not well understood. This chapter will 
investigate the implications of WT1 expression in cells and provide some 
further insight into the molecular genetics of WT1 in vivo using next-generation 
sequencing and transcriptomic gene expression analysis. 
WT1 is a relatively typical zinc-finger transcription factor containing four C-
terminus C2H2 Krüppel-type zinc-fingers with a high specificity for GC-rich 
regions (Rauscher et al., 1990; Bickmore et al., 1992). It is capable of 
activating and repressing gene expression with both transcriptional repression 
and activation domains (Madden, Cook and Rauscher, 1993; Wang et al., 
1993). Two isoforms of WT1, named +KTS and –KTS, are of particular 
importance, as it has been hypothesised that -KTS isoforms are mainly 
involved in transcriptional regulation of DNA, while +KTS isoforms have been 
implicated more in a post-transcriptional role in RNA processing (Larsson et 
al., 1995). However, the situation is more complicated as both isoforms 
probably function in transcription and post-transcriptionally processes (Hastie, 
2017). A recent, comprehensive study confirmed that WT1 binds to the 3’ 
untranslated regions (UTRs) of target mRNAs involved in developmental 
processes and regulates their turnover (Bharathavikru et al., 2017). As an 
added level of complexity, binding of WT1 to a number of co-factors alters 
transcriptional regulation by these WT1 complexes (Wang et al., 2001, 2015; 
Reynolds et al., 2003; Green et al., 2009; Essafi et al., 2011). Given the 
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complexity of transcriptional regulation by WT1, it is understandable that it has 
such a complex and elusive mechanism of action. 
Chromatin immune-precipitation sequencing (ChIP-seq) has proved a 
powerful tool for validating direct targets of WT1 (Kim et al., 2007, 2009; Sunny 
Hartwig et al., 2010; Motamedi et al., 2014; Kann et al., 2015). These identified 
target genes are involved in a range of processes including; growth and 
development, cell differentiation, EMT/MET, cell adhesion and cytoskeletal 
organisation, cell proliferation, cell migration and apoptosis. Many of the 
targets of WT1 are also transcription factors. From in vitro DNA binding assays 
and ChIP-seq, a number of WT1-binding motifs have been discovered 
(Rauscher et al., 1990; Wang et al., 1993; Hamilton, Barilla and Romaniuk, 
1995; Nakagama, Heinrich and Pelletier, 1995; Little et al., 1996). However, 
to understand the functional role of WT1, it is not enough to just understand 
the genes WT1 is capable of regulating, as its transcriptional regulation is 
context dependent and so, this knowledge must be combined with an 
understanding of the role of WT1 expressing cells in vivo; not always a simple 
task. 
In recent years, high-throughput sequencing has revolutionised analysis of 
gene expression. Unlike qPCR, high-throughput sequencing does not require 
selection of specific genes to be assessed and hence can provide an unbiased 
analysis of the entire gene expression profile of specific cells and tissues. As 
WT1 is a transcriptional regulator, identification of single proteins or genes 
associated with WT1 expression is of limited use; ideally one would build a 
map of the diverse role of WT1 in a particular context and this is the strength 
of sequencing technology. These mechanisms have begun to be applied to 
the study of WT1, revealing a number of new DNA and RNA targets and the 
processes with which WT1 and its targets are associated (Velecela et al., 
2013; Dong et al., 2015; Bharathavikru et al., 2017). Analysis of the gene 
expression profile associated with WT1 in a number of different cell types and 
contexts will build up a picture of the effect of WT1 on gene expression profile. 
This will build up a more complete understanding of the function of WT1, reveal 
new potential areas of interest and ultimately reveal the therapeutic 
consequences of targeting Wt1.  
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5.1.2 Hypothesis  
This chapter aims to address the hypothesis that: 
“Wt1 expression in endothelial cells is associated with angiogenesis 
and induces a more pro-angiogenic gene expression profile.” 
5.1.3 Aims 
1. Determine the cell types in which WT1 is expressed in an in vivo model 
of angiogenesis. 
2. Identify the gene expression profile of WT1 expressing cells. 
WT1 expressing cells will be isolated from the subcutaneous sponge 
implantation model of in vivo angiogenesis by FACs. The identity of these WT1 
expressing cells will then be determined. Using an RNA microarray, the gene 
expression profile of these cells will be characterised and the molecular, 
cellular and physiological processes with which this gene expression profile is 
associated will be determined. This will hopefully provide new insights into the 






5.2 Materials and Methods 
Sponge implantation and FACs sorting in this section were carried out by 
Richard McGregor and You-Ying Chau (University of Edinburgh, IGMM). Data 
extraction and normalisation was carried out by Graeme Grimes at the 
University of Edinburgh Bioinformatics Analysis Core and analysis of 
transcriptomic data was carried out with technical help from Graeme Grimes. 
5.2.1 WT1-GFP Mouse 
WT1-GFP reporter mice (WT1GFP/+) generated by Hosen et al. (2007) have 
knock-in GFP under the control of the Wt1 promoter. This enables detection 
of WT1 expression by generation of GFP. All mice used in this section were 
male and 12-16 weeks of age. 
5.2.2 Fluorescence Activated Cell Sorting (FACs)   
Sponges were implanted into 10 Wt1GFP/+ mice, and 4 Wt1+/+ (GFP-) controls 
as in Section 2.7. Five Wt1GFP/+ mice and 2 GFP- controls were culled at day 
7 and at day 21 post-implantation.  
5.2.2.1 Isolation of GFP+ Cells 
Single cell suspensions from the sponges and kidneys of WT1-GFP mice were 
processed for FACS analysis. Sponges were removed and immediately 
placed Leibovitz's L-15 Medium (Invitrogen, L5520). In sterile conditions, 
sponges were disrupted using forceps and a scalpel. This homogenate was 
resuspended in 10 mL PBS plus BSA (4mg/mL, Sigma-Aldrich, A2058) with 
1mg/mL Collagenase B (Roche, COLLB-RO). Samples were incubated for 45 
minutes at 37°C before digestion was stopped by addition of 15ml Leibovitz's 
L-15 Medium +10% FCS. Digested sponge tissue was strained through a 
100μm sterile cell strainer (Scientific Laboratory Supplies, 431752), then a 
70μm sterile cell strainer (Scientific Laboratory Supplies, 431751). Sieved cells 
were washed by centrifugation, (1200rpm, 5 minutes) (Beckman Coulter, 
Allegra X-22R). Supernatant was discarded and pellet resuspended in 1mL 
Red Blood Cell lysis buffer (Biolegend, 420301) for 3mins at R.T. 15mL PBS 
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was added and suspension was centrifuged at 1200rpm for 5mins. 
Supernatant was discarded and pellet re-suspended in 1mL PBS containing 
2% FCS. The sample was filtered through a 40μm sterile cell strainer 
(Scientific Laboratory Supplies, 431750). Cell suspensions of PBS +5% PBS 
were prepared for sorting. 
5.2.2.2 Fluorescence Activated Cell Sorting on Sponges from 
WT1-GFP Mice 
FACS was performed by Elisabeth Freyer (University of Edinburgh, MRC) 
using the BD FACSAriTM II System (BD Biosciences). Cell suspensions were 
sorted for GFP+ and GFP- cells by FACs. Cells were incubated at 4°C for 15 
minutes with the antibodies in Table 5.2.1, washing with PBS between 
antibodies. Cell suspensions were then sorted for the expression of these 
antibodies in GFP+ and GFP- populations. Sorting gates were generated from 
sponge and kidney cells from GFP- mice. Isotype control antibodies and 
OneComp eBeads (eBioscience, 01-1111) were used as negative controls for 
background staining. And GFP+ kidneys were used as positive controls. 
FlowJo Software Version 7.6.5 (TreeStar) was used for analysis.  
Antibody Conc. Company 
CD140b (Pdgf-β) Anti-Mouse, PE 1/100 Biolegend (136005) 
CD31 Anti-Mouse, APC 1/80 eBioscience (17 0311-82) 
Rat IgG2a Kappa Isotype, PE 1/500 Biolegend (400507) 
Rat IgG 2a Kappa Isotype, APC 1/80 eBiosience (17 4321-41) 
Table 5.2.1: Antibodies used for fluorescence activated cell sorting. Antibody 
description/name, concentration used, provider and catalogue number are all 
provided. 
5.2.3 Whole Genome RNA Micro-Array 
Samples sorted by FACs (Section 5.2.2.2) were analysed using the 
MouseWG-6 or MouseRef-8 v2 Expression BeadChip with Illumina iScan by 
the Illumina Whole Genome Expression Profiling Service (Qiagen) (Section 
168 
 
2.13.2). This was carried out on 3 WT1-GFP WT1GFP/+ mice per time point 
(n=3). 
Data from this was processed by Graeme Grimes and the IGMM 
Bioinformatics Core (University of Edinburgh). Raw microarray data 
(experimental probes and control probe files) was read into R using the 
bioconductor package limma using the function read.ilmn(). Microarray data 
was normalised using limma's neqc() function. This performs background 
correction using negative control probes followed by quantile normalization 
using both negative and positive control probes. Control probes were then 
removed from further analysis. Additionally, probes not detected on any array 
(Illlumina p.value of detection greater than 0.01) were also removed from 
further analysis. Differential expression of genes was then performed by a 
fitting a linear model to each probe. The empirical Bayes moderation was 
applied to the linear model fit to compute moderated t-statistics, moderated F-
statistic, and log-odds of differential expression. The Benjamini & Hochberg 
(alias FDR) method was used to correct p-values for multiple testing. This 
generated p-values which were used in all further analysis. 
5.2.4 Transcriptomic Analysis 
Two different programs were used for analysis of processed data from 5.2.3; 
DAVID (Huang, Sherman and Lempicki, 2008, 2009) and GOrilla (Eden et al., 
2007, 2009), with ReviGO (Supek et al., 2011) used for representation of some 
of the results of these. Data was input into these programs based on 
significance determined from data processing (Section 5.2.3) and log10 fold 
change in expression of genes between GFP+ and GFP- groups.  
For DAVID, data is entered in a non-sorted manner with a list of genes of 
interest and a background list. In this case, the list of interest was significantly 
differentially expressed genes and the background list was all the genes listed 
in the array. For GOrilla, data is entered in a ranked list, which in this case was 
ranked on log10 fold change in expression between GFP+ and GFP- groups. 
GOrilla was generally used for identification of processes of interest and 
169 
 
DAVID was used when it was not possible to rank genes, or to identify 
pathways and cell types.  
Potential direct targets of WT1 in the entire genome and from this list of genes 
identified by micro-array were determined using validated WT1-binding motifs 
and the programs BLASTN (Ensembl) (Aken et al., 2016) and RSAT (Medina-
Rivera et al., 2015). See Section 2.13.4 for full details.  
As it was not possible to rank genes generated from this analysis, DAVID was 
used for analysis of the generated data, with either the entire mouse genome 
or all genes detected by micro-array as the background, depending on the 
data used for analysis. 
5.2.5 Statistical Analysis 
Except in the case of the analysis of FACs data, all statistical analysis in this 
chapter is either from the initial data processing (Section 5.2.3) or p-values 
from the programs’ (DAVID, GOrilla, RSAT, Ensembl, ReviGO) own statistical 










5.3.1 A Small Proportion of WT1+ Cells from WT1-GFP FACS 
in Sponges express CD31 
Sponges from WT1-GFP mice were FACS sorted for the expression of GFP 
and hence, WT1, at day 7 and day 21 in order to identify the cell type of WT1+ 
cells in vivo. Implantation of sponges and subsequent FACS analysis was 
carried out Richard McGregor and You-Ying Chau (University of Edinburgh). 
WT1-GFP mice had a distinct population of GFP+ cells in kidney, day 7 sponge 
and day 21 sponge tissue, in comparison to WT1-GFP- controls which had 
negligible GFP+ cells in any of these tissues (Figure 5.3.1 A-E). There were 
significantly more GFP+ cells in sponges at day 7 than at day 21 (p<0.0001) 
(Figure 5.3.1 F). GFP- and GFP+ cells from sponges at both time points were 
FACS sorted for expression of CD31 and PDGF-β (Figure 5.3.2). CD31+ 
(PDGF-β+ and PDGF-β-) cells made up a small minority of total GFP+ cells 
(day 7 = 2.49%, day 21 = 1.07%).  Notably, the largest proportion of GFP+ 




























Figure 5.3.1: There are significantly fewer GFP+ (WT1+) cells in sponges at day 
21 v day 7.  Fluorescence activated cell sorting (FACS) scatter plots of side scatter 
(cell size) (y) against GFP fluorescence (x) in A) GFP+ kidney, B) GFP- kidney, C) 
day 7 GFP+ sponge, D) day 21 GFP+ sponge, E) day 21 GFP- sponge. F) 
Quantification of cell counts from FACS sorting reveals significantly fewer GFP+ cells 
at day 21 v day 7. **** p<0.0001, Student’s t-test. D7 = day 7, D21 = day 21. Boxes 




























Figure 5.3.2: The majority of GFP+ (WT1+) cells from SSI sponges are CD31- and 
PDGF-β-. Fluorescence activated cell sorting (FACS) scatter plots of PDGF-β 
fluorescence (y) against CD31 fluorescence (x) in SSI sponges. A) Key showing 
defined quartiles for CD31 and PDGF-β positivity and negativity. Scatter plot of FACs 
in WT1-GFP sponges B) with CD31 and PDGF-β isotype control antibodies, C) at 
day7 and D) at day 21. Quantification of cell counts from FACs sorting showing % of 
sorted E) GFP+ and F) GFP- cells at day 7 and 21 which also express CD31 and 
PDGF-β. * p<0.05, *** p<0.005, Student’s t-test. GFP+ cells = green, Pdgf-β+ cells = 










5.3.2 RNA-Sequencing and Transcriptomic Analysis of WT1-
GFP Sponges  
Sorted GFP+ and GFP- cells from WT1-GFP sponges in 5.3.1 were sent for 
microarray analysis for gene expression. This was carried out primarily in order 
to identify the cell type of the WT1+ cells which are CD31-/PDGF-β- and 
determine the involvement of WT1+ cells in angiogenesis. This returned the 
gene expression levels of 12,964 genes, 17,958 transcripts (due to multiple 
transcripts/gene) in GFP+ (herein referred to as WT1+) and GFP- (herein 
referred to as WT1-) cells at day 7 and day 21 by assessing mRNA abundance. 
This accounts for roughly 56% of the total mouse genome (~25,000 genes 
(Guénet, 2005)) 45.4% of these genes were not expressed at significantly 
different levels in WT1+ v WT1- cells at either time point. 54.6% of genes were 
expressed at significantly different levels in WT1+ v WT1- cells at day 7 or day 
21 (Figure 5.3.3). Only 12.4% of genes were higher at both day 7 and 21 
(~6.4% of the mouse genome) and 11.2% lower at both (~5.8% of the mouse 
genome). 
  
Figure 5.3.3: WT1+ and WT1- cells have different gene expression profiles. WT1+ 
(GFP+) and WT1- cells were sorted from WT1-GFP SSI sponges at day 7 and 21 and 
gene expression was assessed by mRNA abundance from microarray analysis. 
Shown is a pie-chart of cells which have significantly higher (red) or lower (blue) gene 
expression in WT1+ cells v WT1- cells, or unchanged (orange) expression between 
the two at day 7, day 21 and both day 7 & day 21. 
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5.3.2.1 WT1+ Cells are Primarily Immune Cells  
DAVID (Huang, Sherman and Lempicki, 2008, 2009) was used to determine 
the identity of WT1+ cells from their entire gene expression profile. In order to 
reduce false positives and/or allow changes in cell type over time to affect 
results, only genes expressed at a significantly higher level in WT1+ cells v 
WT1- cells at both day 7 and day 21 were selected and analysed to identify 
the cell types. Only the 12,964 genes detected in our micro-array were used 
as the background for analysis, to avoid any context-dependent bias. DAVID 
revealed 7 cell types which the WT1+ gene expression profile significantly 
matched (Table 5.3.1). By far the most significant match was for macrophages, 
identified by 200 matching genes (p=3.41E-15). Four other immune cell types 
were also significant matches (mast cells, dendritic cells, peritoneal 
macrophages and pre-B cells), as well as fibroblasts, mesenchymal stem cells 
and endothelial cells. The genes which significantly match with the endothelial 
cell profile were VCAN, CD93, B9D1 and VCAM1. It is worth noting that these 
results are unable to reveal the relative abundance of these different types of 
WT1+ cells. 
Cell Type P-Value Gene 
no. 
% 
Macrophage 3.41E-15 200 6.14 
Mast Cell 1.20E-05 84 2.47 
Dendritic Cell 3.33E-05 48 1.74 
Fibroblast 8.06E-05 38 1.05 
Peritoneal Macrophage 2.27E-02 7 0.23 
Pre-B Cell 3.03E-02 9 0.23 
Mesenchymal Stem Cell 4.76E-02 13 0.46 
Endothelial Cell 4.83E-02 4 0.18 
Table 5.3.1: The identity of WT1+ cells. DAVID (Huang, Sherman and Lempicki, 
2008, 2009) was used to identify the cell types with which the gene expression profile 
of WT1+ significantly matched, using genes that were elevated in WT1+ v WT1- cells 
at both day 7 and day 21. The p-value for identifying each cell type is shown, along 
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with the number of elevated genes which match with this cell type (Gene no.) and the 
% of the total elevated genes this equates to (%). n=6. 
5.3.2.2 WT1+ Cells are Associated with Angiogenesis  
Using GOrilla (Eden et al., 2007, 2009), genes were ranked by log10 fold 
change (WT1+ v WT1-) from highest to lowest to carry out transcriptomic 
analysis of the gene expression profile of WT1+ cells. This identified the gene 
ontology terms (GOterms) Angiogenesis, Regulation of Angiogenesis, 
Positive Regulation of Angiogenesis and Negative Regulation of 
Angiogenesis as being significantly associated with the gene expression 
profile of WT1+ cells (Table 5.3.2) 
 
P-value 
Process Day 7 Day 21 
Angiogenesis 3.11E-08 1.07E-09 
Regulation of Angiogenesis  4.02E-12 1.86E-04 
Positive Regulation of Angiogenesis  4.60E-07 2.58E-05 
Negative Regulation of Angiogenesis  1.51E-04 1.86E-04 
Table 5.3.2: WT1+ cells are involved in angiogenesis. GOterms identified by 
GOrilla (Eden et al., 2007, 2009) as being associated with the gene expression profile 
of WT1+ cells at day 7 and day 21, along with the identified p-value. 
 
GOrilla also provided the names of genes associated with these terms which 
were significantly elevated in WT1+ cells at day 7 and day 21 (Figure 5.3.4 & 
5.3.5, respectively). Some of these, were expressed at higher levels at day 7 
and day 21, such as Hif1a, Thbs1 and Ets1, while others were only higher at 
one time point.  
5.3.2.2 WT1+ Cells have higher gene expression of a number 
of collagens, MMPs and EMT genes 
Given what is known about WT1 function from previous studies, the 
expression of a number of collagen genes, matrix metalloproteinases (MMPs) 
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and genes involved in EMT/MET were examined. The gene expression of a 
number of collagens (Figure 5.3.6 A,B) and MMPs was significantly elevated 
in WT1+ cells at day 7 and day 21(Figure 5.3.6 C,D). Col1a2, Col3a1, Col5a1, 
Col5a2, Col5a3, Col6a1, Col6a2, Col6a3, Col8a1, Col9a3, MMP3, MMP14 
and MMP23 were all significantly higher at both time points in WT1+ cells. 
WT1+ cells also had a significantly different gene expression profile for genes 
involved in EMT/MET at day 7 and day 21 (Figure 5.3.6 E,F), with Snai1, Slug, 
Twist1, Twist2, ETS-1 and ZEB1 all higher in WT1+ cells at both time points 
































































































































































































































































































Figure 5.3.4: WT1+ cells at day 7 have higher expression of a number of genes involved in angiogenesis. Graph shows log10 mRNA 
expression in WT1+ and WT1- cells of various genes identified by GOrilla (Eden et al., 2007, 2009) as being associated with angiogenesis 
(regulation, positive regulation and negative regulation, denoted below graph). Cells were FACS sorted from SSI sponges from WT1-GFP mice 















































































































































































































































































































Figure 5.3.5: WT1+ cells at day 21 have higher expression of a number of genes involved in angiogenesis. Graph shows log10 mRNA 
expression in WT1+ and WT1- cells of various genes identified by GOrilla (Eden et al., 2007, 2009) as being associated with angiogenesis 
(regulation, positive regulation and negative regulation, denoted below graph). Cells were FACS sorted from SSI sponges from WT1-GFP mice 




































































































































































































































































































































































































































































































































































Figure 5.3.6: WT1+ and WT1- cells have higher expression of a number of collagens, MMPs and genes involved in cell transition. Graph 
shows log10 mRNA expression in WT1+ and WT1- cells of A, B) collagen genes at day 7 and 21, respectively, C, D) matrix metalloproteinases 






epithelial transition (MET) at day 7 and 21, respectively. Cells were FACS sorted from SSI sponges from WT1-GFP mice at day 7 and day 21. 
Gene names are the official gene symbols. *fdr q<0.05, limma R bioconductor package, WT1- v WT1+. n=
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5.3.2.4 Differentially Expressed Genes in WT1+ Cells are 
Involved in a Number of Processes 
Using GOrilla (Eden et al., 2007, 2009), genes were ranked by log10 fold 
change between WT1+ and WT1- cells to determine the cellular locations at 
which WT1 was inducing genetic changes (Figure 5.3.7). The molecular 
functions (Figure 5.3.8) and biological processes (Figure 5.3.9) associated 
with WT1-expressing cells were also determined. This was all carried out at 
day 7 and day 21 separately and it was found that the WT1+ gene expression 
profile at day 7 and day 21 was similar enough that much the same GOterms 
were significant at both. GOterms were presented using ReviGO (Supek et al., 
2011), which reduces down long lists of GOterms by removing redundant 
terms and spatially distributes terms based on biological similarity. 
WT1+ cells primarily had different gene expression to WT1- cells in genes 
associated with the membrane and extracellular space of cells (Figure 5.3.7). 
Genes encoded proteins involved with the function of the plasma membrane, 
extracellular vesicles, extracellular matrix and collagens. There were also 
genes associated with the actin filament bundle, actomyosin and stress fibres, 
as well as blood microparticles and platelet alpha granules. 
As well as molecular functions relating to RNA polymerase II, with which WT1 
is known to interact, the genes expressed at higher levels in WT1+ cells were 
associated with a number of molecular activities (Figure 5.3.8). One group of 
biologically related molecular functions related to binding of proteins including 
Laminin-1, Integrins, Fibronectin, Actin and other growth factors. Another 
group of related functions concerned the activity of a number of different 
peptidases. Other functions include, metal ion binding, calcium binding and 
heparin binding. 
In terms of biological processes (Figure 5.3.9), while angiogenesis was a 
process significantly associated with WT1+ cells, the WT1+ gene expression 
profile also significantly correlated with general cellular processes, including 
cell growth, proliferation, locomotion, adhesion and death. WT1+ cells were 
also involved in a general response to hypoxia, oxygen levels and wounding 
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and wound healing. A number of processes related to extracellular matrix and 




























Figure 5.3.7: The cellular location of genes differentially expressed in WT1+ 
cells. The gene expression profile of WT1+ cells was analysed by GOrilla, in 
comparison to that of WT1- cells to determine significant GOterms associated with 
the expression profile. This was sorted for redundancy and visualised by ReviGO 
(Supek et al., 2011) for A) day 7 and B) day 21. Each circle is a GOterm. Size of circle 
indicates log size of changes in expression and colour represents log10 p-value for 
significance of each term. X and Y axis are semantic space, such that GOterms that 
























Figure 5.3.8: Molecular functions associated with the gene expression profile 
of WT1+ cells. The gene expression profile of WT1+ cells was analysed by GOrilla, 
in comparison to that of WT1- cells to determine significant GOterms associated with 
the expression profile. This was sorted for redundancy and visualised by ReviGO 
(Supek et al., 2011) for A) day 7 and B) day 21. Each circle is a GOterm. Size of circle 
indicates log size of changes in expression and colour represents log10 p-value for 
significance of each term. X and Y axis are semantic space, such that GOterms that 


























Figure 5.3.9: Biological processes associated with the gene expression profile 
of WT1+ cells. The gene expression profile of WT1+ cells was analysed by GOrilla, 
in comparison to that of WT1- cells to determine significant GOterms associated with 
the expression profile. This was sorted for redundancy and visualised by ReviGO 
(Supek et al., 2011) for A) day 7 and B) day 21. Each circle is a GOterm. Size of circle 





significance of each term. X and Y axis are semantic space, such that GOterms that 
are biologically similar are closer together. n=3. 
5.3.2.5 Pathway Analysis of WT1+ Cells 
DAVID (Huang, Sherman and Lempicki, 2008, 2009) was used, as previously 
described (5.3.2.1) to identify pathways from the KEGG pathway database 
with which the gene expression profile of WT1+ cells was significantly 
associated. Again, only genes expressed at a significantly higher level in WT1+ 
cells v WT1- cells at both day 7 and day 21 were selected and analysed. 29 
KEGG pathways were significantly associated with WT1+ cells (Table 5.3.3), 
suggesting these pathways are upregulated in WT1+ cells. The pathway with 
the most associated genes (PI3K-Akt signalling pathway) had 67 genes from 
the pathway elevated in WT1+ cells.  
Pathway Genes P-Value 
Lysosome 54 2.54E-08 
Phagosome 50 1.32E-06 
Rheumatoid arthritis 32 4.18E-05 
Amoebiasis 36 1.02E-04 
Platelet activation 36 2.77E-04 
Protein digestion and absorption 21 2.79E-04 
ECM-receptor interaction 24 5.04E-04 
Focal adhesion 51 0.0023 
Rap1 signalling pathway 49 0.0035 
Intestinal immune network for IgA 
production 
14 0.0045 
Calcium signalling pathway 35 0.0051 
Jak-STAT signalling pathway 34 0.0051 
Transcriptional misregulation in cancer 41 0.0071 
Regulation of actin cytoskeleton 48 0.0072 
Steroid hormone biosynthesis 9 0.0096 
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Proteoglycans in cancer 51 0.0108 
Leukocyte trans-endothelial migration 28 0.0127 
Collecting duct acid secretion 10 0.0130 
Synaptic vesicle cycle 17 0.0137 
Malaria 17 0.0137 
Mineral absorption 13 0.0140 
Bacterial invasion of epithelial cells 23 0.0160 
Cytokine-cytokine receptor interaction 43 0.0161 
Cell adhesion molecules (CAMs) 31 0.0184 
Adherens junction 21 0.0202 
PI3K-Akt signalling pathway 67 0.0227 
Ras signalling pathway 45 0.0272 
Hematopoietic cell lineage 21 0.0322 
Endocytosis 60 0.0369 
Table 5.3.3: KEGG pathways upregulated in WT1+ cells. 29 pathways were 
identified as being associated with genes elevated in WT1+ cells using DAVID 
(Huang, Sherman and Lempicki, 2008, 2009) and the KEGG pathway database. Only 
genes higher in WT1+ cells at both day 7 and day 21 were analysed. Shown are the 
number of genes in that pathway elevated in WT1+ cells and the p-value for identifying 





The experiments in this chapter were intended to determine what cell types were 
expressing WT1 in vivo, in the context of angiogenesis, using the gene expression 
profile of these cells. Additionally, some insights into the role of these WT1 expressing 
cells were deduced from their gene expression. Characterisation of the effect of WT1 
on a molecular level is essential to understanding the implications of WT1 expression 
and manipulation of this expression, on a cellular, tissue and organismal level. 
Furthermore, unbiased gene-sequencing as carried out here has the potential to 
reveal new areas of importance in relation to WT1, which would not otherwise have 
been envisioned; effectively allowing a ‘bottom-up’ approach to interrogation of WT1 
and its function.   
This chapter investigated the gene expression profile of WT1 in a number of different 
cell types in a model of in vivo angiogenesis, working on the hypothesis that WT1 
would be expressed in endothelial cells and that this expression would induce a more 
pro-angiogenic gene expression profile. Cell sorting and analysis of the gene 
expression profile of these cells revealed that the vast majority of WT1 expressing 
cells were non-endothelial and that while WT1 positive cells were involved in 
angiogenesis to some extent, they were also implicated in a number of other cellular 
and physiological processes.  
5.4.1 Issues to Consider in Transcriptomic Analysis 
It is important to note here a few caveats regarding this analysis. Firstly, changes in 
gene expression between WT1 positive and WT1 negative cells simply reflect genes 
which are expressed to a greater or lesser extent in WT1 expressing cells. Hence, 
while changes in the expression of particular genes may be correlated with WT1 
expression, this does not prove that they are regulated by WT1 directly or indirectly. 
Instead, the gene expression of these different cells can provide insights into the 
processes WT1 expressing cells are involved in. For example, it is more than possible 
that a specific factor could transcriptionally activate Wt1 and another gene, 
simultaneously increasing expression of both genes (and protein levels), or that Wt1  
and other genes in question could be activated by the specific process a cell is 
undergoing or the location of this cell within the tissue. 
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As all cells were sorted from sponges for WT1 expression and the total RNA levels of 
all these cells then quantified, the gene expression profiles will be from a number of 
different cell types which can complicate analysis. For example, if more inflammatory 
immune cells express WT1 than do not express WT1, the expression of genes 
associated with these cells will, necessarily, be elevated in the WT1 positive cell 
population; this could appear as if WT1 is associated with activation of inflammatory 
genes, when, in fact, it may be involved in entirely different processes in these cells. 
However, this also does not preclude a role for WT1 in inflammation and certainly, the 
fact that WT1 is expressed to a greater degree in these cell types would be of 
relevance. While this broad transcriptomic analysis was necessary to enable further 
identification of different cell types, it would be interesting in the future to carry out 
sequencing comparing WT1 positive and WT1 negative cells of a particular cell type, 
such as endothelial cells or macrophages. 
There are a number of things that this whole-genome sequencing cannot tell us about 
the molecular genetic environment associated with WT1. Where there are changes in 
gene expression and identification of different processes associated with WT1 
expression, it is not possible to tell, for example, whether this is the result of a large 
change in a subpopulation of WT1 expressing cells, or a small change in all WT1 
expressing cells. Different WT1 protein isoforms (particularly +/- KTS) have been 
shown to have different effects on cellular function, but this sequencing does not 
provide any information on WT1 isoform expression. Moving forward, it would be very 
interesting to sort and compare the expression profile of +KTS WT1 and –KTS WT1 
to provide more insight into the role of these different isoforms. The sequencing carried 
out in this chapter is based on RNA expression, while in practice protein function 
depends on a number of post-transcriptional modifications such as phosphorylation, 
methylation and acetylation. Therefore, increases in gene expression do not always 
correlate with increases in protein function, though in the majority of cases and for the 
purpose of this investigation, it is fair to assume that an increase in gene expression 
effectively means an increase in protein function.  
5.4.2 WT1 is Expressed in a Number of Non-Endothelial Cell Types 
In the context of angiogenesis, the focus has primarily been on WT1 in endothelial 
cells (Wagner et al., 2014). In previous chapters it was shown that WT1 is expressed 
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in endothelial cells, but also in a number of other cell types, including vascular mural 
cells and non-vascular cells. Cell sorting revealed that a greater proportion of cells are 
WT1 positive in sponges 7 days post-implantation that 21 days post-implantation, 
supporting the idea that WT1 has a role relatively acutely after injury. Identification of 
cell types from the sponges revealed that a very small proportion (less than 2%) of 
WT1 positive cells were endothelial. A larger proportion of WT1 positive cells 
expressed the pericyte marker PDGFR-β, but this still accounted for less than 6% of 
all WT1 positive cells. Interestingly, a proportion of endothelial cells expressed 
endothelial and pericyte markers, especially at day 7 where this accounted for the 
majority of endothelial cells. This is interesting as it supports the possibility that WT1 
positive endothelial cells often sit in a transitionary state, as has been seen in vivo and 
in vitro in the previous chapters. 
Although endothelial cells made up a very small proportion of WT1 expressing cells, it 
is understandable, given that vessels comprise a small proportion of the total cells in 
sponges post-implantation. However, the proportion of WT1 positive cells which were 
endothelial was about half the proportion of WT1 negative cells which were 
endothelial. While many genes are ubiquitously expressed, certain genes are only 
expressed in certain cell types, and so from gene-sequencing, it is possible to 
determine from genes that are more highly expressed in WT1 positive cells than WT1 
negative cells, what cell types are expressing WT1. From this it was determined that 
a proportion of WT1 expressing cells were endothelial cells.  
Utilising the gene sequencing, a fascinating array of cell types were found to comprise 
the WT1 positive cell population. The majority of WT1 positive cell types identified 
were of an immune cell lineage; macrophages, mast cells, dendritic cells, peritoneal 
macrophages and pre-B cells. Two mesenchymal cell types were also identified; 
fibroblasts and mesenchymal stem cells. While it is not possible to determine which 
cells most abundantly express WT1, it is worth noting that 200 genes (6.14% of all 
genes assessed) matched with the macrophage cell identity while 84, 48 and 38 genes 
matched with the mast cell, dendritic cell and fibroblast cell identities, respectively. The 
approach used here (sequencing to identify the potential cell types associated with a 
gene, protein, or process followed by FACs sorting for markers of these cells) would 
appear to be effective in contexts where there is little prior information, especially as 
sequencing technology becomes cheaper and more accessible. Now that it has been 
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confirmed that WT1 is expressed in these cell types, further FACs should be carried 
out in sponges to identify the relative proportions of these cells that express WT1 and 
how much of total WT1 expression this comprises. This would confirm the robustness 
of this method of analysis for identifying specific cell types and could then be applied 
to other contexts in which WT1 is of interest, such as different types of cancer (avoiding 
arduous and imprecise histological analysis for every cell type). The first context in 
which this should be applied is the hindlimb ischaemia model, where our work 
suggests WT1 may additionally be expressed in myocytes and satellite cells. 
That WT1 is expressed in a range of immune cells, is an exciting discovery, with far 
reaching implications. There has been little specific focus on WT1 in immune cells to 
date, despite previous evidence suggesting WT1 may regulate immunity. WT1 
expression has been previously noted in macrophages, where it regulates Il-10 and 
macrophage differentiation (Smith et al., 1998, 2000; Sciesielski et al., 2010) and B-
lymphocytes, which are generated by pre-B cells (Spinsanti et al., 2000; Marcet-
Palacios, Davoine, et al., 2007), but not (to the best of this author’s knowledge) in pre-
B cells themselves, mast cells, or dendritic cells; this should be assessed by histology 
in vivo, both in the context of cardiovascular diseases, where inflammation is a key 
component and other inflammatory diseases. WT1 is involved in haematopoiesis and 
haematopoietic stem cell (HSC) growth, proliferation and differentiation (Leif W Ellisen 
et al., 2001; Alberta et al., 2003; Cunningham et al., 2013). Macrophages (including 
peritoneal macrophages), mast cells, dendritic cells and pre-B cells all arise from 
HSCs during haematopoiesis, suggesting that all HSC-derived cells could have the 
potential to express WT1. Furthermore, all of these cell types are involved in 
angiogenesis, raising questions about the interactions between WT1 expressing 
endothelial cells and immune cells during angiogenesis.  
It is well established that WT1 is expressed in fibrotic tissue and fibroblasts in a number 
of contexts. Following myocardial infarction, WT1 is expressed in areas of fibrosis 
(Braitsch et al., 2013) and fibroblasts are derived from WT1 expressing epicardium 
(Zhou and Pu, 2012). Detection of fibroblasts from gene sequencing is in concordance 
with WT1 transcriptionally regulating fibroblast genes and fibrosis. Mesenchymal stem 
cells (MSCs) are a fascinating pluripotent cell type with the capacity to generate 
fibroblasts, endothelial cells, adipocytes, chondrocytes, osteoblasts and all forms of 
muscle cells (Uccelli, Moretta and Pistoia, 2008). They also have immunomodulatory 
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function (Aggarwal and Pittenger, 2009) and form a niche in the bone marrow, along 
with HSCs, from which they both  mobilise (Méndez-Ferrer et al., 2010). In this respect, 
MSCs seem to be a crucial link between a number of the functions of WT1 and the 
cell types detected here. Surprisingly, however, the role of WT1 in MSCs is largely 
unknown. Supporting this link between WT1 and MSCs, FACs and gene-sequencing 
of cells isolated from Wilms’ tumours with Wt1 mutations had gene expression 
characteristic of MSCs (Royer-Pokora et al., 2010). In a more cardiovascular context, 
a population of MSCs was discovered in the heart which was derived from WT1 
positive proepicardium (Chong et al., 2011). The importance of WT1 in MSCs needs 
to be determined in vivo, as they are not only sources of a number of important cell 
types, but have been shown to be beneficial in promoting angiogenesis when 
implanted into ischaemic hindlimbs (Al-Khaldi et al., 2003; Li et al., 2011). 
5.4.3 The Gene Expression Profile is Consistent with a Role for WT1 
in Angiogenesis 
As well as identifying WT1 in endothelial cells and other cell types involved in 
angiogenesis, the gene expression profile of WT1 expressing cells was consistent with 
these cells having a role in angiogenesis. At both day 7 and day 21 post-implantation 
of sponges, it was determined that WT1 expressing cells were involved in positive and 
negative regulation of angiogenesis, through increased expression of pro-angiogenic 
and anti-angiogenic factors. Some of these factors are known to be regulated by WT1, 
such as Ets1 (Wagner et al., 2008), Col4a1 (S.-R. Chen et al., 2013) and Thbs1 
(Dejong et al., 1999), while Hifa is known to regulate Wt1 (Wagner et al., 2003). 
However, the majority of these genes have not previously been implicated with WT1. 
Hif1a encodes the HIF-1α protein, a major regulator of response to hypoxia. Both HIF-
1α and WT1, transcriptionally activate Vegf. Concordantly, VegfC expression was 
increased at day 21 in WT1 positive cells, while a number of other genes in the VEGF-
signalling pathway were changed with WT1 expression. This supports a role for WT1 
in VEGF-signalling as a possible mechanism through which WT1 influences 
angiogenesis (Cash et al., 2007; Hanson et al., 2007; Wagner et al., 2008; McCarty, 
Awad and Loeb, 2011); though it is worth considering WT1 and VEGF interact not only 
in angiogenesis, but haematopoiesis too (Cunningham et al., 2013). In line with the 
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role of WT1 as a transcriptional regulator, WT1 likely has a regulatory role in 
angiogenesis, rather than being pro-angiogenic or anti-angiogenic.  
It is important to note however, that correlation does not mean causation and it is 
possible that WT1 is expressed in cells undergoing angiogenesis for unrelated 
reasons. It is also not clear whether this association between WT1 expression and 
other gene expression occurs in a particular subset of WT1 positive cells (for example 
only in endothelial cells) or in numerous cell types expressing WT1. Regardless of 
whether WT1 is directly regulating angiogenesis, it is a robust conclusion that Wt1 is 
transcriptionally activated in cells undergoing angiogenesis, or that initiation of 
angiogenesis results in transcriptional activation of Wt1.  
It is interesting to note that the majority of genes which change in expression with WT1 
expression encode proteins located at the cell surface, suggesting WT1 not only 
induces changes in the cell in which it is expressed, but also affect cell-cell and cell-
matrix interactions. This is further supported by association between WT1 expression 
and signalling via cellular vesicles. Perhaps expression of WT1 in clusters of proximal 
cells within the vasculature (observed in vivo in the HLI and sponge models), where 
WT1 could activate WT1 expression in proximal cells by cell-cell interactions or 
through factors released in vesicles. It would be interesting to assess the difference in 
the composition of vesicles released from WT1 positive and negative cells in vitro. 
Furthermore, endothelial or immune cells expressing WT1 may be releasing 
circulating signals into the vasculature, such as cytokines and chemokines (Velecela 
et al., 2013). 
5.4.4 WT1 Expressing Cells have a Number of Non-Angiogenic 
Functions 
Alongside a clear role for WT1 in cells undergoing angiogenesis, the transcriptomic 
analysis carried out here reveals a role for WT1 in a number of processes in vivo in 
the sponge model, including a general response to hypoxia, wounding and wound 
healing. As previously mentioned, certain processes could solely be correlated with 
WT1 expression, due to the cell types in which WT1 is expressed. However, WT1 
affected cellular processes not specific to any particular lineage including proliferation, 
growth, locomotion, adhesion and death, as has been previously described 
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(Maheswaran et al., 1995; Roberts, 2008; Wagner et al., 2008; Shandilya and Roberts, 
2015). One of the key roles of WT1 is regulation of EMT (Hastie, 2017). Concordantly, 
the key EMT regulators Snail, Slug, Twist1, Twist2, Ets1 and Zeb1 are all expressed 
at higher levels in WT1 positive cells, suggesting that at least a proportion of these 
cells are undergoing a transition event. It was also evident that WT1 expressing cells 
were undergoing cytoskeletal rearrangements. These are necessary for changes in 
cellular function, to increase cell motility and in transitions such as EMT (reviewed by 
Yilmaz & Christofori 2009). Given the regulatory role WT1 plays in cellular processes 
including EMT and cell migration, it would not be surprising if WT1-induced 
modification of the cytoskeleton was a part of this and in fact, changes in cytoskeletal 
structure have been previously shown in relation to WT1 in a number of contexts 
(Hosono et al., 2000; Barbolina et al., 2008; Scholz, Wagner and Wagner, 2009; Brett, 
Pandey and Fraizer, 2013b). 
 Numerous collagen and MMP genes were highly expressed in WT1 positive cells, 
consistent with WT1 expression in fibroblasts and immune cells and a role in collagen 
and extracellular matrix turnover (Goetzl, Bando and Leppert, 1996; Distler et al., 
2005). While this could be solely due to the expression of WT1 in cell types involved 
in collagen deposition, such as fibroblasts, all cells interact with the extracellular matrix 
(ECM) and basement membrane to some extent. The focal adhesion pathway was 
associated with WT1 as were numerous processes relating to interaction of cells with 
collagen and ECM, which potentially implicates WT1 in regulation of cellular interaction 
with ECM components. In agreement with this, in the testis, WT1 directly regulates 
Col4a1 and Col4a2 (S.-R. Chen et al., 2013), both of which were more highly 
expressed in WT1 positive cells, here. Modulation of cell-ECM interaction is essential 
in angiogenesis, regeneration, cell proliferation, migration and differentiation (Newby, 
2006; Guilak et al., 2009; Schultz and Wysocki, 2009). 
5.4.5 Conclusions 
This chapter set out to address the hypothesis that WT1 is expressed in endothelial 
cells and that WT1 expression induces a more pro-angiogenic gene expression profile 
in these cells. Through cell sorting and transcriptomic analysis, it was confirmed that 
WT1 was expressed in endothelial cells, but that this only comprised a very small 
proportion of WT1 expression. WT1 was expressed in immune cells (macrophages, 
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peritoneal macrophages, dendritic cells and mast cells), fibroblasts and mesenchymal 
stem cells. However, all of these cells are also known to influence angiogenesis and 
indeed, from transcriptomic analysis, WT1 positive cells were clearly involved in 
angiogenesis. The gene expression analysis carried out also attempted to identify the 
gene expression profile of WT1 expressing cells to help draw functional conclusions 
about the implications of WT1 expression in vivo. This confirmed that WT1 was also 
involved in a more broad regenerative response with roles in previously discovered 
processes such as migration, proliferation, apoptosis and cell transition, including 
EMT.  
Ultimately, the work in this chapter provided a wealth of stimulating molecular genetic 
data, which needs to be corroborated by in vivo and in vitro work. It proved the efficacy 
of this kind of transcriptomic approach in novel contexts where little prior information 
is available. In the context of WT1 and angiogenesis, it was shown that WT1 was 
involved in cells undergoing angiogenesis, as shown previously in vivo, but could not 
confirm that this was the direct result of WT1 expression. Importantly, endothelial cells 
do not seem to be the only cell in which WT1 plays a role in angiogenesis and future 
investigation should also focus on immune cells, mesenchymal cells and progenitor 
populations. It seems likely, given the roles of WT1 in cellular function and 
differentiation that WT1 is required to induce cellular changes necessary to facilitate 
angiogenesis, though there are no doubt functions of WT1 in angiogenesis and 





















Discussion & Conclusions 
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Cardiovascular disease is the leading cause of mortality worldwide, accounting for 4 
million deaths a year across Europe, 45% of all mortality (Townsend et al., 2016). 
While the treatment of cardiovascular complications, such as myocardial infarction, is 
improving, patients are still left with detrimental functional impairment; for sufferers of 
peripheral arterial disease, this may mean limb amputation and for those unsuitable 
for amputation there is an even more severe and potentially fatal prognosis. 
Furthermore, the increasingly sedentary lifestyles and unhealthy diets of many people 
are increasing the prevalence of a number of cardiovascular diseases (Go et al., 
2014). This all means the need has never been greater to develop regenerative 
strategies for deployment during and after cardiovascular events, for example, by 
increasing angiogenesis which is capable of reperfusing ischaemic tissue, hence 
augmenting repair processes (Khurana et al., 2005). However, trials of pro-angiogenic 
therapeutics, primarily focusing on growth factors such as VEGFs and FGFs, have to 
date, been ineffective in clinical trials (Bouïs et al., 2006; Brenner et al., 2016); this 
suggests the need for a new approach to therapeutically targeting angiogenesis in 
cardiovascular disease.  
One such approach could be targeting transcriptional regulation of a number of 
different factors simultaneously. In this respect, WT1 came to light as a potential factor 
of interest, due to its known regulation of a range of cellular and physiological 
processes (reviewed by Hastie 2017) and its implication in angiogenesis in cancer. 
(Timár et al., 2005; Dohi et al., 2010; Wagner et al., 2014). WT1 has been further 
implicated in angiogenesis by in vitro experiments showing that inhibition of WT1 
impairs angiogenesis (Wagner et al., 2008, 2014; Duim et al., 2015) and that in vivo, 
post-MI, WT1 is expressed in the ischaemic (and potentially angiogenic) vasculature 
(K. Wagner et al., 2002; Duim et al., 2015). In fact, among the numerous transcriptional 
targets of WT1 are factors such as VEGFs (Cash et al., 2007; Hanson et al., 2007; 
McCarty, Awad and Loeb, 2011) and FGFs (Bra et al., 2014) and pro-angiogenic drugs 
against these targets have previously gone to clinical trials. All of this suggests WT1 
could be a powerful therapeutic target, manipulation of which could have therapeutic 
benefits on outcomes from cardiovascular diseases.  
Whilst previous work has strongly implicated WT1 in angiogenesis, this has not been 
sufficient to elucidate the role which WT1 is playing in ischaemic vasculature in 
cardiovascular disease. The work contained in this thesis was designed to clarify the 
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role of WT1 in angiogenesis and tissue repair in the context of cardiovascular disease. 
The work utilised a number of experimental approaches to provide a fuller picture of 
the role of WT1 in ischaemic, regenerative angiogenesis and hence reveal whether it 
is a promising target for further investigation.  
6.1 WT1 in Angiogenesis 
WT1 is expressed in the cardiac vasculature throughout development (Duim et al., 
2016), but not in the majority of quiescent, adult vasculature; the blood vessels of the 
female endometrium and mammary being examples of exceptions to this, due to the 
physiological remodelling that occurs in these tissues (McGregor et al. 2014). 
However, WT1 is reactivated in the ischaemic cardiac vasculature post-MI (K. Wagner 
et al., 2002; Duim et al., 2015) and is also expressed in tumour vasculature (Timár et 
al., 2005; Dohi et al., 2010), two contexts in which angiogenesis is known to occur. 
Inhibition or deletion of WT1 has been shown to reduce angiogenesis in the in vitro 2D 
tube formation and ex vivo aortic ring assays (Wagner et al., 2008, 2014; Duim et al., 
2015); while inhibition of WT1 specifically in the vascular endothelium impaired 
angiogenesis ex vivo as well as in vivo in the context of tumour angiogenesis (Wagner 
et al., 2014). The experiments detailed in this thesis support these findings, while to 
some extent questioning the previous assertions on the role of WT1 in angiogenesis 
and adding new information to the field. 
Visualisation of WT1 expression during angiogenesis, ex vivo in the aortic ring assay 
and in vivo in the subcutaneous sponge implantation and hindlimb ischaemia models, 
confirmed that WT1 was expressed in the vascular endothelium of a proportion of 
blood vessels, showing that WT1 is activated during angiogenesis and ischaemia. It 
is unclear whether this expression is due to activation of WT1 during hypoxia, as has 
been previously demonstrated (Wagner et al., 2003), or due specifically to 
angiogenesis. However, as the ex vivo aortic ring assay was carried out in normoxic 
conditions, it seems likely the expression of WT1 is related to angiogenesis. This was 
confirmed by cell sorting of sponges which showed endothelial cells and pericytes 
comprised an identifiable, though relatively small proportion of, WT1-expressing cells. 
Transcriptomic analysis confirmed the presence of WT1-expressing endothelial cells 
and showed that WT1-expressing cells were involved in angiogenesis. Which occurs 
first, activation of WT1, or initiation of angiogenesis is undetermined. In the HLI model, 
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WT1-expressing vessels were more evident acutely after induction of injury, with 
considerably less vascular WT1 later on, suggesting WT1 is playing a role in the 
induction or early stages of angiogenesis. This is promising for WT1 in a therapeutic 
context, where manipulation of angiogenesis would be most beneficial if it could be 
promoted immediately after injury.  
However, WT1 was not expressed solely in the endothelial component of the 
vasculature in angiogenic tissues.  There was also considerable expression of WT1 in 
other mural cells (pericytes and VSMCs) of the vasculature, often concurrent with 
endothelial WT1 expression within the vessel. This was confirmed by cell sorting which 
identified a population of WT1 positive pericytes, in vivo. There were also what 
appeared to be immune cells in close proximity to the vasculature and in one instance, 
what could be a haematopoietic cell (both WT1 positive) in contact with WT1 positive 
vascular endothelium. Transcriptomic analysis confirmed that WT1 is expressed in a 
number of different immune cells; macrophages, including peritoneal macrophages, 
dendritic cells, mast cells and pre-B cells. All of these cells arise by haematopoiesis, 
in which WT1 is involved (Ariyaratana and Loeb, 2007) and have a role in 
angiogenesis. Of these cell types, WT1 has only previously been shown to be 
expressed in macrophages and never in the context of angiogenesis (Smith et al., 
1998, 2000; Sciesielski et al., 2010). This has exciting implications in a number of 
contexts, but in angiogenesis, it is very feasible that activated, WT1 positive immune 
cells migrate to the site of other WT1 positive cells and promote angiogenesis. 
Following in vivo confirmation that WT1 is important in these cell types, these findings 
may open many novel areas of investigation. Finally, WT1 was also expressed in two 
other cell types from transcriptomic analysis; fibroblasts and MSCs. Both of these have 
been shown to express WT1 (Chau et al., 2011; Braitsch et al., 2013) and influence 
angiogenesis (Newman et al., 2011; Ubil et al., 2014; Gong et al., 2017). Clearly then, 
endothelial cells are not the only angiogenesis-associated cells in which WT1 has a 
role in tissue repair. 
Interestingly, there were often clusters of WT1 expressing cells proximal to each other 
within the vasculature, in endothelial cells and mural cells and on some occasions 
there was clear focal disruption of the basement membrane, with endothelial cells 
migrating outwards. This is consistent with the processes which occur at the early 
stages of angiogenesis, in which the basement membrane is degraded and endothelial 
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and mural cells migrate outwards to form the initial angiogenic vascular outgrowth 
(Carmeliet and Jain, 2011). Endothelial cells expressing WT1 had a more 
mesenchymal-like shape and mural cells expressing WT1 also expressed endothelial 
and mesenchymal markers simultaneously. WT1 is known to have a role in EMT 
(Miller-hodges and Hohenstein, 2012), though it has not been investigated in the 
context of the related process EndMT. These observations could be explained by WT1 
inducing complete or partial EndMT and in the future, the role of WT1 in EndMT should 
be investigated. Indeed, it has been hypothesised that partial EndMT is an essential 
step in angiogenesis (Welch-Reardon et al., 2014; Welch-Reardon, Wu and Hughes, 
2015). A sensible first step would be using an in vitro EndMT assay (Zeisberg et al., 
2007) to assess WT1 expression during EndMT and the effect of WT1 inhibition on 
EndMT.  
6.2 The Angiogenic Implications of Endothelial WT1 KO 
WT1 was knocked-out selectively in the vascular endothelium in an inducible manner 
(VE-Wt1 KO). The mice generated in this way had a significant reduction in endothelial 
WT1 expression (in the uterus) following KO of WT1 in the endothelium. Consistent 
with the findings described above, endothelial WT1 KO significantly impaired 
angiogenesis in the ex vivo aortic ring assay, delaying the formation of angiogenic 
vessel outgrowths. This suggests that WT1 does have an endothelial role in 
angiogenesis. When VEGF-A was added to the media, though, angiogenesis was not 
impaired. This could be due to VEGF-A providing an improved angiogenic 
environment, but could also reflect a role for WT1 in activating VEGF, supporting 
previous findings that WT1 directly regulates VEGF (Cash et al., 2007; Hanson et al., 
2007; McCarty, Awad and Loeb, 2011). Transcriptomic analysis also supported this, 
by showing increased VEGF-C expression in WT1 positive cells and a potential role 
for WT1 in the VEGF signalling pathway. WT1 expression also correlated with 
regulation of a number of other cellular processes including proliferation, cell cycle, 
migration, survival and apoptosis (Aksamitiene, Kiyatkin and Kholodenko, 2012).  
In the endothelial WT1 KO mouse, however, WT1 had no detectable effect on in vivo 
angiogenesis in sponges or in muscles from the ischaemic hindlimb, despite 
endothelial WT1 expression in these models. WT1 has never previously been 
investigated in the HLI model, but previous work on the sponge model using a mouse 
201 
 
effectively identical to our endothelial WT1 KO (Université de Nice), found an eight 
fold reduction in vessel density following endothelial WT1 KO (McGregor et al. 2014). 
When we analysed these samples there was no difference found in any measures of 
angiogenesis. The reason for this discrepancy is unclear. The in vivo and ex vivo 
results initially appear contradictory, but there are a number of possible explanations 
for the differing outcomes; this is also a nice demonstration of the importance of using 
ex vivo and in vivo approaches to tackle the same question.  
First, it is possible that the reduction in WT1 induced in our endothelial WT1 KO mouse 
is insufficient to impair angiogenesis in vivo, as the knockout of WT1 in the 
endothelium is incomplete. A complete endothelial WT1 KO may impair angiogenesis 
in vivo and completely inhibit angiogenesis ex vivo. Furthermore, as WT1 is a 
transcriptional regulator, a 50% reduction in Wt1 expression would not lead to 
complete activation or inactivation of target genes. However, an incomplete WT1 KO 
in vivo was previously shown to achieve dramatic effects in adult tissues (Chau et al., 
2011).  
Another explanation is that as WT1 is expressed in a number of different cell types, 
not only endothelial cells. It is possible that expression in these other cell types is 
sufficient to compensate for the reduction in endothelial WT1 expression. Factors 
released by non-endothelial WT1 cells could also be sufficient to elicit the same effect 
in WT1 KO endothelial cells. Given the potential of a number of other cell types 
(including pericytes, fibroblasts and macrophages) to transition into endothelial cells, 
it is also possible these cells transition into endothelial cells in the KO to generate 
endothelial cells capable of WT1 expression. While the mechanisms behind this could 
be interrogated in further detail, this could first be confirmed by determining whether a 
ubiquitous tamoxifen-inducible WT1 KO (siRNA or Cre-lox (Chau et al., 2011)), 
impaired angiogenesis to a greater extent in the ex vivo aortic ring assay than an 
endothelial WT1 KO alone. Then, an inducible endothelial WT1 KO combined with an 
inducible mural cell and/or macrophage WT1 KO could be used in the sponge and HLI 
models to determine if there was any inhibition of angiogenesis. Previous work in the 
aortic ring assay and in murine tumours found that KO of WT1 impaired angiogenesis 
and tumour growth to a much greater extent under the control of Tie2 CreERT2, which 
is also expressed in haematopoietic cells including monocytes and HSCs (Kisanuki et 
al., 2001; Arai et al., 2004), than when under the control of VE-Cadherin CreERT2 
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(Wagner et al., 2014). Therefore, it would be logical to assume that Tie2 positive non-
endothelial cells have an effect on angiogenesis and in the HLI model it was shown 
that delivery of Tie2 expressing monocytes and macrophages dramatically increases 
in vivo angiogenesis and improves outcomes (Patel et al., 2013).  
Finally, the difference in timing between the ex vivo and in vivo models is likely to 
contribute, in part, to impaired of angiogenesis having been observed ex vivo, but not 
in vivo; that is to say that angiogenesis could be measured much more acutely ex vivo 
than in vivo, due to the nature of the models themselves. The evidence from this work 
suggests that WT1 is having an acute role in angiogenesis, which may be missed at 
the later time points at which angiogenesis could be quantified in vivo. As previously 
mentioned endothelial WT1 KO only delayed angiogenesis in the aortic ring model, 
with an early, transient reduction in vessel density that recovered by one week after 
start of angiogenesis. In the HLI model, WT1 was more widely expressed acutely after 
injury than later on. The implication is that in the in vivo models, an acute impairment 
of angiogenesis may also occur, but be unquantifiable and function is recovered by 
compensatory mechanisms by the time neovascularisation is quantified. The murine 
model of mouse menstruation developed by Brasted et al. (2003) and adapted by 
Cousins et al. (2014) could be a model of in vivo angiogenesis in which the effect of 
endothelial WT1 KO could be quantified at earlier time points. 
6.3 Physiological Roles of Vascular WT1 
WT1 has been shown herein to have a role in regenerative angiogenesis; however, 
putative evidence suggests a broader function of WT1 within the vasculature. As WT1 
is not known to be expressed in healthy adult vasculature, especially in males used in 
these experiments (Chau et al. 2011, McGregor et al. 2014), it was not envisioned that 
WT1 would affect normal vascular endothelial function in non-pathological 
circumstances. In agreement with this, endothelial WT1 KO had no effect on the 
morphology of a number of tissues. However, it was observed that the male gonad 
was visibly enlarged after sustained (<4 weeks) endothelial WT1 KO, while 
conversely, the testis was reduced in size. This suggests endothelial WT1 plays a 
normal physiological role in the testicular vasculature, which is disrupted following 
disruption of WT1 function. In line with this hypothesis, WT1 was, for the first time, 
found to be expressed in endothelial cells of a number of testicular blood vessels. This 
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adds to the very few known contexts in which WT1 is expressed in the adult 
vasculature and shows that along with the female uterine tract and mammary, WT1 is 
expressed in the vascular component of a number of reproductive tissues (McGregor 
et al. 2014). WT1 expression should also be assessed in the seminal vesicles and 
epididymal fat to determine whether WT1 is also expressed in the vasculature here, 
which would confirm that WT1 is expressed in the vasculature of all reproductive 
tissues. However, the weight of the seminal vesicles and epididymal fat was 
unchanged in endothelial KO mice, so it is likely WT1 is expressed in the vasculature 
to a lesser extent in these tissues.  
As the testis continues to develop and grow throughout early adulthood (Sharpe et al., 
2003), the simplest explanation for the reduced testis size, given the function of WT1 
in angiogenesis, is that impaired angiogenesis in the endothelial WT1 KO results in 
impaired testicular growth. It is also possible, however, that atrophy of the testis, , is 
contributing to the reduced testis weight observed. Atrophy was also observed in the 
heart, spleen and pancreas of mice ubiquitously deleted for WT1 (Chau et al., 2011). 
In this same study (Chau et al., 2011), a small, though non-significant reduction in 
testis weight was seen, though endothelial WT1 KO was maintained for a longer period 
of time.  The mechanism responsible for reduced testis size could be identified by 
observing endothelial WT1 expression in older adult mice in which testes are fully 
developed and then inducing endothelial WT1 KO in these older mice to see whether 
it results in a reduction in testicular size. Regardless, WT1 in the adult testicular 
vasculature is a completely novel area which demands further investigation.  
Given the reduced testis size and unchanged epididymal and seminal vesicle size, the 
simplest explanation for the enlarged male gonad is that endothelial WT1 KO is 
resulting in increased vascular permeability, leading to fluid accumulation and 
oedema. Generalised oedema was also observed following ubiquitous WT1 KO in 
adult mice (Chau et al., 2011), for which the deletion of WT1 in the endothelium may 
have been responsible. Whether oedema is localised to the gonad or more widespread 
following endothelial WT1 KO needs to be determined. WT1 regulates VEGF in the 
endothelium (Wagner et al., 2003) which regulates angiogenesis, but also vascular 
permeability (Nagy, Dvorak and Dvorak, 2007). This all leads to the hypothesis that 
WT1 regulates physiological vascular permeability in endothelial cells. This should be 
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explored further, looking at the vascular permeability in endothelial WT1 KO mice 
using an in vivo permeability assay (Chen et al., 2009).  
Myography was used to determine if endothelial WT1 KO impaired normal endothelial 
function. Surprisingly, endothelial WT1 KO aortae exhibited increased contractile 
responses to two vasoconstrictor agonists, 5HT (serotonin) and NA (noradrenaline) 
(though not potassium), with vasodilation unaffected. Therefore, in all likelihood WT1 
has a role in serotonin and noradrenaline signalling in endothelial cells and VSMCs 
which is disrupted by endothelial WT1 KO, though it is worth considering it could be 
an indirect effect. WT1 may prove to have a role in physiological regulation of vascular 
tone. In support of this hypothesis, hypertension is evident in some glomerulopathies 
resulting from Wt1 mutation (Little et al., 1993; Wagner et al., 2008; Lipska et al., 2014) 
and WT1 has been shown to regulate NO signalling (Johannesen et al., 2003; Mazzei 
et al., 2010). Intriguingly, serotonin and noradrenaline signalling are intertwined 
(Molderings et al., 1990) and both are involved in angiogenesis, in some cases through 
factors associated with WT1 (either previously or in this work), such as 
Thrombosponin-1 (Qin et al., 2013), Akt (Iwabayashi et al., 2012), PI3K (Steinle et al., 
2003) and VEGF (Yang et al., 2006).  
Part of what makes these results surprising is that WT1 is not thought to be expressed 
in quiescent adult vasculature, such as the aorta. Two possible options are that WT1 
is expressed at very low levels in the aorta, or is rapidly activated in response to these 
vasoconstrictors. The expression of WT1 in the adult aorta should be assessed by 
histology. The function of WT1 in regulation of vascular tone should first be examined 
by assessing the blood pressure of endothelial WT1 KO mice in vivo as a role for 
endothelial WT1 in regulation of vascular tone and blood pressure would be highly 
relevant in the context of cardiovascular disease, where hypertension is a significant 
risk factor. Angiogenesis, vascular permeability and vascular tone are all linked and 
the regulation of the latter two processes is required for regulation of angiogenesis. 
Furthermore, factors (including Akt, NO and VEGF) associated with WT1 (either here 
or previously) are involved in all three processes (Fukumura et al., 2001; Shiojima and 




6.4 Non-Vascular Functions of WT1 
The work described in this thesis confirms that WT1 has a number of roles outside the 
vasculature. Transcriptomic analysis revealed that, alongside angiogenesis, WT1 
expressing cells were involved in a number of cellular processes including cell 
proliferation, growth, locomotion, adhesion and death; all previously shown to be 
regulated by WT1 (Maheswaran et al., 1995; Roberts, 2008; Wagner et al., 2008; 
Shandilya and Roberts, 2015). These processes are all important to enable cells to 
participate in angiogenesis, but also reflect the role of WT1 as a broad regulator of 
cellular function and demonstrate that the role of WT1 is unlikely to be restricted 
exclusively to angiogenesis. This was confirmed by histology which showed WT1 
positive cells were involved in EMT (by colocalisation with Snail) in HLI and a 
proportion of these cells were proliferative. While the in vivo models deployed herein 
are primarily used as models of angiogenesis, they also encompass other 
regenerative responses to damage (Andrade, Fan and Lewis, 1987; Limbourg et al., 
2009). 
In the sponge and HLI models WT1 was expressed in cells which were 
morphologically consistent with fibroblasts and inflammatory immune cells. In 
ischaemic muscle following induction of HLI, there was acute infiltration of immune 
cells which were WT1 positive and the greatest expression of WT1 throughout this 
muscle tissue occurred acutely after injury. Transcriptomic analysis indicated that 
fibroblasts, macrophages, dendritic cells, mast cells and pre-B cells comprised a 
proportion of WT1 expressing cells. Furthermore, in the sponge and HLI models, there 
was putative evidence that endothelial WT1 KO affected macrophage infiltration and 
collagen deposition, respectively. WT1 has been previously shown to be involved in 
fibrosis (Braitsch et al., 2013) and inflammation (Smith et al., 1998, 2000; Sciesielski 
et al., 2010); one of the interesting things about this result is that WT1-expressing 
endothelial cells may act cooperatively with fibroblasts and immune cells, as 
endothelial WT1 KO affects fibrosis and inflammation. Transcriptomic analysis further 
confirmed changes in collagens, MMPs and immune markers associated with WT1 
expression, as well as involvement of WT1 expressing cells in ECM remodelling and 
immune processes. One such process was leukocyte transendothelial migration, a 
process in which endothelial cells increase vascular permeability to allow leukocytes 
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into specific tissues (Aghajanian et al., 2008). This may represent one instance of the 
cross-talk between WT1 expressing endothelial and immune cells.  
WT1 expressing cells were also involved in a general wound healing response, 
activated by hypoxia, as confirmed by transcriptomic analysis. One of the most striking 
and exciting observations in the HLI model of critical limb ischaemia was that skeletal 
muscle cells comprised a large proportion of WT1 expressing cells. This myocyte WT1 
expression was particularly widespread and persistent in areas of muscle damage 
within the gastrocnemius, where there was also increased angiogenesis, implicating 
WT1 in skeletal muscle regeneration. This is a completely novel observation; however, 
WT1 has recently been found to be strongly expressed in developing human skeletal 
muscle tissue (Parenti et al., 2013; Magro et al., 2015) and deletion of Wt1 from the 
kidney mesenchyme results in activation of myogenic markers and ectopic muscle 
formation (Berry et al., 2015). Skeletal muscle has its own resident stem cell 
population, satellite cells, which when activated in part by macrophages and 
fibroblasts, induces extensive muscle regeneration (reviewed by Wang & Rudnicki 
2011). Preliminary histological analysis suggested that WT1 may be expressed in 
satellite cells in quiescent and damaged skeletal muscle. This needs to be investigated 
in more detail in vitro and in vivo, but a working hypothesis based on these results is 
that WT1 is expressed in satellite cells which contribute to a WT1-regulated 
regenerative myogenesis. 
This is intriguing in isolation, but it is also easy to see the parallels between this 
situation and the maintained WT1 expression in the epicardium which has the potential 
to generate cardiomyocytes post-MI (van Wijk et al., 2012; Braitsch et al., 2013). This 
contributes to the known adult stem cell populations in which WT1 is essential, which 
along with epicardial cells comprises haematopoietic stem cells (Cunningham et al., 
2013) and adipose progenitor cells (Chau et al., 2014), while transcriptomic analysis 
carried out here also contributes pre-B cells and MSCs to this list. It is tempting to 
propose that WT1 is expressed in a large proportion of adult tissue-resident stem cell 
populations and should therefore be investigated in other populations, including 
mesenchymal stem cells. One particular population of interest, given the role for WT1 
demonstrated in this work could be endothelial progenitor cells. These cells of 
haematopoietic origin have high regenerative potential, contribute to adult 
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vasculogenesis (Zammaretti and Zisch, 2005) and undergo EndMT in certain 
circumstances (Díez et al., 2010).  
EMT, a process in which WT1 is known to be essential (Martínez-Estrada et al., 2010), 
has been shown to induce stem cell-like properties in transitioning cells (Mani et al., 
2008), generating the following hypothesis; constant WT1 expression is required to 
maintain stem cell characteristics in adult stem cell niches, while transient WT1 
expression is required to activate these stem cell-like characteristics in differentiated 
cells, such as when undergoing transition, before being inactivated to allow return to 
a quiescent adult cell type.   
6.5 Future Work 
Alongside interrogating the areas investigated herein in more detail and the future 
work already suggested within this chapter, there are some other experiments which 
were started during the course of this work, but have not yet yielded revealing data in 
relation to WT1. 
6.5.1 Determining the Function of WT1 in Endothelial Cells In Vitro  
In order to provide further insight into the functional implications of WT1 expression in 
vitro, endothelial cell culture was initiated. This would be useful to investigate the role 
of WT1, specifically in EndMT using an EndMT assay, but could also be applied to a 
2D-tube formation assay to confirm endothelial WT1 KO does impair angiogenesis as 
seen in the aortic ring assay. 
Endothelial cells were extracted from VE-Wt1 KO and CC mice and cultured for up to 
7 days post-extraction (Figure 6.1). Initial small colonies of endothelial cells attached 
to the bottom of the plates as early as Day 3 and began to proliferate and migrate out 
to form a monolayer. By Day 7, confluence was achieved and cells were re-plated. 
Both VE-Wt1 KO and CC endothelial cells had the capacity to form a monolayer and 
reach confluence and there was no noticeable difference in speed or extent of cell 
proliferation or migration, though this was not quantified. This shows it is possible to 
isolate and culture VE-Wt1 KO endothelial cells for further experiments. However, 
alongside cells with a typical ‘cobblestone’ endothelial morphology, more spindle-
shaped non-endothelial cells were noted, suggesting some mesenchymal cells had 
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also been isolated from aortae. This technique will need to be further optimised to 
reduce contamination from non-endothelial cell types.    
 
Figure 6.1 Cultured endothelial cells from CC & VE-Wt1 KO aortae in vitro. Endothelial 
cells were extracted from A-C) CC & D-F) VE-Wt1 KO aortae with collagenase and cultured 
in vitro. Endothelial cells attached, proliferated and migrated to form a monolayer, though other 
cell types were present. Images are from brightfield microscopy at Day 3, Day 5 & Day 7 (left 
to right). A, B, D, E) magnification 5x, C, E) magnification 10x. CC = Cre control, VE-Wt1 KO 
= vascular endothelial WT1 KO. Representative images from n=5. 
6.5.2 Murine Menstruation as an Acute Model of Angiogenesis  
The murine model of mouse menstruation developed by Brasted et al. (2003) and 
adapted by Cousins et al. (2014) could be a model of in vivo angiogenesis in which 
the effect of endothelial WT1 KO could be more effectively quantified. This model may 
also exhibit more dramatic effects as a result of endothelial WT1 KO, due to the 
previously observed WT1 expression in the vessels of the adult uterine tract.  
Surgical work was carried out by Dr. Douglas Gibson and Prof. Philippa Saunders 
(Centre for Reproductive Health, University of Edinburgh) who kindly provided 
samples. Samples from this model of menstruation were provided at 8 hours, 12 hours, 
24 hours and 48 hours after induction of decidualisation of the endometrial layer. WT1 
was found to be expressed in the stromal cells of the endometrium and in a proportion 
of the endothelial cells of the uterine blood vessels. 
A B C 









Figure 6.2 WT1 is expressed in the murine model of menstruation. The murine model of 
mouse menstruation (Cousins et al., 2014) was assessed for WT1 expression by Isolectin-
B4/αSMA/WT1/DAPI staining at A) 8 hours, B) 12 hours, C) 24 hours and D) 48 hours after 
induction of decidualisation. WT1 was also assessed by WT1 immunoprecipitation staining. 
D) 8 hours, E) 12 hours and F) 24 hours after decidualisation. WT1 was found to be expressed 
in the stromal cells and in the endothelium of vessels. Vessels indicated by dotted lines. 
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6.5.3 Wire Injury Model of Neointima Remodelling 
As WT1 was discovered to have a role, not only in angiogenesis, but in general 
vascular function, the wire injury model of neoinitimal remodelling was thought to be 
an effective model of the effect of WT1 on general vascular function. This model is of 
relevance to retinosis and atherosclerosis, in which endothelial proliferation and 
regeneration, fibrosis and inflammation are integral. 
Intra-luminal injury was surgically induced in the left femoral artery using a wire injury 
model (Sata et al., 2000). In C57Bl/6 mice, the role of WT1 should be assessed in this 
model by histology over the course of damage and regeneration, to determine when 
and where WT1 is expressed in vessels during damage, repair and remodelling. 
Neointimal remodelling was assessed in 3D by optical projection tomography (Kirkby 
et al., 2011) at day 21 after induction of injury in VE-WT1 KO and CC mice. 
Quantification of lesion size could be carried out in the future from 3D images and by 
histology to determine if VE-WT1 KO mice have larger lesions than controls.  
 
Figure 6.3 Neointima remodelling in the wire injury model. 3D Optical Projection images 
in CC mice from the wire injury model of neointima remodelling. A) A whole femoral artery at 
21 days following wire injury. Wire injury was carried out at the top of the artery where 
remodelling is evident by increased tissue mass. Cross sections through the vessel shown in 
B) and C) are indicated by dotted red lines. CC = Cre control, VE-Wt1 KO = vascular 








6.5.4 WT1 in Human Limb Ischaemia 
To confirm the relevance of the findings from HLI in humans, clinical samples from 
limb amputation were obtained from patients at the Royal Infirmary of Edinburgh with 
limb ischaemia, as a result of diabetes or critical limb ischaemia. Samples were kindly 
provided with the help of Dr. Richard McGregor, Dr. Rachael Forsythe and Dr. Ross 
Jones (Royal Infirmary of Edinburgh). Samples were taken distally within diseased 
tissue and proximally in relatively healthy tissue. WT1 expression should be assessed 
in the vessels and muscle tissue in both these locations to determine the involvement 
of WT1 in ischaemia and ischaemic angiogenesis.  
6.6 Conclusions 
This thesis set out to determine the role of WT1 in cardiovascular disease, specifically 
in endothelial cells in ischaemic angiogenesis, utilising in vivo and ex vivo models of 
angiogenesis, alongside a murine endothelial WT1 KO and integrating comprehensive 
transcriptomic analysis. The hypothesis explored in this thesis was that WT1 is 
intrinsically involved in the response to ischaemic cardiovascular disease and hence, 
WT1 KO in the vascular endothelium would impair angiogenesis. Ultimately, this thesis 
adds to an exciting field, consolidating the role of WT1 in angiogenesis and in 
cardiovascular disease in general, while generating some completely novel insights 
relating to WT1 in areas which demand further investigation. 
WT1 is an important factor in angiogenesis, though the focus on endothelial cells is 
too narrow to be physiologically relevant in cardiovascular disease. In agreement with 
this, endothelial WT1 KO impairs angiogenesis ex vivo, but not in vivo, with WT1 
having a relatively early, transient role in angiogenesis. WT1 additionally acts as a 
transcription factor in mural cells, fibroblasts and immune cells both in the context of 
angiogenesis and beyond. Whether WT1 is directly regulating factors of importance to 
angiogenesis is unclear; it seems possible WT1 is enacting a functional shift in cells 
which increases their capacity to undergo angiogenesis through cellular processes 
such as migration and proliferation and potentially, through inducing a partial EndMT 
to improve their regenerative potential.  
Certainly, WT1 has a broader scope of influence than previously anticipated. Within 
the vasculature, intriguing preliminary evidence suggests WT1 also regulates 
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vasculature tone and vascular permeability; both important in angiogenesis and 
cardiovascular disease in a broader sense.  Outside of the vasculature, WT1 is also 
implicated in fibrosis and inflammation. One novel exciting observation is that WT1 
may play a role in regenerative myogenesis in satellite cells and skeletal muscle 
myocytes. Along with identification of WT1 expressing MSCs and pre-B cells, this 
questions the broader implications of WT1 expression in adult stem cell populations; 
WT1 may be an essential regulator of adult stem cell function and differentiation, in 
part through EMT. 
Angiogenesis and the other processes in which WT1 is implicated in cardiovascular 
disease in vivo could prove to be beneficial or detrimental depending on the nature of 
WT1 regulation; either WT1 may prove to be a silver bullet which can therapeutically 
target, angiogenesis, fibrosis, inflammation and muscle regeneration in one shot, or 
these may throw up unwanted side effects. This work questions the established 
consensus on WT1 as an important regulator of angiogenesis in endothelial cells alone 
and suggests WT1 may be regulating a number of cellular, vascular and regenerative 
processes of therapeutic relevance to targeting regeneration in cardiovascular 
disease, but also in a number of other pathological contexts. Finally, WT1 retains its 
status as a potentially beneficial therapeutic target in cardiovascular disease, but 
should be considered not only in endothelial cells in angiogenesis, where WT1 has 
scope to influence a number of processes, but in the vasculature in general and in the 
general pathophysiology and regeneration central to a number of cardiovascular 
diseases 
5.3.3 Identification of Potential WT1-Binding Sites in the Genome 
BLASTN by Ensembl (Aken et al., 2016) is a tool for searching the genome for the 
location of short nucleotide sequences. Using three validated WT1-binding sequences 
the entire Mus musculus genome was screened for the location of these sequences 
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A.i. Identification of Potential WT1-Binding Sites in the Genome 
BLASTN by Ensembl (Aken et al., 2016) is a tool for searching the genome for the 
location of short nucleotide sequences. Using three validated WT1-binding sequences 
the entire Mus musculus genome was screened for the location of these sequences 
within genes. In total, 2683 hits were found (Table A.i), most of these were within 
introns.  
Sequence BP Source Hits 
5’- GCGTGGGAGT  -3’ 10 (Nakagama, Heinrich and Pelletier, 
1995; Motamedi et al., 2014; Kann 
et al., 2015) 
881 
5’- GCG-TGG-GCG- 
(T/G)(G/A/T)(T/G)  -3’ 
12 (Hamilton, Barilla and Romaniuk, 
1995; Motamedi et al., 2014; Kann 
et al., 2015) 
319 
5’- GGAGAGGGAGGATC -3’ 14 (Little et al., 1996; Motamedi et al., 
2014; Dong et al., 2015) 
1483 
Table A.i: BLASTN screening for potential WT1-binding sites within the mouse genome. 
Three validated WT1-binding sequences were used to identify potential WT1 binding within 
the Mus musculus genome. Shown are the sequences, number of base pairs (BP) in the 
sequence, the earliest source where this sequence was identified and the number of hits within 
the genome for each sequence. 
 
The overlap between these genes and the gene expression data obtained from the in 
vivo microarray data was assessed, examining the number of genes identified from 
BLASTN that were also identified from the gene expression data (Table A.ii). However, 
between the two datasets, the number of genes which overlapped was not larger in 
genes whose expression was different between WT1+ and WT1- than in genes which 
were completely unchanged. Further, 45.88% of all the genes identified from the 
microarray, whether changed or not between WT1+ and WT1- cells, were also 
identified by BLASTN screening. While there will likely be direct targets of WT1 in this 
list of genes, the false hit rate is too high for meaningful analysis; these 12,964 genes 
comprise ~56% of the total mouse genome, which suggests the number of hits from 





 Matches Genes/category Overlap 
Increased at day 7 only 76 1,100 6.91% 
Increased at day 21 
only 
70 772 9.07% 
Increased at day 7 & 21 166 1,611 10.30% 
Decreased at day 7 
only 
106 1,488 7.12% 
Decreased at day 21 
only 
38 647 5.87% 
Decreased at day 7 & 
21 
102 1,457 7.00% 
Unchanged 539 7,520 7.17% 
Total 1097 12,964 45.88% 
Table A.ii:Overlap between genes identified by BLASTN and in vivo SSI microarray 
data. There is very little overlap between genes which are changed in WT1+ v WT1- cells and 
those identifies by BLASTN screening for WT1-binding motifs. “Increased” and “Decreased” 
refers to genes which have higher and lower expression in WT1+ cells, respectively. 
“Unchanged” are ones which weren’t changed with WT1 expression and “Total” are all genes 
in the database.  Number of matches are shown,   genes/category in total are shown and the 
overlap as a % of these genes in each category. 
A.ii. Potential WT1-Binding to Promoter Sequences 
Genes with higher or lower expression at both day 7 and day 21 were analysed with 
RSAT (Medina-Rivera et al., 2015) to extract the Mus musculus promoter sequences 
of all these genes and then screen promoters for the location of previously identified 
and validated WT1-binding motifs (Table A.iii).  Three motifs elicited a number of hits. 
False hit rates were identified by generating a number of random nucleotide 
sequences of equal length to the actual motif and screening promoters for hits. The 
WT1-binding motif GGAGG(A/G) (Reynolds et al., 2003) elicited 1786 hits, but with a 
67.1% false hit rate due to its short length of 6bp, so was removed from further 
analysis. To reduce the number of false positive hits, no substitutions in sequence 




Sequence Source False hits # hits 
GCGGGGGCG or 
CGCCCCCGC 
(Rauscher et al., 1990) 24.9% 128 
TCCTCCTCCTCCTCTCC (Wang et al., 1993; Lefebvre 
et al., 2015) 
- 0 
GCGTGGGAGT (Nakagama, Heinrich and 
Pelletier, 1995; Motamedi et 
al., 2014; Kann et al., 2015) 
- 3 
GGAGG(A/G) (Reynolds et al., 2003; 
Motamedi et al., 2014; Dong 
et al., 2015) 
67.1% 1786 
GCGTGGGCG(T/G)(G/A/T)(T/G) (Hamilton, Barilla and 
Romaniuk, 1995; Motamedi 
et al., 2014; Kann et al., 
2015) 
1.8% 22 
GGAGAGGGAGGATC (Little et al., 1996; Motamedi 
et al., 2014; Dong et al., 
2015) 
- 1 
Table A.iii: Number of potential WT1-binding sites in promoter sequences from RNA-
seq genes. Genes changed at both day 7 and day 21 in WT1+ v WT1- cells had their promoter 
sequences screened for the location of WT1-binding motifs using RSAT (Medina-Rivera et al., 
2015). The sequences, their source, the false hit rate (determined with randomly generated 
nucleotide sequences of the same length) and the number of hits in the extracted promoter 
regions is shown.  
The 22 genes identified with the GCGTGGGCG(T/G)(G/A/T)(T/G) sequence 
(Hamilton, Barilla and Romaniuk, 1995) in their promoter and 128 genes with the 
GCGGGGGCG or CGCCCCCGC sequence (Rauscher et al., 1990) in their promoter 
are shown in Figure A.i. The majority of these genes had one, or often multiple, WT1-
binding motifs in the promoter within 200bp of the upstream start site of the promoter 
region. Some of these identified genes are already recognised as genes that are 







































Figure A.i: WT1-binding sites in promoter sequences from RNA-seq genes are primarily 
at the 3’ end of the promoter. Genes changed at both day 7 and day 21 in WT1+ v WT1- 
cells had their promoter sequences screened for the location of WT1-binding motifs using 
RSAT (Medina-Rivera et al., 2015). Sequences matching with known WT1-binding motifs are 
shown by coloured lines (above the line for 5’-3’ and below for 3’-5’). Scale indicates number 
of base pairs from the 3’ end of the promoter sequence.  
A.iii. Role of Potential WT1 Target Genes 
DAVID (Huang et al. 2008; Huang et al. 2009) was used to identify GOterms 
associated with the genes identified by RSAT (Medina-Rivera et al., 2015). Only the 
12,964 genes detected in our micro-array were used as the background for analysis, 
to avoid any context-dependent bias. GOterms were reduced by redundancy and 
presented using ReviGO (Supek et al., 2011) to show the cellular locations (Figure A.ii 
A), molecular functions (Figure A.ii B) and biological processes (Figure A.ii C) with 
which these genes are associated. There were a degree of overlap between these 
GOterms and the GOterms identified with the WT1+cell gene expression profile in 
section A.i. 
In terms of cellular localisation (Figure A.ii A), as in 5.3.2.4, actin filament bundle, 
actomyosin and stress fibres were identified. There were also terms relating to 
extracellular space and extracellular matrix and different types of vesicles. However, 
there were more references to cytoplasmic terms, cell-cell junctions and the nucleus 
than in section A.i. 
In terms of molecular functions (Figure A.ii B), the two main groups of GOterms 
overlapped to some extent with section A.i. One group related to the binding of various 
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metal ions, while the other related to binding of various proteins, including Laminin-1. 
There were also significant GOterms relating to the activity of various peptidases. 
In terms of biological processes (Figure A.ii C), as in section A.i, angiogenesis was 
important. There were also processes relating to cell migration, proliferation, adhesion 
and death. Regulation of stem cell differentiation was significant, as was vesicle 
mediated transport, collagen catabolism and actin filament-based process. Some 
other processes related to DNA transcription, such as DNA-binding and RNA 















































Figure A.ii: Cellular locations, molecular functions and biological processes associated 
with potential WT1 target genes. Genes detected as having potential WT1-binding sites 
within their promoter regions were analysed using DAVID (Huang, Sherman and Lempicki, 
2008, 2009) to determine GOterms associated with these genes. Terms were sorted for 
redundancy and visualised by ReviGO (Supek et al., 2011) for associated A) cellular locations, 
B) molecular functions and C) biological processes. Each circle is a GOterm. Size of circle 
indicates log size of changes in expression and colour represents log10 p-value for significance 
of each term. X and Y axis are semantic space, such that GOterms that are biologically similar 














A.iv. Pathway Analysis of Potential WT1 Target Genes 
DAVID (Huang, Sherman and Lempicki, 2008, 2009) was used, to identify pathways 
from the KEGG pathway database with which potential WT1 target genes were 
significantly associated. 9 KEGG pathways were significantly associated with these 
genes (Table A.iv), suggesting these pathways may be directly regulated to some 
extent by WT1.  
Pathway Genes P-Value 
Leukocyte trans-endothelial 
migration 6 2.22E-03 
Proteoglycans in cancer 6 1.90E-02 
Focal adhesion 6 2.05E-02 
Bacterial invasion of epithelial cells 4 2.15E-02 
Regulation of actin cytoskeleton 6 2.33E-02 
Galactose metabolism 3 2.46E-02 
Phosphatidylinositol signalling 
system 4 3.77E-02 
Chemokine signalling pathway 5 6.22E-02 
Long-term potentiation 3 9.03E-02 
Table A.iv: KEGG pathways associated with potential WT1 target genes. 9 pathways 
were identified as being associated with potential WT1 target genes using DAVID (Huang, 
Sherman and Lempicki, 2008, 2009) and the KEGG pathway database. Only genes higher in 
WT1+ cells at both day 7 and day 21 were analysed. Shown are the number of genes in that 
pathway elevated in WT1+ cells and the p-value for identifying that pathway.  
 
A.x. Integrative Analysis of WT1+ Gene Profile and Potential WT1 
Binding 
In order to attempt to further refine the effect WT1 has on gene expression how this 
impacts the function of WT1+ cells, integrated analysis on the data from RNA-seq and 
RSAT was carried out. As previously mentioned, analysis of both the RNA-seq and 
RSAT data revealed WT1 as a significant process. Using data from RNA-seq, 
integrated with the RNA-seq expression data and genes selected by DAVID as being 
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associated with angiogenesis, the change in gene expression was quantified between 
WT1+ cells and WT1- cells in the 11 genes associated with angiogenesis which are 
potentially directly regulated by WT1 (Figure A.iii). This revealed expression of 8 of 
these genes was higher in WT1+ cells at day 7 and day 21 and expression of 3 was 
lower.  
 














Figure A.iii: WT1 directly affects gene expression of 11 genes involved in angiogenesis. 
Graph shows log10 fold change in mRNA expression between WT1- and WT1+ cells of various 
genes identified as being associated with angiogenesis and which also have potential WT1 
binding sites in their promoters. Cells were FACS sorted from SSI sponges from WT1-GFP 
mice at day 7 and 21. RNA-seq was carried out to determine expression levels. Promoters of 
genes were screened for WT1-binding motifs using RSAT (Supek et al., 2011) Gene names 
are the official gene symbols or full names. *fdr q<0.05, limma R bioconductor package. WT1- 
v WT1+. n=3. 
 
From previously identified KEGG pathways, 5 of the 9 pathways identified as being 
significant from analysis of RSAT WT1-binding genes (Section A.ii) overlapped with 
significant pathways from the pathways identified relating to the RNA-seq data 












































































































pathways were visualised, demonstrating thes stages in the pathways in which there 
were changes in gene expression between WT1+ and WT1- cells and the stages in the 
pathway at which WT1 was potentially directly regulating intrinsic genes. VEGF-
Signalling (Figure A.iv), Leukocyte Trans-Endothelial Migration (Figure A.v), 
Regulation of Actin Cytoskeleton (Figure A.vi) and Focal Adhesion (Figure A.vii) were 
visualised. These WT1 appears to having an effect at multiple stages in these 
pathways and these pathways interact with each other to some extent. From 
visualising these pathways, it became clear that Phosphoinositide 3-kinases (PI3Ks) 
played a role in all these pathways and number of PI3Ks were influenced by WT1. On 
interrogation of the PI3K-Akt pathway (Figure A.viii), it was evident that more than a 
third of all the genes in the pathway were significantly higher of lower in WT1+ cells v 
WT1- cells at day 7 or day 21. WT1 potentially directly regulates 4 genes in this 
pathway; Pkn1, Bcl2l11, Lamc1 and Thbs1. 
 Matches by Dataset 
Pathway RNA-seq WT1-
binding 
Bacterial invasion of epithelial cells   




Proteoglycans in cancer   
Regulation of actin cytoskeleton   
Table A.v: Biological pathways in which changes in WT1 expression and direct 
regulation by WT1 have an effect. KEGG pathways were identified by DAVID (Huang, 
Sherman and Lempicki, 2008, 2009) from RNA-seq data and RSAT Wt-binding data. Shown 





















Figure A.iv: The effect of WT1 on VEGF signalling. The VEGF signalling pathway, as extract from KEGG. Annotated are the 
changes in the expression of genes at each step in the pathway, where up arrows indicate increased expression in WT1+ cells and 
down arrows indicate decreased expression in WT1+ cells from WT1-GFP RNA-seq data. If no annotation, day 7 & 21, 7 = day 7 only, 

















Figure A.v: The effect of WT1 on Leukocyte transendothelial migration. The leukocyte transendothelial pathway, as extract from KEGG. 
Annotated are the changes in the expression of genes at each step in the pathway, where up arrows indicate increased expression in WT1+ 
cells and down arrows indicate decreased expression in WT1+ cells from WT1-GFP RNA-seq data. If no annotation, day 7 & 21, 7 = day 7 only, 



















Figure A.vi: The effect of WT1 on regulation of actin cytoskeleton. Regulation of actin cytoskeleton, as extract from KEGG. Annotated are 
the changes in the expression of genes at each step in the pathway, where up arrows indicate increased expression in WT1+ cells and down 
arrows indicate decreased expression in WT1+ cells from WT1-GFP RNA-seq data. If no annotation, day 7 & 21, 7 = day 7 only, 21 = day 21 
only. Stars indicate genes identified from RSAT (Supek et al., 2011) as being potential direct targets of WT1.   
253 
 
Figure A.vii: The effect of WT1 on focal adhesion. The focal adhesion pathway, as extract from KEGG. Annotated are the changes in the 
expression of genes at each step in the pathway, where up arrows indicate increased expression in WT1+ cells and down arrows indicate 
decreased expression in WT1+ cells from WT1-GFP RNA-seq data. If no annotation, day 7 & 21, 7 = day 7 only, 21 = day 21 only. Stars 

















Figure A.viii: The effect of WT1 on the PI3K-Akt signalling pathway. The PI3K-Akt pathway, as extract from KEGG. Annotated are the 
changes in the expression of genes at each step in the pathway, where up arrows indicate increased expression in WT1+ cells and down arrows 
indicate decreased expression in WT1+ cells from WT1-GFP RNA-seq data. If no annotation, day 7 & 21, 7 = day 7 only, 21 = day 21 only. Stars 
indicate genes identified from RSAT (Supek et al., 2011) as being potential direct targets of WT1.
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